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New antimalarials are desperately needed to overcome growing P. falciparum resistance to 
the current drugs. Successful quinoline-based drugs target haemozoin formation causing a 
cytotoxic accumulation of free haem (Fe(III)PPIX) in the parasite, a target which remains 
promising for future treatments. Much research has been undertaken on the quinoline 
antimalarials, which has led to several hypotheses of haemozoin inhibition and drug 
accumulation mechanisms, however, relatively few studies have been carried out for 
haemozoin antimalarials with alternate chemotypes. High throughput screening (HTS) can 
be used to identify novel scaffolds that inhibit β-haematin (βH - synthetic haemozoin) 
formation and which have favourable P. falciparum activities.  
In this project, HTS has been carried out on 43,520 small, organic, drug-like compounds as 
part of a larger screen of 144,330 Vanderbilt University Institute of Chemical Biology (VU) 
chemical library compounds and 530 were found to be good inhibitors of βH relative to the 
chloroquine (CQ) and amodiaquine (AQ) controls. A further 171 compounds were found to 
inhibit parasite growth, showing improved hit rates from previous HTS efforts. Two scaffolds 
(A=benzamides and B=triarylimidazoles) were selected for further analysis, whereupon 
analogues were synthesised.   
The benzamides (Scaffold 1) were synthesised from the corresponding acid chloride via 
conventional amide coupling. SAR analysis revealed that these planar molecules can π-π 
interact optimally with Fe(III)PPIX to inhibit βH, and the two most potent analogues, both 
pyridylbenzamides, showed in vitro parasite IC50s of 0.7 ± 0.2 µM and 0.6 ± 0.1 µM against 
the CQ-sensitive NF54 strain. Amine side chains were introduced to increase basicity, an 
aspect that is believed to promote pH trapping in the acidic DV of the parasite. The 
predicted cellular accumulation ratios (CARs) of the new analogue and the quinoline 
antimalarials, CQ and AQ, were all ~7000 based on theoretical or measured pKa values, 
whereas the pyridylbenzamides were predicted not to accumulate via pH trapping. 
Conversely, accumulation studies via the inoculum effect revealed experimental CARs of 
~1000, ~6000  and ~100,000 for the basic derivative, non-basic pyridylbenzamides and 





between the theoretical accumulation due to pH trapping and the experimental CARs. 
Fe(III)PPIX association data for the benzamides revealed relatively weak Fe(III)PPIX binding 
(logK of ~3.2), since the benzamide-haem interaction is exclusively via π-π interactions, 
compared to the quinolines which can form cation-π interactions (logK of 5.5 and 5.3 for CQ 
and quinidine respectively). Selected analogues were shown to inhibit haemozoin formation 
within P. falciparum cell cultures, causing unusually high levels of free haem above 50% at 
2.5 times the IC50 compared with that for CQ of only 15%. These data suggested that haem 
binding may be primarily responsible for drug accumulation.  
Triarylimidazole derivatives (Scaffold 2) were synthesised via a condensation with the 
appropriate aldehyde, benzil and ammonium acetate using literature procedures. The 
minimum pharmacophore for βH inhibition was identified as a triaryl-substituted imidazole 
with either a 2-pyridyl or a substituted 2-phenyl ring. However, SAR analysis for parasite 
growth inhibition showed that activity is highly dependent on the substitution pattern of the 
2-phenyl ring, whereby derivatives with 3,5-methoxy-4-hydroxy substituents were 
significantly more potent, possibly as a result of improved solubility. Analogues from this 
chemotype were also shown to cause high levels of free haem, >50% at 2.5 times the IC50. 
The structures and activities of the synthesised derivatives together with the VU HTS data 
and previous GlaxoSmithKline (GSK) and St Jude Children’s Research Hospital HTS data were 
used in training sets to create and optimise activity models based on Bayesian statistics, in 
order to predict the probability for inhibitory activity of other compounds as βH and 
parasite-growth inhibitors at a specified IC50 cut-off. The models for βH inhibition (100 µM 
IC50 cut-off) and parasite growth inhibition (2 µM IC50 cut-off) were used to identify six novel 
βH-inhibiting and two potent biologically-active compounds (27-fold and 100-fold 
enrichment respectively over random screening). It also predicted all six of the known βH 
antimalarials to lie within the top 2.5% of all 1510 FDA-approved drugs when ranked by the 
likelihood of being biologically active using Bayesian scores. Future activity results with 
additional compounds can be used to update the model. This continually updated model 
may be employed in virtual screening of other compound libraries, possibly even those 
generated in silico. This approach has potential for prioritising future libraries for more 
efficient screening, and for determining the most appropriate analogues for synthesis. 
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1.1 Historical background 
Malaria is one of the most prevalent and oldest documented human infections, particularly 
in tropical regions.1 The signs and symptoms of the disease, including headaches, chills, 
intermittent fevers and enlarged spleens were described in early writings from Egypt, India 
and China.2 While initially believed to be caused by evil spirits, Hippocrates described the 
clinical symptoms of malaria in 400 BC, which were attributed to the vapour, mist and other 
“bad air” ascending from swamps and marshes. As a result, the disease was named 
“Mal’aria” by the Romans.2,3,4 It was only 2500 years later that scientific studies could be 
carried out, after Charles Louis Alfonse Lavern discovered spherical parasites inside fresh 
red blood cells.5 In addition, a black pigment similar to that observed more than a century 
before in the brain and spleen of malaria victims, was detected within the malaria parasite.6 
Mosquitoes were subsequently identified as the vector by Ronald Ross in 1897, when 
parasites containing the same black pigment, were found in the mosquito’s gut.7 Since then, 
approximately 200 mammalian, avian and reptile species of parasite, belonging to the genus 
Plasmodium, have been reported.8,9 Of the five that infect man, P. falciparum is the most 
pathogenic, prevalent and deadly.1,2 
 
1.2 The current global malaria disease burden 
The latest malaria report from the World Health Organisation (WHO),10 which summarises 
data from 97 malaria-endemic countries, describes the expansive deployment of 
artemisinin-based combination therapies (ACTs) in 2013 (Section 1.5.1), leading to a 47% 
decrease in global mortality rates from 2010 to 2013. Despite this decline in malaria-related 
deaths, 430,000 annual child mortality cases were recently reported from Africa alone. 
These deaths accounted for 74% of the 584,000 total global mortality figures. Furthermore, 
198 million cases of the disease occurred globally and about 60 million children with malaria 




did not receive treatment with ACTs. Biological, funding and systemic challenges, together 
with emerging drug resistance, continue to threaten the current treatments and the WHO 
encourages researchers to act with urgency. The global distribution of the disease epidemic 
is detailed in Figure 1.1.  
 
Figure 1.1 Spatial distribution of the P. falciparum malaria endemicity in 2010. The parasite 
rate is age-standardized to the two to ten year age-range (PfPR2-10) for every 5×5km pixel, 
to account for the fact that malaria is more prevalent in children. The percentage population 
infected is indicated by the blue to red colour scale. Grey regions indicate the P. falciparum 
annual parasite incidence (PfAPI). Reproduced from Gething et al.11 
 
1.3 The malaria parasite life cycle 
By 1900, the basic features of the life cycle of the parasite were recognized, but it was only 
in the 1950s that all three stages of human malaria parasites were comprehensively 
described.2 The five species that infect humans have very similar life cycles which comprise 
the mosquito, liver and blood stages, as shown in Figure 1.2 for P. falciparum. The bite of a 
female Anopheles mosquito inoculates the human host with about ten motile sporozoites 
which transit through the human dermis to access blood vessels and then, upon reaching 
the liver, rapidly through Kupffer cells, the liver macrophages, to invade parenchymal 
hepatocyte cells. Here, the liver stage of the life cycle occurs, during which the sporozoites 




multiply asexually to form liver schizoints over approximately one week. This causes cell 
rupture and over 100,000 merozoites are released into the blood stream.12 Rapid invasion 
of erythrocytes initiates the asexual blood stage, which occurs in 48 h cycles and causes the 
typical malaria symptoms. The blood cycle begins as rings within a parasitophorous vacuole. 
Further growth development into trophozoites and then blood schizonts is fuelled by host 
Hb degradation. At this stage, the formation of the black “malaria pigment” takes place. 
Following maturation of the schizont, the red blood cell (RBC) bursts open and merozoites 
flow into the bloodstream where they invade new erythrocytes to reinitiate the blood cycle 
and increase parasitemia (percent infected RBC) levels. This process continues until 
intervention through treatment, host response regulation or death of the victim. During this 
stage, gametocytogenesis also takes place, forming male and female gametocytes over 
approximately ten days. These have a characteristic crescent shape and circulate in the 
blood for up to four days until being taken up by a mosquito upon feeding. Following 
maturation of a gametocyte into a gamete within the gut of the mosquito, fertilisation 
occurs to form a motile zygote (ookinete), which penetrates the gut membrane and 
becomes an oocyst. Multiplication of the oocyst produces sporozoites which then travel to 
the mosquito’s salivary glands, ready to begin the P. falciparum life cycle again.2,3,13 





Figure 1.2 The life cycle of the Plasmodium malaria parasite. Copyright © 2008 American 
Society for Clinical Investigation, Greenwood et al.13  
  




1.4 Haemoglobin degradation 
During the blood stage of the life cycle, the malaria parasite ingests the major cytosolic host 
cell protein, haemoglobin (Hb). This is initiated by endocytosis via the cytostome (cell 
mouth), which extends between the parasite and red cell cytoplasm allowing the 
trophozoite to feed on Hb from the host cytoplasm. Vesicles containing Hb are then 
transported to the digestive vacuole (DV), an acidic secondary lysosome with a pH of 4.8-
5.2.14 Here, the Hb is degraded in order to supply the parasite with the necessary amino 
acids for its growth and maturation, since neither their acquirement via de novo synthesis 
nor exogenous uptake are possible.15 In addition, the parasite requires space to grow and 
divide so that it does not exceed the lytic volume of the host red cell.16 Indeed, one study 
showed that only ~16% of the 65% degraded host Hb was incorporated into the parasite 
proteins and hence, only a fraction of the acquired amino acids are used as nutrients.17 Acid 
and alkaline proteases in the DV break down Hb into denatured globin, releasing a haem 
molecule as a by-product.15 Further degradation of the globin by the aspartic protease 
enzymes plasmepsin I, II and IV and histo-aspartic protease (HAP), by the falcipain cysteine 
proteases and by the zinc protease, falcilysin provides peptides that are then hydrolysed to 
the vital amino acids, where a fraction are incorporated into parasite proteins.18 Some 
studies indicate that up to 75% of erythrocyte Hb can be digested during a single blood cycle 
and as a result, the parasite has developed an efficient and specific pathway for Hb 
proteolysis.19 In the process, the parasite faces a unique problem, since it is unable to 
degrade haem (Fe(II)PPIX) enzymatically, as it appears to lack a functional haem oxygenase. 
Instead Fe(II)PPIX is auto-oxidised by O2 to Fe(III)PPIX, which is capable of lipid peroxidation 
and is therefore cytotoxic. In order to deal with the vast amounts of Fe(III)PPIX produced, a 
type of biomineralisation process takes place, whereby the toxic Fe(III)PPIX is converted into 
an inert and highly insoluble crystalline material known as haemozoin.18,20 This process is 
shown in Figure 1.3. 
  





Figure 1.3 Haemoglobin (Hb) degradation in a parasitised red blood cell, resulting in amino 
acids for parasite growth and cytotoxic Fe(III)PPIX which is crystallised to form non-toxic 
haemozoin. 
 
1.5 Malaria chemotherapy 
Four major drug classes are currently used to treat malaria, namely, the antifolates, the 
artemisinin derivatives, the antimicrobials and the quinoline-related compounds. The 
majority of drugs from the quinoline class act during the red blood cell stage of the parasite 
life cycle and are believed to target the haemozoin formation process discussed in Section 
1.4. 
  




1.5.1 Non-haemozoin inhibiting antimalarials 
An intensive search for antimalarials in the United Kingdom during the Second World War 
identified proguanil (Figure 1.4a), an open pyrimidine derivative (biguanide), as having 
better activity than the well-established drug quinine (QN), although its action was slow 
against acute malaria and it appeared to induce drug resistance in some parasite strains.1 
Other pyrimidines, namely the 2,4-diaminopyrimidines were also shown to be parasite 
growth inhibitors, the most active of which was pyrimethamine (Figure 1.4b), developed in 
1951 by Falco and Hitchings.21 However, this compound readily induced resistance and as a 
result, pyrimethamine (P) was later used in combination with sulfadoxine (S), a sulfonamide 
antibiotic (Figure 1.4c), which together have a synergistic effect. These compounds target 
the essential folate biosynthesis pathway of the parasite by inhibiting the enzymes 
dihydrofolate reductase and the dihydropteroate synthesase.22 As of 1996, proguanil (Pg) 
was administered in combination with atovaquone (Ato), an inhibitor of mitochondrial 
electron transport in the parasite (Figure 1.4d). Studies in the early 1990s showed that the 
Ato/Pg combination was significantly more effective than several different haemozoin-
inhibiting drugs in Thailand, Gabon and Peru.23 Ato, while possessing a favourable safety 
profile, induces an unacceptable rate of recrudescent parasitemia and resistance and is thus 
never given as a monotherapy. 
 
  

















Figure 1.4 a,b,c) The antifolate drugs based on the pyrimidine chemotype which inhibit a,b) 
the dihydrofolate reductase enzyme and c) the the dihydropteroate synthesase enzyme and 
d) the antibiotic, given in combination with proguanil, which prevents parasite 
mitochondrial electron transport. 
 
Currently, ACTs are the generally preferred treatment for malaria infections.10 Artemisinin 
was extracted from the Chinese herb Artemisia annua, also known as sweet wormwood and 
was used as a powerful antimalarial in China for over two thousand years.24 However, the 
active ingredient was only identified as artemisinin, an unstable sesquiterpine lactone with 
an unusual endoperoxide bridge, in the early 1970s, (Figure 1.5a).25 It has been proposed 
that upon cleavage of this peroxide bond by reduction with Fe(II), reactive radicals which 
destroy the parasite, are released. As a result, this moiety has been demonstrated to be 
essential for the activity of artemisinin.26 However, the mechanism of action of artemisinin 
remains controversial.27 Other reports discuss the importance of carbon-centered radical 
formation and an electrophilic epoxide, a potent alkylating agent,28 which specifically 




alkylates malarial proteins but not those of intact erythrocytes29. Artemisinin also forms a 
covalent complex with haem and some describe the inhibition of Hb breakdown and 
haemozoin formation by artemisinin,30 however the artemisinin-haem adduct has been 
shown to have weak parasite activity.31 Furthermore, the release of toxic free iron upon 
haem degradation by artemisinin has been proposed, but increases in free iron have not 
been detected in artemisinin-treated parasites.32 The artemisinin-haem adduct is therefore 
not believed to be related to drug activity mechanisms, especially since there is reportedly 
no influence by artemisinin on the amount of haemozoin formed within cultured parasites.33 
Other hypothesised drug targets include the sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA) pump of the parasite,34 or the mitochondrial electron transport chain.35 Artemisinin 
and its derivatives are highly selective for parasites, readily partitioning into membranes as 
a result of the hydrophobicity of the chemical scaffold. A 1000-fold increase in artemisinin 
concentration is required for comparable toxicity in mammalian cells.32 
 In the 1980s, further developments led to the synthesis of more stable derivatives such as 
artemether, a methyl-ether analogue (Figure 1.5b) and artesunate, a succinic acid derivative 
with improved aqueous solubility (Figure 1.5c). However, these were identified as pro-drugs 
with dihydroartemisinin as the active metabolite.25 Artemisinin has been shown to be active 
against all of the asexual blood stages of the parasite, unlike the 4-aminoquinoline drugs.36 
According to the WHO, by the end of 2013, ACTs had been adopted as national policy for 
first-line treatment of malaria in 79 of 88 countries where P. falciparum is endemic. 
However, the quinoline-based drug, CQ, discussed in Section 1.5.2 was still being used in 
nine Central American and Caribbean countries where it remains efficacious.10  
  




a) b) c) 
  
 
Artemisinin Artemether Artesunate 
Figure 1.5 Structures of the artemisinin derivatives. 
 
1.5.2 Quinoline and related antimalarials 
For at least 2000 years, the roots, leaves and flowers of many different plants were used in 
an attempt to treat the fevers associated with malaria, most of them having no great effect. 
The first potent chemotherapy for disease control was identified in the 1630s as a result of 
European contact with Spanish priests, who brought the bark of “fever trees” from the 
Peruvian Andes. The bark was given the latin name cinchona after the Countess of Chinchon 
was supposedly cured of a fever following administration of an infusion of the bark. 
Powdered preparation of the crude cinchona bark were popular for 200 years before 
isolation of the two cinchona alkaloids, quinine (QN) and cinchonine (CN) in 1820 by the 
French chemists Pierre Pelletier and Joseph Caventou. It was not long before the other two 
alkaloids, quinidine (QD) and cinchonidine (CD) were isolated too and factories for 
manufacture of salts of QN were established. However, the popularity of the new drug led 
to destruction of the native chinchona forests in Peru and tree plantations became essential 
to meet the growing demands. By the 1930s, 10 million kilograms of cinchona bark were 
produced per year by Dutch plantations in Java, providing 97% of the world’s QN 
requirements.1,37 
The four alkaloids isolated from the cinchona bark are chemically related via their quinoline 
ring and with respect to symmetry at the chiral centres C-8 and C-9. As shown in Figure 1.6, 
QN (9R, 8S) and QD (9S, 8R) are diastereoisomers with a methoxy substituent at the 6-




postion of the quinoline ring. Cinchonine (CN, 9S, 8R) and cinchonidine (CD, 9R, 8S) are 
analogues of QD and QN respectively, containing hydrogen in place of the methoxy 
moiety.37 
a) a)     b) 
  
Figure 1.6 The structures of the cinchona alkaloids (a) QD and CN with the same 
stereochemistry and the corresponding diastereoisomers (b) QN and CD. 
 
The synthesis of artificial QN analogues was pioneered by German chemists during the First 
World War when they found themselves isolated from India and Java, the world’s main 
suppliers of QN alkaloids. In addition, Ehrlich observed the therapeutic effect of methylene 
blue on malaria patients, which together with development of a technique for assessing the 
effectiveness of compounds, initiated the search for synthetic antimalarials.1 The best of the 
synthesised compounds discovered at this early time was quinacrine (QC, Figure 1.7a), 
discovered in 1933. However, a couple of years later, the German chemist, H. Andersag 
synthesised a 4-aminoquinoline with comparable activity, called Resochin, while working in 
the Elberfeld laboratories of the Bayer I.G. Farbenindustrie. Initial reported toxicity tests 
indicated that Resochin was unsuitable for use in humans and its subsequent abandonment 
became known as the “Resochin error”. This was revealed after screening of around 16,000 
compounds in birds, to assess the activity of synthetic compounds against avian malarias, 
was carried out in the U.S. from 1943. Following toxicological and pharmacological studies in 
smaller animals, approximately 80 compounds were selected for testing on humans. The 
venture exposed a new compound, chloroquine (Figure 1.7b), which in 1946 was subjected 




to U.S. clinical trials in 5000 individuals to study and describe the subsequent symptoms and 
side effects. Chloroquine (CQ) was found to be structurally identical to Resochin and 
superior to all previous medications, resulting in 137,250,000 tablets being purchased per 
year by 1962.38 Several other synthetic quinoline-based antimalarials (Figure 1.7c-e) 
including primaquine (PQ), amodiaquine (AQ) and mefloquine (MF) had been discovered by 
the late 1970s. The 4-quinolinemethanol MF was identified during a screen of 250,000 
compounds, which was conducted as a result of the emergence of CQ resistance in the 
1960s. This screen revealed four primary scaffolds, namely the 4-quinolinemethanols and 
the non-quinoline-based chemotypes: 9-phenanthrenemethanols, 2,4-diaminoquinazolines 
and 2,4-diaminotriazines.1 Despite efforts to improve chemotherapies, CQ turned out to be 
the drug of choice for over four decades and was a critical part of the world-wide malaria 
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Figure 1.7 The synthetic acridine and quinoline antimalarials discovered before 1980, of 
which CQ was the most widely used for prophylaxis and treatment. 
  




1.6 Drug resistance 
Antimalarial drugs play a crucial role in controlling the spread and rate of P. falciparum 
infections. Between 2000 and 2013, a 47% global decline in the number of malaria-related 
deaths was observed, according to the WHO, along with a major expansion in the 
distribution of ACTs.10 However, there appears to be a correlation between the 
development of resistance to antimalarials with the extent of their clinical use. As a result, 
there is a continuous need for novel compounds, particularly for use in combination 
therapies in order to combat this resistance.   
The first case of P. falciparum CQ-resistance was reported in 1960 by American workers 
Young and Moore when a dose of CQ failed to treat a P. falciparum infection from 
Colombia.1 Shortly after, further reports of unresponsive malaria infections to the usual 
doses of CQ appeared from Brazil and Venezuela. It is believed that evolution to the 
resistant phenotype required mutations in several genes, since development of resistance 
to CQ was relatively slow, despite the extensive use of the drug.  Nevertheless, CQ 
resistance was soon established in south-east Asia and later spread to the other continents 
(Figure 1.8). This resulted in CQ, once the first-line malaria treatment, being declared 
ineffective in most parts of the world.14,39 Even in the absence of drug pressure, the 
resistance phenotype persisted and appeared to be stable.40 Although reversion to CQ-
sensitivity has been observed in some areas, such as Malawi.41 
  





Figure 1.8 Age standardised (2-10 year age-range) P. falciparum endemicity map for 2010. 
The appearances and global spread of CQ resistance in P. falciparum are overlaid. White 
circles indicate the six independent origins of resistance which later spread and was 
established on the African East coast in 1978. Copyright © 2012 Elsevier, Ecker et al.42 
 
QN, although the oldest known antimalarial, has retained efficacy considerably longer than 
CQ, since it has been used much less extensively.14,43 However, its efficacy in Southeast Asia 
has fallen below 50% owing to its accelerated use for the treatment of CQ-resistant 
malaria.44 On the other hand, resistance to the quinolinemethanol, MF, developed rapidly 
over just five years in Thailand due to its intensive use since it was introduced.45,46 The 
mechanism of resistance to this drug has been associated with the P. falciparum multidrug 
resistance gene (Pfmdr1) and overexpression of its protein product Pgh-1.47 However, some 
MF-resistant strains show no alternation of this gene and hence it is probable that 
resistance can arise by more than one mechanism.48 Although resistance to all of the 
quinoline based drugs has been reported, cross resistance between the 4-aminoquinolines 
and the quinoline methanols does not develop readily and in some cases, resistance 
between these two classes is inversely correlated.14 This suggests that parasites that are 
highly resistant to CQ may be more sensitive to the quinoline methanols. The appearance of 
resistance to the most widely-used antimalarial drugs is summarised in Figure 1.9. 
Interestingly, after the first report of resistance, QN, CQ and AQ remained effective for over 
a decade before resistance spread to other regions. Figure 1.9 also highlights other 




shortcomings of the known antimalarial drugs, such as halofantrine (Halo), which was not 
used after 1998 owing to cardiotoxicity concerns or AQ, which was temporarily disapproved 
as a drug owing to serious side effects. It was subsequently reinstated six years later when 
the benefits were believed to outweigh the risks. As of 2008, clinical resistance to 
artemisinins had not been demonstrated; however, this status has changed in the last seven 
years.  
 
Figure 1.9 The emergence of resistance to the clinically important antimalarials. The years 
shown beside the drug bars represent the date the drug was first introduced to the year of 
first reported resistance. The circles indicate the approximate period for the spread of QN, 
CQ, AQ, S/P and MQ resistance through different geographical areas. 
 
Evidence of resistance to artemisinin was first reported in 2008 along the Thai–Cambodian 
border after unexpected high failure rates associated with artemisinin monotherapy as well 
as reduced in vitro drug-susceptibility data were reported.49,50 This is despite the fact that 
artemisinin should not be given as a monotherapy, owing to its short half-life in patients. 
Instead, it should be administered in combination with drugs which have a long half-life, like 
MF or lumefantrine.45 However, as of 2014, the marketing of artemisinin-based 
monotherapies was still allowed in eight countries by 24 pharmaceutical companies, a major 
decline since 2007 when the WHO prescribed ACTs as first-line treatment of uncomplicated 




falciparum malaria. As a result, ACTs have since been used in almost all the malaria-endemic 
countries.10 Nonetheless, the WHO reports that addressing the threat of artemisinin 
resistance should focus on eliminating monotherapies entirely and identifying additional 
therapeutic resources.  
For over five decades, the mechanisms of drug resistance were investigated in order to 
characterise the nature of physiological changes to the parasite. Particular focus has been 
given to CQ resistance mechanisms. The primary characteristic of CQ-resistant parasites is 
that they accumulate less CQ in their DV, compared with CQ-sensitive ones.51,52 Although, 
there was much debate over the molecular basis for this decreased drug accumulation for 
many years, the key genetic mechanisms that determine resistance have now been 
established.14  
The first proposal for the mechanism of decreased accumulation was as a result of reports 
that CQ-resistant parasites released accumulated CQ from the DV almost 50 times faster 
than the sensitive strains.53 Drug efflux has been shown to be the mechanism by which less 
drug is accumulated in many types of cancer cells.54 This multidrug resistance can be 
reversed by exposure to verapamil (Figure 1.10).55  
 
 
Figure 1.10 The chemical structure of verapamil. 
It was believed that the mechanism of CQ resistance in P. falciparum is similar to that of 
multidrug resistance in cancer cells due to the decreased accumulation of CQ observed in 
resistant strains52 and the ability of verapamil to reverse CQ-resistance.56 Before the year 
2000, several other mechanisms were proposed, including altered CQ uptake or drug efflux 
at the cytoplasmic membrane of the parasite; altered H+ flux or CQ uptake at the DV 
membrane; increased detoxification of the CQ-haematin complex, mediated by glutathione 
S-transferase; and reduced access of CQ to haematin.56,57,58,59 However, Fidock et al.60 
identified a DV transmembrane protein, P. falciparum CQ resistance transporter (PfCRT) as 




the primary determinant of CQ resistance. This was made possible by a detailed analysis of a 
genetic cross between the HB3 (CQ-sensitive) and Dd2 (CQ-resistant) strains where a highly 
interrupted gene, with eight point mutations compared to the wild type, was observed. 
Furthermore, allelic exchange experiments allowed for these mutations to be applied to a 
CQ-sensitive clone whereupon lower CQ activity, chemosensitisation by verapamil and 
reduced CQ accumulation, all the features of resistance, were observed. In particular, the 
K76T mutation, in which the amino acid lysine (K) is substituted by threonine (T) at position 
76 was identified as being central to CQ resistance and has since been used as a molecular 
marker.61,62  A study in 2008 further showed that a fluorescently tagged analogue of CQ is 
able to bind to PfCRT.63 The mutant PfCRT protein has also been claimed to cause an 
increase in the acidity and volume of the DV in resistant strains Dd2 and GCO3/C3Dd2, the 
latter of which is CQ-resistant via transfection with mutant PfCRT. This DV biogenesis was 
demonstrated by Roepe and co-workers64 using fluorescence imaging with spinning disk 
confocal microscopy, allowing for 3D z-stack images of live parasites at different time 
intervals. 
There is also evidence to suggest that other genes contribute to CQ resistance. In particular, 
the Pfmdr1 protein causes important physiological changes in the DV.60,65 These multigenic 
mutations are due to the unrestrictive, widespread and prolonged use of individual drug 
compounds, which put drug pressure on parasite populations.66  
Very recently, in 2015, PfCRT was shown to actively transport CQ across proteoliposome 
membranes from a lower to higher pH, mimicking that of efflux out of the DV.67 The active 
CQ-uptake, measured after one minute, from an environment with a pH of 6 to one with a 
pH of 8, was shown to be enhanced in PfCRT from resistant isolates 7G8 and Dd2 relative to 
the wild type. This was also the case for uptake by PfCRT of the resistance reversal agent, 
verapamil. In addition, the transport of CQ could be inhibited by 25% with verapamil 
concentrations of approximately 100 µM and by 80% at 1000 µM verapamil. The 
observation agreed with that reported in 2009, where both the wild-type and resistant 
forms of PfCRT were expressed at the surface of Xenopus laevis oocytes and showed 
remarkably different CQ uptake levels.68 The efflux mechanism is believed to reduce CQ 
levels in the DV below those required to inhibit haemozoin formation.69   
 




1.7 Mechanism of antimalarial drug action for the quinoline and 
related compounds 
The persistent development of resistance to antimalarial drugs by P. falciparum has led to 
an urgent need for a better understanding of the multiple aspects of the blood-stage 
parasite biology as well as the mechanisms by which antimalarial drugs exert their 
therapeutic action. This has been made possible by the development of techniques for the 
in vitro cultivation of malaria parasites in a laboratory environment, which have become 
vital for determining compound activity and probing their structure-activity relationships 
(SARs). 
 
1.7.1 P. falciparum cell culturing and drug sensitivity assays 
The technique for culturing P. falciparum was established in 1976 by Trager and Jensen70 
and has since been adapted and refined in many versions, optimising oxygen pressure, fluid 
dynamics, nutrient availability, and temperature.71  The red blood cell stage of the parasite’s 
life cycle is now the most widely analysed, since it is during this 48 h subcycle that severe 
malaria symptoms occur.72 In addition, most antimalarial drugs act to inhibit parasite 
growth at this stage. Access to sufficient numbers of infected cells for experimenting is 
made possible by massive parasite multiplication within easily obtainable host human red 
cells. Detecting the parasitised erythrocytes is achieved using Giemsa stain, a common 
technique in use since 190473 which binds specifically to the phosphate groups of DNA, 
allowing for the pink erythrocytes and dark purple parasite cells to be readily distinguished 
(Figure 1.11).  
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Figure 1.11 Geimsa-stained cultures of P. falciparum, showing different phases within the 
erythrocytic stage of the life cycle; a) rings and b) trophozoites and mature schizonts having 
burst just burst from the red blood cell (indicated by arrows). Copyright © 2008, The Society 
for Experimental Biology and Medicine, A. U. Orjih.74 
Techniques for synchronising parasite cultures to the same phase are well established and 
often necessary for experiments sensitive to ratios of rings (Figure 1.11a) and trophozoites 
(Figure 1.11b).72,75 Such a protocol is necessary for dose response experiments to determine 
50% inhibitory concentrations of test compounds. Many variations of drug sensitivity assays 
have been developed over the past five decades, most of them involving radioactive 
substrates, such as [3H]isoleucine, [3H]hypoxanthine and [3H]ethanolamine, to measure 
parasitic growth.76,77,78 Although these methods were reliable, they were very expensive and 
required special handling and hence resulted in the development of alternate procedures. 
One such method is the enzymatic parasite lactate dehydrogenase (LDH) assay reported in 
1993 by Makler et al.79 Another, reported in 2001, detects parasites via a colorimetric highly 
sensitive double-site LDH enzyme-linked immunosorbent assay (ELISA) that recognises 
specific P. falciparum antigens.80 More recently, high throughput assays involving 
fluorescent nucleic acid intercalating dyes, which bind specifically to DNA and allow all 
stages of parasites to be distinguished from the non-DNA-containing erythrocyte, have been 
successfully used to obtain IC50 values comparable to those in other assays.81,82,83 In 
particular, the SYBR Green I-based fluorescence assay has been shown to be a simple, cost-




effective, relatively safe, robust and accurate method for high throughput screening (HTS) to 
identify inhibitors of P. falciparum.84 
 
1.7.2 Nucleic acid and proteins as possible targets of chloroquine  
Early studies on the mechanism of action of CQ revealed its interaction with DNA and toxic 
effect on a wide range of mammalian cells.85 However, the ability of quinolines to inhibit 
DNA replication and RNA synthesis cannot account for their three orders of magnitude 
higher potency against P. falciparum. Nor do the plasmodial enzymes involved in DNA 
replication appear to be direct targets of CQ.86,14 More convincing evidence as to the drug 
target of CQ in the malaria parasite came in 1970 from observations that the drug is only 
active against the erythrocytic stage, particularly while the parasite is degrading Hb.87 It was 
then shown that several quinoline antimalarials directly inhibit the activity of partially 
purified haemoglobin-degrading proteases.88 Inhibition of protein degradation was also 
demonstrated in CQ treated trophozoite-infected erythrocytes, leading to the idea that the 
parasite is killed by subsequent starvation as a result of its inability to feed on Hb.89 This 
protease inhibition process is reversible upon removal of the drug, but the inhibition of 
parasite growth by quinoline antimalarials is irreversible.90,57 This observation was critical 
for concluding that CQ must have more specific, irreversible effects on the parasite.  
 
1.7.3 Haemozoin inhibition 
Studies have shown that a typical red blood cell contains 310–350 mg/mL of Hb and that 
25% to 75% is degraded by the parasite during a 48 h intraerythrocytic cycle.91,92 This results 
in a haem concentration of approximately 20 mM if averaged throughout the red cell. 
However, if concentrated in the DV, which makes up 3-5% of the erythrocyte volume, a 
much larger haem concentration of 200-500 mM would be possible. This massive toxic 
waste problem faced by the parasite is overcome by the formation of haemozoin (Section 
1.4) and is an ideal target for chemotherapy. Indeed, studies in the mid-1990s showed that 
quinacrine treated P. falciparum-infected patients contained gametocytes with reduced 
malaria pigment.14 Furthermore, CQ resistant strains of Plasmodium were reported to 




contain less pigment than the sensitive strains.93 In 1986, Fitch et al.94 proposed that CQ 
interferes with haemozoin formation by forming a complex with haem, after it was shown 
that CQ and haem interact stongly.95 This was then supported by Slater and Cerami in 1992 
when they demonstrated that haemozoin formation in vitro can be inhibited by high 
micromolar concentrations of CQ.96 Since then there has been much debate over the precise 
mechanism by which the inhibition of crystal formation takes place (see Section 1.8.2). 
Before techniques to measure differences in haemozoin and free haem levels within the 
parasite were developed, evidence in favour of this drug target was often obtained by 
attempting to find correlations between synthetic haemozoin (β-haematin) inhibition 
activity and parasite activity. The first study in the early 1990s which endeavoured to find a 
relationship between β-haematin (βH) formation and parasite activity, reported no 
correlation when comparing different quinoline subclasses such as CQ and QN.96 However, 
Dorn et al.97 criticised the trophozoite lysate based method, which this study used to 
promote haematin crystallisation, owing to the nonspecific binding of drugs to cytosolic 
proteins. Instead, they used a radio-labelled [14C]-haemin assay method described in Section 
1.8.5 to carry out correlation analysis on the quinoline antimalarials. A significant correlation 
was identified  between the βH inhibition activity and the CQ-sensitive NF54 parasite 
activity (Figure 1.12) for seven clinical antimalarial drugs, halofantrine (HF), pyronaridine 
(PYR), AQ, CQ, QN, QC, MQ and the experimental bisquinoline, Ro 48-6910.  This was 
remarkable considering the structural diversity of these compounds. Furthermore, although 
HF was the only non-quinoline drug, it fitted the trend established by the quinolines, 
strongly suggesting that haemozoin formation was the target. 
  





Figure 1.12 Correlation of βH inhibition (incorrectly referred to as haematin polymerisation) 
and P. falciparum NF54 activity (r2 = 0.91, P = 0.002) for antimalarials of which seven out of 
eight were quinolines. Copyright © 1998 Elsevier, Dorn et al.97  
 
There is strong evidence to suggest that the physicochemical properties of quinolines, as 
well as the proton gradient between the intra- and extracellular parasite environment 
influences compound concentration within the parasite DV.58,98 This results in different 
accumulation ratios at the site of haemozoin formation, which was first linked to parasite 
activity in the mid-1990s.98 Hawley et al.99 showed that this accumulation parameter was an 
essential factor for correlating βH inhibition to parasite activity, without which, no 
statistically significant correlation was found (r < 0.25;  P > 0.28) using multiple strains of P. 
falciparum, namely the CQ-sensitive 3D7 and HB3, and the CQ-resistant K1 and PH3. The 
cellular accumulation ratio (CAR) for seven quinoline antimalarials was normalised to the 
largest CAR within each strain and then multiplied by the corresponding parasite IC50. Figure 
1.13 shows the resulting relationship between βH inhibition and the accumulation-
normalised CQ-sensitive parasite activity. Interestingly, no significant correlation was found 
for the resistant strain (r = 0.17, P = 0.72) since drug accumulation at the specific target site 
is disturbed by the efflux mechanism in resistant strains, despite the observed accumulation 
of drug in the parasite cytosol.99 





Figure 1.13 Correlation of βH inhibition (inaccurately labelled “heme polymerase”) and the 
accumulation normalised P. falciparum 3D7 activity (r = 0.81, P = 0.026) for known quinoline 
antimalarial drugs. Copyright © 1998, American Society for Microbiology, Hawley et al.99 
 
Another early study to relate the βH and parasite activities of synthetic CQ analogues was 
reported in 1999 by Vippagunta et al.100 Thirteen CQ analogues varying in chain length and 
quinoline substituents were evaluated. In addition, binding constants (Ka), a measure of 
their affinity for haem, were reported. This turned out to be important for SAR analysis 
since a modest correlation was identified when the βH inhibition activity for each analogue 
was normalised to the corresponding strength of haem interaction by dividing the IC50 by Ka 
(r = 0.61, P = 0.046). They reported that knowledge of the accumulation ratios for the 
compounds would have likely improved the correlation statistics; however, no attempt was 
made to determine CARs. Nonetheless, this result was intriguing since it indicated that 
haem binding may have some effect on parasite activity, which may have been as a result of 
its influence on accumulation. 
The second study on this matter that also involved CQ analogues, was reported in 2002 by 
Kaschula et al.101 where measured βH inhibition values were derived from the assay based 
on the differential solubilisation of haematin in Dimethyl sulfoxide (DMSO; see Section 
1.8.5).102 This study reported no statistically significant direct correlation between CQ-
sensitive D10 parasite activity and βH inhibition. Rather, an impressive correlation was 




observed with βH inhibition when the parasite activity was first normalised by multiplying 
the IC50 by the relative vacuolar accumulation ratio (α) for each derivative. The 
accumulation ratio for a specific derivative was based on its pKa values and gave an 
indication of the extent of pH trapping within the DV. To calculate α, this ratio was divided 
by that of CQ to account for the relative amount of pH trapping each compound was 
capable of achieving. Since the substituents of the different derivatives displayed a range of 
electron withdrawing and releasing properties, the basicity of the quinoline nitrogen varied 
significantly between derivatives, resulting in a 10-fold difference in pH trapping ability. 
Consequently, a good correlation between βH inhibition and parasite activity, normalised to 
account for pH trapping in the DV, was observed with an r2 of 0.83 and a P value of 0.0043 
(Figure 1.14).  
 
 
Figure 1.14 a) The synthesised quinoline derivatives and b) structure-activity relationship 
(SAR) trends showing no correlation between the βH inhibition (BHIA50) and the D10 
parasite activity (IC50) and c) an excellent correlation for βH inhibition with the normalised 
parasite activity (IC50 x α). All correlations were carried out with logged values. Reprinted 
(adapted) with permission from Kaschula et al.101 Copyright © 2002, American Chemical 
Society.  
  
Advances in the βH inhibition assay procedure enabled superior correlations (Figure 1.15)  
to be found for these compounds using the biological activity data supplied by Kaschula et 
al.101 This came after the development of the ferrihemochrome method by Egan and co-
workers.103 (see Section 1.8.6). Although no direct correlation between βH inhibition and 
parasite IC50 was previously identified, the improved free haem detection technique gave 
βH IC50 values (Phiβ) which did correlate with parasite activity (r2 = 0.68 and p = 0.0005). 




Furthermore, multiple correlation analysis revealed a relationship whereby a linear 
combination of the βH activity and the vacuolar accumulation ratio (VAR) were capable of 
predicting parasite activity at the 99% confidence level.  
 
Figure 1.15 Correlations for the Kaschula et al.101 quinoline derivatives using the 
ferrihemochrome βH inhibition assay method.103 The parasite activity was related to βH 
inhibition via a) direct correlation or b) multiple correlation analysis with log(1/IC50) = 
0.61*log (1/IC50(Phiβ)) + 0.17*logVAR + 6.98 (r2 = 0.84, F = 21.3; >Fcrit = 8.65 at the 99% 
confidence level), where VAR is the vacuolar accumulation ratio. Copyright © 2005, Elsevier, 
Ncokazi, et al.103 
 
Using the same assay method for βH inhibition, some years later the same group 
synthesised a series of 4-amino-7-chloroquinolines with dibenzylmethylamine (dibemethin) 
side chains, which were also shown to exhibit a correlation with biological activity against 
the parasite.104 Here, several interesting trends were observed, although no statistically 
significant correlations were identified directly relating βH inhibition to either the parasite 
activity or the accumulation normalised activity. An additional parameter, pos, was defined 
to account for the position (ortho, meta or para) of the aminoquinoline group on the 
dibemethin phenyl ring. This enabled a good multiple linear correlation of log IC50 with the 
accumulation ratio, log βHIC50, and pos at the 95% confidence level.  
Similar trends have also been observed for non-quinoline compounds. In 2002, several 
phenothiazines were shown to be good βH inhibitors, although only a subset of them 
displayed potent antimalarial activities. In addition, the βH IC50 values were not able to 
predict the relative parasite growth inhibition activities on the basis of different levels of 




uptake, reported to be a combination of haem binding and pH trapping.105 A series of 
xanthones with side chains ranging from two to eight carbon atoms in length were reported 
to show a correlation between the haem binding constants and D6 (CQ-sensitive) parasite 
activity (Figure 1.16).106 This result was intriguing in light of the results reported by 
Vippagunta et al.,100 which required the division of βH inhibition values by haem binding 
constants to achieve a significant correlation with the parasite IC50. These studies suggested 
a possible connection, the particulars of which are unknown, between these two features, 
namely haem binding and in vitro parasite activity.  
 
 
Figure 1.16 Correlation of CQ-sensitive D6 antimalarial potency (IC50) versus haem binding 
affinity (Ka) for the 3,6-bis-ω-N,N-diethylaminoalkoxyxanthones. Copyright © 2002, 
American Society for Microbiology, Kelly et al.106 
 
Recently, numerous reports detailing correlations between βH inhibition and parasite 
activity have been published for neocryptolepines and isocryptolepines. Lu et al.107 reported 
a very weak correlation between the log of NF54 activity with the βH activity (Figure 1.17a), 
showing that the biological activity of a compound depends on more factors than its ability 
to inhibit haemozoin, if this is indeed the target. In fact, the parasite activity could be well 
correlated using multiple physicochemical parameters such as the mean water of hydration 
(H2O.hyd), polar surface area (PSA) and number of hydrogen bond donating atoms (HBD) by 
log(NF54IC50) = -0.299(H2O.hyd) + 0.028(PSA) - 0.652(ln(HBD)) + 3.108 (r2 = 0.904, P < 
0.0001), which was statistically significant at the 99% confidence level (Figure 1.17b). 
Further analysis of this equation revealed that a balance between the hydration and polarity 




of a molecule must be established for good biological activity. This was also the case in a 
study by Wang et al.108 for N-6-Me-neocrytolepines. A statistically significant correlation was 
observed for a four-parameter model involving solubility (Sol), H2O.Hyd, logP and the square 
of the dipole moment (μ2) as log(NF54IC50) = 0.302(Sol) − 0.188(H2O.hyd) + 0.446(log P) + 
0.002(μ2) − 4.670, (r2 = 0.940, P < 0.0001), statistically significant at the 99% confidence level 
(Figure 1.17c). Although this specific correlation did not involve βH inhibition, a good 
correlation between the log of the βH inhibition and the log of the NF54 parasite activity 
was observed when only the five compounds with basic amino side chains were considered 
(Figure 1.17d). This result indicated that activity against the parasite is strongly influenced 
by the ability of a compound to inhibit haemozoin formation, at least for those that are able 
to accumulate in the DV through pH trapping. Yet another study, this time involving 
isocryptolepine analogues, showed correlations between βH inhibition and NF54 activity, 
albeit weak (Figure 1.17e).109 In addition, the statistics could be improved by incorporation 
of physicochemical parameters, namely solubility (sol.) and percentage hydrophilic surface 
area (%hydrophil.) so that log(NF54IC50) = 0.193(Sol.) - 0.027(%Hydrophil.) - 
10.069(1/βHIC50) - 2.208, r2 = 0.61, P < 0.0001, statistically significant at the 99% confidence 
level (Figure 1.17f). This result was in agreement with the trend found previously by Wang 
et al.,108 again reflecting the balance of  properties relating to hydration and polarity for 
optimum parasite activity. Upon hybridisation of the isocryptolepines with artesunate, no 
correlations between βH inhibition and parasite activity could be found.110 In fact, the 
hybrid derivative with the lowest βH activity exhibited the highest antimalarial activity. This 
result further confirmed the disconnection between the IC50 values from the extracellular 
βH assay and intracellular parasite growth assay.  





Figure 1.17 Correlations reported for neocryptolepines and isocryptolepines. (a) a very weak 
correlation between the log of NF54 activity with the βH activity (r2 = 0.43, P = 0.001) and 
(b) multiple correlation analysis to give log(NF54IC50) = -0.299(H2O.hyd) + 0.028(PSA) - 
0.652(ln(HBD)) + 3.108; (r2 = 0.904, P < 0.0001) statistically significant at the 99% confidence 
level. Reproduced from Lu et al.107 Copyright © 2013, Elsevier. (c) Multiple correlation 
analysis to give log(NF54IC50) = 0.302(Sol) − 0.188(H2O.hyd) + 0.446(log P) + 0.002(μ2) − 
4.670; (r2 = 0.940, p < 0.0001) statistically significant at the 99% confidence level and (d) a 
good correlation between the βH inhibition and the NF54 parasite activity only observed for 
compounds with basic amino side chains (filled circles). Reproduced from Wang et al.108 
Copyright © 2013, The Pharmaceutical Society of Japan. (e) A weak correlation between βH 
inhibition and NF54 activity (r2 = 0.41, P < 0.0001) and (f) multiple correlation analysis to 
give log(NF54IC50) = 0.193(Sol.) - 0.027(%Hydrophil.) - 10.069(1/βHIC50) - 2.208; (r2 = 0.61,  
P < 0.0001) statistically significant at the 99% confidence level. Reproduced from Wang et 
al.109 Copyright © 2014, Elsevier.  
 




In 2006, the effect of CQ on haemozoin levels within live erythrocytic parasites was 
observed using spinning disk confocal microscopy by Roepe and co-workers.111 By 
measuring pixel density in 3D differential interference contrast transmittance z-stack 
images, haemozoin production at various time intervals and concentrations of CQ were 
measured. While CQ did not affect the initial rate of haemozoin formation at 15 to 22 h, it 
was found to restrict the normal haemozoin levels reached at 27 to 29 h in a dose 
dependent manner for both CQ-sensitive HB3 and CQ-resistant Dd2 strains at the relevant 
IC50 (Figure 1.18). The addition of a resistance reversal agent, verapamil, resulted in 
haemozoin inhibition at the lower HB3 IC50 in the Dd2 strain. Furthermore, preformed 
haemozoin was not destabilised, even at high CQ concentrations, for either strain. 
 
Figure 1.18 A linear relationship between the percent haemozoin inhibition and the percent 
parasite growth inhibition for the CQ-resistant Dd2 (black markers) and CQ-sensitive HB3 
(white markers) strains without verapamil (squares), with verapamil (triangles) or with a 
combination of CQ and verapamil (diamonds). Reprinted with permission from Gligorijevic 
et al.111 Copyright © 2006, American Chemical Society. 
 
In 2010, a series of CQ analogues containing resistance reversal-like moieties were 
synthesised and shown to overcome CQ resistance.112 Upon testing βH inhibition IC50 values, 
a correlation with parasite growth inhibition was observed with r2= 0.66. More suggestively, 
two potent compounds, 1 and 22 (Figure 1.19), were shown to cause a decrease in 
haemozoin formation in parasites. The haemozoin was isolated from lysed parasites by 
centrifugation and washing and then quantified via dissolution in 0.2 M sodium hydroxide 




solution and UV-vis absorbance measurements at 400 nm. After normalisation to account 
for the haematocrit and parasitaemia, a per parasite concentration of haemozoin was 
plotted versus the concentration of drug (Figure 1.19a), clearly revealing a concentration 
dependent reduction in haemozoin. This was also demonstrated using microscopy, where 







Figure 1.19 a) Haemozoin production in D6 and Dd2 parasites with varying concentrations of 
CQ and resistance reversal analogues 1 and 22; b) microscope images showing a reduction 
of haemozoin in the DV in the presence of CQ, 1 and 22 relative to the control for the D6 
strain (top) and little or no haemozoin for the Dd2 strain in the presence of 22 (bottom). 
Reprinted with permission from Burgess et al.112 Copyright © 2006, American Chemical 
Society. 




Studies that demonstrate a reduction of haemozoin in P. falciparum whole cells with test 
compounds, while supporting haem detoxification via haemozoin formation as the 
mechanism of action, do not conclusively validate the target, as diminished quantities of 
haemozoin may result from reduced Hb uptake or digestion, which would also result in less 
free haem. A more convincing experiment was reported more recently by Combrinck et 
al.,113 where cell fractionation was used to directly measure both the amount of haemozoin 
and free haem in cultured P. falciparum whole cells. They reported a dose-dependent 
decrease in haemozoin and a simultaneous increase in toxic free haem in the presence of 
known quinoline antimalarial drugs. Furthermore, the dose-response curve for the increase 
in free haem as well as that for parasite survival crossed over at their respective 50% 
inhibitory concentration (IC50) values, confirming a correlation between these two events. 
They also showed that the antifolate pyrimethamine and its combination with sulfadoxine 
do not inhibit cellular haemozoin formation, as expected. In particular, CQ showed the 
largest effect in the free haem to haemozoin ratio at three times its IC50 (Figure 1.20). This 
study provided direct evidence in support of haemozoin inhibition as the mechanism of 
action of CQ. 
  











Figure 1.20 The effect of CQ on a) % haemozoin, b) % free haem and c) % parasite survival 
overlaid with % free haem. SP specifies the negative control, sulfadoxine/pyrimethamine, P 
represents pyrimethamine and asterisks indicate statistical significance relative to the 
control (2-tailed t-test): *P < 0.05; **P < 0.01; ***P < 0.001, n = 3. Copyright © 2013, 
American Chemical Society, Combrinck et al.113 
  




1.7.4 Accumulation of quinoline antimalarials in the DV 
In the 1970s, many papers were published revealing the extraordinary ability of malaria 
parasites to accumulate CQ,114 AQ,115 QN116 and QC.117 In 1974 Fitch et al.52 showed that the 
accumulation of CQ is sensitive to the pH gradient between the DV and the extravacuolar 
environment by varying the pH of the latter. A decade later, Yayon et al.51 determined the 
internal pH of the subcellular compartments of P. falciparum within the RBC. The DV, where 
sequestering of toxic free haem takes place, was determined using fluorescent probes to 
have an acidic pH of ~5. A year later they reported high pH-dependent accumulation levels 
of CQ in the DV, investigated by flow dialysis, in which diffusion across a membrane can be 
measured118 as well as the tracing of CQ via fluorescence or a 14C labelled analogue.119 
Millimolar concentrations of CQ were predicted to exist in the DV at therapeutic doses, 
accounting for the high activity of the drug.  In the 1990s, more sophisticated methods 
allowed the proton gradients to be varied, by decreasing the extravacuolar pH with the 
acidifying agent NH4Cl or via inhibitors of vacuolar proton pumps.120,121 Accumulation 
measurements under these conditions showed that lowering the external pH results in less 
accumulation and hence these studies concluded that CQ accumulates in the acidic DV as a 
result of its weak base properties. This pH-dependent accumulation can be explained via the 
phenomenon of pH trapping, whereby a neutral species passively diffuses into the acidic DV 
and is protonated to form a less lipophilic (lower logD) charged species, which is then 
unable to cross the membrane. CQ, which has two protonatable sites, namely the quinoline 
nitrogen (pKa1 = 8.4) and diethylamino moiety (pKa2 = 10.1), exists almost entirely as the 
diprotonated species (CQH22+) at a pH of 5.122 Neutral CQ can diffuse into the DV where it 
will become protonated and trapped, with a lower intravacuolar concentration of neutral 
species present. Since equilibrium requires equal concentrations of the neutral species (CQ) 
both intravacuolarly and externally, more CQ will diffuse in, until concentrations of the 
neutral species are equal. The great majority of the available drug will exist in the DV as the 
CQH22+ species (Figure 1.21).123 
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Figure 1.21 Representation of CQ pH-based accumulation (non-saturable uptake) in the 
acidic DV (red) from the neutral extravacuolar environment (blue). In a) neutral drug 
diffuses from high to low concentration, after which equilibrium is established in b) with the 
diprotonated species (CQH22+) existing in a large excess, trapped in the DV.  
The principle of pH trapping has also been reported to account for the accumulation of 
other quinoline antimalarials since they all possess two basic atoms.124 However, in 1996 
Hawley et al.98 measured the accumulation of AQ analogues with varied side chains, 
possessing a range of pKa values and lipophilicities. They found that experimental 
accumulation ratios were much greater than those calculated theoretically based on drug 
pKa, compartmental pH, and Henderson-Hasselbach considerations. Later experiments by 
the same group showed that a saturable uptake of CQ, possibly due to haem binding, is 
responsible for the large accumulation observed.59 This was identified after the availability 
of free haem was blocked via a specific inhibitor of Hb digestion and a concentration 
dependent reduction in CQ-binding sites was demonstrated. This saturable uptake 
completely accounted for the reduced CQ activity and accumulation in CQ-resistant strains 
as well as the reversal of resistance by verapamil (VP) as shown in Figure 1.22. In addition, 
erythrocyte ghost cells, loaded with Fe(III)PPPIX, could model this saturable CQ binding and 
was dependent on the Fe(III)PPIX concentration.125  





Figure 1.22 The CAR of CQ versus the inverse IC50 in three CQ-sensitive strains (HB3, 3D7 
and T9-96) and three CQ-resistant strains (K1, TMS5 and TMS6) with and without verapamil 
(VP). Copyright © 1998-2010, Molecular Pharmacology Online, Bray et al.59 
 
Although the non-saturable binding from pH trapping only accounts for 5-12% of the total 
observed accumulation, a review in 2001 by Egan noted that without this factor, the CAR of 
CQ would be negligible.123 This is due to the fact that, in the absence of pH trapping, the 
concentration of CQ in the DV would be equivalent to the external concentration, which for 
CQ at its IC50 is ~20 nM. At this low concentration, an insignificant amount of CQ-Fe(III)PPIX 
complex is able to form based on the measured Fe(III)PPIX binding constant (K) of CQ of 3.3 
x 105 M-1 and a free haem concentration ([Fe(III)PPIX]) of 20 µM (Eq. 1.1). Therefore, 
Fe(III)PPIX binding, which accounts for the majority of the cellular accumulation, requires pH 
trapping to achieve a sufficient drug concentration to form a Fe(III)PPIX-CQ complex in the 
DV.123 
𝐾 =  
[𝐶𝑄−𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]
[𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋][𝐶𝑄]
         Eq. 1.1 
 
  




1.8 Haemozoin and β-haematin 
Although malaria pigment, now known as haemozoin, has been studied for centuries, the 
exact mechanism by which it forms and by which its formation is inhibited, remains 
unknown. Given that many successful antimalarials act by inhibiting this process, there has 
been much research interest surrounding ferriprotoporphyrin IX (Fe(III)PPIX), the structure 
of haemozoin and techniques for producing haemozoin extracellularly, over the past several 
decades.   
 
1.8.1 The structure of haemozoin and β-haematin 
In 1717, an Italian physician, G. M. Lancisi reported a brown discolouration of the liver, 
spleen and brain of patients infected with malaria.126 However, it was more than a century 
later that this dark brown pigment was connected to malaria infections, after being found 
by the German anatomist, J. H. Meckel, in the blood and spleen of a mentally ill 
patient.127,128 The structural identity of malaria pigment remained unknown for over six 
decades. Originally proposed to be melanin, the pigment was identified as being of 
haematin origin in 1911 by W.H. Brown.129 However, it was believed that it could not be 
pure haematin, but rather a Fe(III)PPIX-protein complex.130 Until the late 1980s, the general 
belief was that the parasite detoxified haem into a crystalline complex with a specially 
synthesised protein, as the purest preparations of malaria pigment contained a glycine-rich 
polypeptide.131  
In 1987, isolation of pure haemozoin from mouse erythrocytes infected with Plasmodium 
berghei NYU-2 parasites was achieved by Fitch and co-workers, via extensive washing.132 
The necessary removal of both protein and lipid contaminants was carried out by 
breakdown of the crude material with a non-specific protease and extraction in chloroform/ 
MeOH respectively. The pure material was much less soluble and contained a lower 
percentage of oxygen than that of haematin purchased from Sigma. Soon after, Slater et 
al.133 revealed further structural details via characterisation of haemozoin using a range of 
spectroscopic techniques and by comparison with synthesised haemozoin, βH. An 
absorbance peak at about 650 nm was observed in both the synthesised and parasite-
extracted haemozoin, characteristic of an aqueous suspension of the intact substance which 




had been reported previously by Fitch et al.132 Furthermore, the elemental composition 
data for βH was similar to haemozoin and also consistent with the previous report. 
Solubilising haemozoin in 0.1 M NaOH resulted in UV-vis absorbance and mass spectrum 
(MS) data, which were identical to haematin, confirming that haemozoin was closely related 
to haem, without a protein component. However, the chemical structure was elucidated 
when Fourier-transform infrared (IR) spectroscopy showed that the chemical nature of the 
haem carboxylate groups was significantly different for haematin and haemozoin. 
Specifically, characteristic IR bands from the C=O and C-O stretching frequencies, specifically 
assigned to a carboxylate coordinated to a ferric ion with characteristics very similar to 
unidentate acetate coordination, were observed in the haemozoin spectrum but not the 
haematin spectrum. This suggested that haemozoin involved direct coordination between a 
propionate of one haem and the iron (Fe) centre of another. Extended X-ray absorption fine 
structure (EXAFS) spectroscopy, which determines the local environment of a metal centre, 
was another technique used to characterise haemozoin. The data showed that the atom 
type and atom distances in the local environment of the iron centres in haematin and 
haemozoin differed significantly. The combined data strongly suggested that an iron-
carboxylate linkage between two adjacent haem molecules allowed monomers to aggregate 
into an insoluble product, although this was originally thought to form a polymer (Figure 
1.23a).133 In fact, this was not the only misconception regarding the structure of haemozoin 
in the early 1990s. Electron spin resonance (ESR) spectroscopy, which analyses spin state 
and charge, had led to the mistaken conclusion that the central atom in haemozoin was a 
low-spin ferric iron (Fe(III)), and was only corrected when Bohle et al.134 convincingly 
demonstrated that it is the high-spin Fe(III) species that is present in haemozoin. This was 
achieved using electron paramagnetic resonance (EPR) and Mőssbauer spectroscopy 
measurements, which were in agreement. The same group also showed, via powder X-ray 
diffraction (PXRD) patterns, that haemozoin is a microcrystalline material belonging to a 
centrosymmetric space group and is identical to βH.135 This crystallographic data suggested 
that the haem units form antiparallel polymer chains, which hydrogen bond via propionate 
groups (Figure 1.23b). However, at the turn of the century, this proposal was also 
invalidated when Pagola et al.136 analysed PXRD data obtained with synchrotron radiation 
by Rietveldt refinement enabling the crystal structure of βH to be solved. Instead of 
interacting polymer chains, a dimer pair was identified in a single unit cell. Two dimer pairs 




form a hydrogen bond via the propionate group of one Fe(III)PPIX molecule from each 
dimer. These interacting units then stack via π-π interactions, resulting in 3-dimensional βH 
crystal (Figure 1.23c). Furthermore, given the chemical, spectroscopic133 and 
crystallographic135 evidence that βH is identical to haemozoin, these updated structural data 
were justifiably also valid for intracellular haemozoin.  
 





c)                                             
 
Figure 1.23 Evolution of the proposed structures of haemozoin showing a) a polymer b) the 
centrosymmetric polymer chains connected via hydrogen bonds and c) interacting dimers.  
  




1.8.2 The mechanism of haemozoin formation 
It is well accepted that the formation of haemozoin takes place in the acidic DV in order for 
the malaria parasite to avoid the toxicity caused by oxidative stress from liberated free 
haem. However, the exact mechanism by which haemozoin is formed remains elusive 
despite the proposal of several hypotheses including enzyme catalysis,96 protein mediated 
formation,137,138 spontaneous formation,139 autocatalysis140 or lipid mediated formation.141-
143 Haemozoin crystal formation mediated by lipids has recently received the most attention 
owing to strong evidence for this process. A recent study tested the feasibility of haematin 
crystallization from solutions that mimic either the aqueous phase or the lipid structures in 
the DV and found both aqueous and amphiphilic organic solvents to be crucial for formation 
of βH crystals with similar morphology to that of haemozoin.144 Furthermore, haemozoin 
crystals, contained in nanosphere lipid droplets, have been observed during the trophozoite 
stage of the parasite using transmission electron microscopy (TEM) as shown in Figure 1.24a 
and 1.24b.145 Lipid associated with haemozoin was found to be made up of several fatty acyl 
glycerides including monostearic, monopalmitic, dipalmitic, dioleic and dilinoleic glycerols 
which when extracted, individually mediate βH formation. Hydrogen bonding between the 
Fe(III)PPIX propionate groups is favoured in a lipophilic environment and this has been 
proposed as the reason why the crystallisation process occurs at these hydrophobic sites.  
Recently, emulsions of monopalmitoylglycerol (MPG) and of a neutral lipid blend (NLB), 
consisting of MPG, monostearoylglycerol (MSG), dipalmitoylglycerol (DPG), dioleoylglycerol 
(DOG) and dilineoylglycerol (DLG) in a 4:2:1:1:1 ratio, have been shown to form droplets of 
varying size which control the βH crystal size during βH formation.146 The specific 
composition of the NLB was chosen to mimic that associated with haemozoin isolated from 
P. falciparum. Under conditions of temperature, pH and ionic composition that mimic the 
parasite DV, kinetic studies demonstrated the efficiency of the NLB in mediating this 
process.147,148,149 Crystals were found at the surface of the lipid droplets with the {100} 
crystal face in contact with the lipid, which supported the hypothesis that the neutral lipid 
surface acts as a template for βH crystal growth (Figure 1.24c).  
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Figure 1.24 a) TEM of an early stage trophozoite showing haemozoin contained within 
neutral lipid nanospheres and b) Mature trophozoite containing larger crystals inside neutral 
lipid spheres within the parasite DV. Copyright © 2007, The Biochemical Society, Pisciotta et 
al.145 c) The surface of a MPG lipid droplet as a template for βH crystal growth. Reprinted 








1.8.3 The mechanism of haemozoin inhibition 
Despite much research interest into the haemozoin inhibition mechanism, the specific way 
in which haemozoin-inhibiting drugs cause an increase in free haem and a decrease in 
haemozoin formation remains uncertain.150 Elucidation of the inhibition process, especially 
for the quinoline antimalarials, would greatly assist with rational drug design. The inhibition 
of synthetic haemozoin (βH) by CQ and other 4-aminoquinolines has been studied 
extensively. This is despite the widespread resistance to these drugs, since there is no 
indication of modifications to haemozoin formation as the drug target.68 Furthermore, the 
target on which they act is uniquely attractive since the biochemistry within the parasite is 
sufficiently different to that of the human host.18 In 1992, Slater and Cerami proposed that 
CQ and QN inhibit a haem polymerase enzyme, blocking the formation of haemozoin.96 
However in the absence of trophozoite lysate, CQ was also able to inhibit βH formation and 
isolation of the haem polymerase enzyme was never achieved.18,139 It was thus established 
that haemozoin crystal growth is a physio-chemical process and not enzyme-mediated, 
although proteins and/or lipids may be involved with initiation of the process in vitro.140,151-
153 In 1995 this led to the conclusion that CQ inhibited haemozoin formation by binding to 
monomeric haematin.140 However, shortly after, it was conversely reported that quinoline 
antimalarials bind primarily to the µ-oxo dimer and not the monomeric form of haematin, 
leading to the hypothesis that a shift in equilibrium reduces the monomeric haematin 
available for haemozoin formation.97  The formation of the µ-oxo dimer was confirmed very 
recently in 2014, when it was shown that CQ induces its formation at both the 
physiologically relevant pH 7.5 and at pH 5, to mimic that of the DV.150 Furthermore, a 
complex with 2:4 CQ:Fe(III)PPIX stoichiometry in aqueous solution was observed using 
magnetic susceptibility, UV-visible absorption, magnetic circular dichroism (MCD) and 
diffusion techniques. Although this µ-oxo dimer complex likely forms as a result of the free 
haem concentration increase when haemozoin is inhibited, there is uncertainty regarding 
whether it is responsible for the inhibition process. In fact, Pagola et al.136 suggested that 
the interaction of CQ with haematin cannot account for haemozoin inhibition since 
haematin is present at considerably higher concentrations than CQ in the DV. Studies which 
are consistent with this suggestion, report that either quinoline-haem complexes can be 
incorporated into haemozoin to terminate growth137 or that the drug can intercalate 




between the planar iron porphyrin groups on the smallest visible and hence fastest growing 
crystal face to inhibit its growth. The second hypothesis was proposed by Leiserowitz and 
co-workers.154 based on the powder-crystal structure of βH.136 This computational study 
modelled the structure of the haemozoin crystal, allowing CQ to be manually docked into 
the highly corrugated structure of the fastest-growing face, where it presented a convincing 
fit with the surface. This study was also able to explain previously unexplained findings, such 
as the need for the 7-chloro and the 4-amino groups for the βH inhibition activity of CQ. This 
extends to other quinoline antimalarials as well, since the diastereomer of QN, 9-epiquinine, 
and primaquine, which are both βH inactive were shown either to dock with the haemozoin 
crystal surface only by adopting a strained conformation or to be incapable of docking at all, 
accounting for their lack of inhibition activity. Very recently, another study demonstrated 
four surface binding sites on the haemozoin crystal which could accommodate a haemozoin 
inhibiting molecule, using atomic force microscopy.144 They further showed that CQ adsorbs 
onto the terraces between haemozoin growth steps on the {100} crystal face. As a result, 
the mechanism whereby an inhibitor binds to the haemozoin crystal surface to restrict 
solute addition currently appears to be the most successful hypothesis.113,155   
 
1.8.4 Crystal structures of drug-haem complexes  
Although the reduction in haemozoin in the presence of an inhibitor is now believed to be 
as a result of crystal surface adsorption, as opposed to drug-haem complexation in solution, 
several attempts have been made to evaluate the specific interactions between Fe(III)PPIX 
and the quinoline antimalarials.156 In 2008, de Villiers et al.157 reported the first crystal 
structure for a complex of Fe(III)PPIX with an antimalarial drug, in this case, HF (Figure 
1.25a). The structure, obtained by single crystal X-ray diffraction, revealed coordination of 
the hydroxyl group of HF to the Fe(III) centre and a π-π interaction between the 
phenanthrene ring and the porphyrin (Figure 1.25b). This allowed the authors to proposed 
structures for the cinchona alkaloids, QN, QD and their disastereoisomers, 9-epiquinine and 
9-epiquinidine in order to explain their relative βH activities. This was justified by the 
similarity of the UV-vis absorbance spectra of Fe(III)PPIX complexed with HF or QD, 
indicating comparable interactions. Their suggested structures were validated in 2012, when 
Gildenhuys et al.158 reported single crystal structures of QN and QD complexed with 




(Fe(III)PPIX). The observed interactions which gave rise to activity encouraged the authors to 
suggest a pharmacophore scaffold for the aryl methanol compounds which contains three 
components; a secondary alcohol capable of Fe(III) coordination, an inflexible tertiary amine 
for hydrogen bonding and a fused aromatic ring system for π-π stacking interactions (Figure 
1.25c). Knowledge of these key features for strong haem binding have potential to aid in 








Figure 1.25 a) The structure of HF, b) the single crystal structure of Fe(III)PPIX-HF, Copyright 
© 2008 Elsevier Inc, de Villiers et al.157 and the c) the single crystal structure of Fe(III)PPIX-
QD, Copyright © 2012, American Chemical Society, de Villiers et al.158 
 
1.8.5 βH inhibition assays 
The continuous search for new antimalarials requires improved methods for identifying 
active compounds. In particular, target-based drug discovery demands assays which are 
efficient and which mimic the biological environment appropriately. Several assays for 
inhibition of βH have been developed. The first, reported by Egan et al.139 in 1994 was a 
qualitative assay in which infrared spectroscopy was used to confirm the presence of free or 
crystallised haematin based on characteristic peaks. Here, the βH was formed in solution 
containing a high-concentration of acetate buffer, however, the amount of βH formed could 
not be quantified.139 Another assay also used this method for crystal formation, but 
detection was via the differential solubilisation of haematin and haemozoin in DMSO and 
the assay required a long 18 h incubation period.102 Dorn et al.140 reported the formation of 
βH in lower concentrations of acetate buffer and used radio-labelled haematin which could 




be incorporated into preformed haemozoin and then quantitatively determined using 
scintillation counting. Kurosawa et al.159 and Sullivan et al.137 also employed radio-labelled 
haematin, however this method suffers many disadvantages such as requiring skills, special 
equipment and resources that are limited in most laboratories as well as being expensive 
and subject to legal restrictions in some countries. Other methods to initiate crystal 
formation involved trophozoite lysate,96 purified βH140 and a combination of acetonitrile 
extracts of trophozoite lysate and βH.140,141,159 
Until 1999, these assay methods for βH inhibition did not account for the possible role of 
lipids in haemozoin formation.141,142 Thereafter, assays utilising lipids and detergents for the 
formation of βH were reported, the first by Fitch et al.143 since replicating the acidic and 
hydrophobic environment of the DV in vitro is less demanding with the these mediators.160 
Initially, detection of crystallisation was made possible via the differential solubility of 
haematin in aqueous sodium dodecyl sulfate (SDS) solution.143,105 While the neutral lipid 
blends had been shown to promote crystal formation in vitro, they were comparatively 
expensive and involved time-intensive preparation.161 As a result, mimetics of lipid 
mediators, in the form of surfactants, were employed to promote formation of βH in an 
efficient manner, after the individual components of the blend were shown to mediate βH 
formation to some extent.145 
“Surfactant” is an abbreviation of surface-active agent. Examples include detergents, 
dispersants, foaming agents and emulsifiers. They are able to lower the minimum energy 
required to create an interface (interfacial free energy) within a system of immiscible phases 
as they adsorb onto the interface of that system, decreasing the surface tension. 
Amphiphilic surfactants characteristically consist of both a hydrophobic tail group and a 
hydrophilic head group which can either be anionic, cationic, non-ionic or zwitterionic. A 
zwitterionic detergent is neutral overall owing to oppositely charged chemical groups (eg. 
+1 and -1) which form the head group. In water, the system acts by minimising contact 
between the hydrophilic water molecules and the hydrophobic tail groups of the surfactant. 
The result is a layer of specifically oriented surfactant molecules at the surface of the water, 
with the hydrophilic groups pointing into the aqueous phase and the hydrophobic tail 
directed away.162 Surfactants can also form spherical aggregates known as micelles above 
the critical micelle concentration (CMC) which varies with surfactant type, temperature, 




pressure and the presence of other substances.163 The surface of the micelle consists of the 
hydrophilic head groups in contact with the aqueous phase, while the tail groups make up 
the internal structure of the sphere where they are shielded from water molecules.  
In 2007, Huy et al.164 used the detergent TWEEN® 20 to mediate βH formation in their 
inhibition of haem crystallisation assay, which was designed for HTS. This was an important 
simplification of the assay as it reduced the incubation time to 4 h and was much cheaper 
than the neutral lipid blend while producing relatively similar quantities of βH under the 
same conditions. The shortcoming for this assay was in the IC50 values of known βH 
inhibitors that were ~10 fold higher for CQ when compared with the values for the neutral 
lipid blend mediated assay. This result demonstrated that TWEEN® 20 was not the most 
accurate lipid blend mimic. 
Optimisation of the detergent-mediated assay was reported by Carter et al.160 in 2010 in 
which the Nonidet P-40 detergent (NP-40) was determined to be the closest imitator of the 
NLB, resulting in the largest yield of βH crystals. In addition, an assay for haemozoin 
inhibition with the known inhibitors CQ and AQ gave comparable IC50 values when using the 
NLB and NP-40. These authors studied a variety of lipophilic mediators, differing in chemical 
structure and ionic character, in order to optimise the platform for βH formation. 
Specifically, the detergents investigated included Triton™ X-100, NP-40, TWEEN® 20 and 
TWEEN® 80, which are non-ionic and the zwitterionic and anionic detergents, CHAPS and SDS 
respectively. Using ratios of the CMCs for each detergent, the appropriate initial assay 
concentration could be approximated by comparison with the TWEEN® 20 concentration 
employed by Huy et al.164 Firstly, the detergents were tested for their ability to nucleate 
crystal growth and the βH products characterised by infrared spectroscopy (characteristic 
stretches at 1664 cm-1 and 1211 cm-1) and powder X-ray diffraction. Those that successfully 
produced βH which matched that of the Bohle dehydrohalogenation βH product, namely 
TWEEN® 20, TWEEN® 80 and NP-40 (≥69% yields), were subjected to concentration dose 
response experiments using known haemozoin inhibiting antimalarial drugs.165 The anionic 
and zwitterionic detergents were ineffective mediators since they did not mimic the 
hydrophobic nature of the lipids as well as the non-ionic detergents. Overall NP-40 was 
found to be the most suitable detergent since it gave a similar βH yield to the lipid blend 
and comparable IC50 values for AQ and CQ as shown in Table 1.1. The NP-40 concentration 




was varied and the amounts of βH produced under assay conditions were plotted (Figure 
1.26), showing an optimised concentration of 30.6 μM. In contrast, the neutral lipid blend 
was highly efficient at promoting βH formation over a wide concentration range, 
demonstrating the importance of optimising the lipophilic mediator concentration.  
Table 1.1 Data collected by Carter et al.160 for lipophilic mediators of βH formation. NP-40 as 
a mediator was shown to give a good βH yield and IC50s of the standards compared well to 











Neutral Lipid Blend 50 75 23.07 85.26 
NP-40 30.6 74 25.73 50.99 
TWEEN® 20 9.77 71 316.3 262 
TWEEN® 80 14.9 69 201.8 195.7 
SDS 1140 10 225.4 245.6 
Triton™ X-100 58.6 7.4 N/A N/A 
CHAPS 1466 7.0 N/A N/A 
 
a) a)       b) 
  
Figure 1.26 a) The NLB forms βH with similarly high yields over a range of concentrations 
and b) the NP-40 detergent forms the maximum amount of βH at 30.6 μM. Copyright © 
2014 Bentham Science, Cater et al.160 
 




The development of the NP-40 assay was intended for use in HTS in order to identify novel 
βH inhibiting compounds. In such a project, both synthetic and natural products including 
organic and inorganic molecules are typically screened. It is therefore a requirement that 
the βH inhibition assay can be applied to compounds with a wide range of physical 
properties. These properties include logP, PSA, hydrophobic surface area and hydrogen 
bond donor/acceptor parameters which all contribute to the solubility of the compound. 
Since not all compounds are water soluble, a study was carried out in order to evaluate 
assay performance with possible interfering solvents at varying concentrations. Several 
chelating agents, thiol groups, pigments and media extracts were also assessed to increase 
confidence that a “hit” in the HTS was not a result of a common interferent. 
 
1.8.6 Detecting the formation of β-haematin 
Identifying compounds which inhibit the formation of βH requires a method for detecting 
either the amount of βH crystals formed or the amount of non-crystallised free haematin 
remaining. There are several techniques for characterising βH, although many are not 
appropriate for HTS. One such method is IR spectroscopy,166 which not only requires 48 h of 
drying time but also does not quantitatively measure βH formed, as is the case with 
elemental analysis and X-ray powder diffraction, other detection techniques used in the 
1990s.166 In 1996, Sullivan et al.137 reported a method for measuring the amount of βH 
formed. The process required several repetitions to purify the βH crystals via centrifuging 
and washing with 2.5% sodium dodecyl sulfate (SDS) buffered with 0.1 M sodium 
bicarbonate (pH 9.1). The purified βH then had to be dissolved in 0.1 M NaOH and the UV-
vis absorbance read at 400 nm after which the extinction coefficient of 105 could be used to 
determine the haematin concentration. This was a very time consuming and large-scale 
process making it unsuitable for HTS. Later in 2000, Parapini and co-workers102 published a 
technique for quantifying haematin, which took advantage the ability of DMSO to dissolve 
haematin but not βH. The absorption of the haematin solution was then measured against a 
standard curve for concentration analysis. The disadvantage of this technique was the time 
consuming overnight reaction and double centrifugation steps. A solution to the problem 
was developed four years later by Ncokazi and Egan103 using an established method for 
formation of a ferrihemochrome complex.167 The method involved the addition of pyridine 




which forms a low-spin complex with haematin but not with βH. They monitored the 
absorbance spectrum of the pyridine-Fe(III)PPIX complex at 405 nm and found that the 
Soret band increased in intensity, sharpened and shifted from 389 to 404 nm (Figure 1.27a). 
This indicated a change in the speciation of the haematin which is initially in an aggregated 
state, since it forms a dimer in aqueous medium and then becomes monomeric with the 
addition of pyridine.168 This monomerisation is useful since absorbance is directly 
proportional to concentration for monomeric porphyrins, and indeed Beer’s law was obeyed 
for concentrations up to 30 μM haematin at 405 nm (Figure 1.27b). In contrast, aggregated 
porphyrins tend to deviate from Beer’s law because the monomer is favoured at low 
concentrations and aggregation is favoured at higher concentrations.169 The appearance of 
the weak and broad Soret and Q-bands in Figure 1.27a (dimer form) is due to the splitting of 
the absorbance bands. This splitting arises during excitation when interactions occur 
between the transition dipole moments of the two porphyrins that form the dimer. When 
pyridine is added the Q-band intensifies and has an absorbance maximum at 527 nm. This is 
characteristic of a low spin complex,170 suggesting a ligand substitution reaction has taken 
place, in which the axial water ligand is replaced by two pyridine molecules. 
a) b) 
 
Figure 1.27 a) Haematin in aqueous solution with increasing pyridine concentration (shown 
by arrows). CT = Charge Transfer Band and b) Plot of the Soret band of hematin at 405 nm in 
5% (v/v) aqueous pyridine, pH 7.5 (20 mM HEPES) showing Beer’s law is obeyed over the 
concentration range (r2 = 0.9998).103 Copyright © 2005 Elsevier, Ncokazi et al.103 




The increase in intensity of the Soret band upon addition of pyridine is favourable for the 
application of detecting free haem because the sensitivity of the haem-pyridine complex is 
improved relative to aqueous haematin. Another advantage of this method is that the 
pyridine is likely to displace other coordinated substances which would alter the molar 
extinction coefficient of Fe(III)PPIX making it impossible to precisely quantify the free 
haematin.103 
The conditions, such as concentration and pH, under which pyridine coordinates with 
haematin were optimised. At large concentrations of pyridine and at high pH, pyridine is 
able to react with haematin as well as βH since the crystal is less stable under basic 
conditions. However, at neutral pH and lower concentrations, the energy required to disrupt 
the crystal and break the hydrogen bonds of the propionate groups is greater than the 
energy gained from pyridine-Fe coordination. Thus pyridine does not react with βH under 
these conditions. At neutral pH the haematin ligand is H2O, a weak field ligand which is 
easily replaced by pyridine, a strong field ligand, resulting in the reaction of pyridine with 
non-crystallised haem. The ideal conditions were found to be 5% (v/v) pyridine at pH 7.4 (20 
mM HEPES buffer) at room temperature (RT). The reaction is fast and the colour develops 
instantly, maintaining intensity for up to 24 h, suggesting that pyridine does not disrupt βH 
over time. 
 
1.9 High throughput screening in antimalarial drug development 
The many inherent difficulties in discovering and developing novel antimicrobial drugs have 
resulted in no new chemical classes of antimalarials being introduced into clinical practise 
since 1996. In addition, resource commitment towards antimalarial research has been 
relatively lacking in both public and private institutions.171 The shortage of novel, publicly 
accessible antimalarial scaffolds, in particular those with varying mechanisms of action has 
had a negative impact on drug discovery efforts.172 An open-source model for research and 
development (R&D) has been adapted by organisations known as public-private 
partnerships, creating a cost effective way of finding new therapies for neglected diseases, 
with promising results. Open-source genomic and metabolomic information is constantly 




getting richer with terabytes of data being added to the pool while chemical and structural 
data are much more limited. Availability of open-source tools were, until recently, abundant 
in bioinformatics but were lacking in chemistry owing to the dominance of commercial 
software. Fortunately, initiatives such as the launch of PubChem in 2004 and tools such as 
eMolecules and Jmol are revolutionising the way in which chemical information is shared. 
Furthermore, the latest computerised tools are able to efficiently mine data and search the 
literature, and in silico modelling software allows for toxicity prediction, visualisation of 
binding sites and metabolic network mapping.173 As a result of this progress, tools for 
accessing and analysing HTS data previously available only to industry, can now be obtained 
by non-profit scientists. However, the scarcity of data remains a problem for open-source 
R&D. HTS provides a way of rapidly increasing the structure-activity data available for 
medicinal chemists as a starting point for drug discovery. This is particularly important for 
antimalarial drug development, since antimalarial therapies, past and present, are based on 
a limited number of chemotypes (e.g. the quinolones, cycloguanils, tetracylines and 
sesquiterpene lactones) which often leads to cross-resistance.174 Owing to the relatively 
large amount of research on quinoline-based antimalarials, there is an urgent need for 
structural diversity in compounds active against P. falciparum. HTS provides a way of finding 
novel, diverse scaffolds which would otherwise not be investigated as potential 
antimalarials. 
 
1.9.1 Phenotypic vs target based approaches 
Advances in the construction of compound libraries as well as the increasing knowledge of 
drug targets have encouraged parallel advances in HTS. This has led to a new discipline 
focused on assay design, given that most regularly used assays are unsuitable for industrial 
scale screening. Assays should be optimised for speed, efficiency, signal detection and low 
reagent consumption. With these improvements, screening in relatively high throughput has 
been made possible with automated liquid handling and signal detection systems.175 
For the past century, two forms of screening have generally been employed for early stage 
drug development, namely phenotypic screens and target-based screens. Phenotypic 
screens measure the effect of a compound within a cell or tissue, without prior knowledge 




of the mechanism of therapeutic action or the number of druggable targets. In 2011, a study 
by Swinney and Anthony reported that more first-in-class small molecules were found via 
phenotype-based screens between 1999 and 2008 than other screening methods.176 
However, determining the target or in some cases multiple targets of the identified hits, has 
typically been a difficult, time-consuming or even an impossible process.177  In the 1980s, 
advances in molecular biology allowed screens against defined targets to be developed. 
Target-based screening has been the more popular over the past few decades.178 This is 
particularly favourable in the case where large-scale screening against a specific target, 
using a biologically relevant assay, is more efficient and less expensive than testing 
hundreds of thousands of compounds on the whole-cell. It is also possible to combine the 
techniques by employing target-based before phenotypic screening. In this case, once 
target-based screening has been carried out to identify a much smaller fraction of the total 
library as hits, whole-cell testing can then be conducted to take into account other factors 
such as cell permeability and target-site accumulation.  
 
1.9.2 Recent antimalarial HTS efforts 
Target-based HTS of diverse libraries relies on the knowledge of specific P. falciparum 
inhibiting pathways for appropriate assays to be developed. In 2004, GlaxoSmithKline (GSK) 
screened compounds against Plasmodium LDH and identified azole derivatives, which were 
selective for Plasmodium LDH over human LDH. Unfortunately in vitro activity could not be 
linked to enzyme inhibition and they concluded that LDH was not druggable.179 Haemozoin 
inhibition is an alternative, valid pathway since this process has not been directly disrupted 
by the structure-specific efflux mechanism which causes drug resistance in the parasite (see 
Section 1.6).60 Synthetic haemozoin, βH, can be efficiently and reliably synthesised in the 
laboratory with minimal equipment using a variety of methods.139,140,160,165 Furthermore, 
detecting the formation of βH is easily achieved through a number of different techniques 
as discussed in Section 1.8.6. 
The first target-based HTS project for βH inhibitors was carried out by Kurosawa et al.159 on 
over 100,000 compounds from several compound libraries and reported in 2000. They 
employed an assay which incorporates radiolabelled haematin into the βH crystal, where 




the ability of known quinolines to inhibit this process was correlated with their ability to 
inhibit parasite growth. Initiation of crystal formation was via acetonitrile extracts from P. 
falciparum trophozoite lysates, the major components of which were lipids. At the time, this 
was the most appropriate assay for the robotic handling involved in HTS. Compounds were 
obtained from the Roche, SPECS and other diverse compound libraries as well as the NIH 
Clinical Collection (NCC), where they were isolated from microbial broths. Many of the 
compounds were initially screened as cocktails of ten samples and then, if a hit was 
identified, screened individually.  A total of 45 non-quinoline compounds were identified as 
hits (IC50 of <50 µM) with IC50s well below the CQ control of 80 µM, and were primarily 
triarylcarbinols, piperazines, benzophenones, imides, hydrazides, indoles and isoxazoles. 
However, only four of these compounds exhibited activity <5µM in both the CQ-sensitive 
NF54 and CQ-resistant K1 strains of P. falciparum, resulting in a very low overall hit rate. 
An improvement in the hit rate of target-based screening for haemozoin inhibiting 
antimalarials was reported in 2009 by Rush et al.180 They took advantage of the colorimetric 
pyridine-based ferrihemochrome assay developed by Ncokazi and Egan,103 requiring no 
parasite-derived reagents or radioactive materials. Rather, 9.7 M acetate was used to 
initiate βH formation. This method was adapted into a robust HTS assay in a 384-well plate 
format for robotic handling. A total of 16,000 diverse compounds were screened, of which 
~600 were hits with IC50s of <220 µM, well below the CQ control of 374 µM in this assay. 
Subsequently, 17 compounds showed activity against the CQ-sensitive 3D7 and CQ-resistant 
Dd2 strains of P. falciparum, although only seven hits were active below 5 µM. 
Large HTS projects for new antimalarials have also recently been carried out as phenotypic 
screens. Two groups in industry (Novartis181 and GSK171) as well as an academic group (St. 
Jude Children’s Research Hospital172) published their screening results for compounds 
directly active against P. falciparum whole cells in 2008 and 2010. These data are publically 
available from (https://www.ebi.ac.uk/chemblntd/). Novartis screened approximately 
800,000 compounds, reporting 5,655 hits with IC50s < 1.25 µM. Priority was given to 200 
distinct chemical classes for hit-to-lead investigation. GSK screened approximately 2 million 
compounds from their libraries and identified ~13,500 compounds, now referred to as the 
Tres Cantos Antimalarial Set (TCAMS), with IC50s <2 µM. Finally, at the St Jude Children’s 
Research Hospital, ~300,000 compounds were screened against multiple strains of P. 




falciparum, and 560 validated hits with IC50s <2 µM and >10-fold selectivity against 
mammalian cells, were reported. Of these, 170 compounds with diverse structures were 
profiled in silico and 80% were predicted to have novel mechanisms and no cross resistance. 
1.9.3 The scope for novel βH inhibitors discovered via HTS  
The Novartis, GSK and St. Jude’s screens were primarily focused on finding novel active 
compounds intended for development towards clinical antimalarials. However, target-based 
screening for haemozoin inhibitors offers the additional opportunity to use the data, both 
active and inactive, to probe mechanistic aspects as well as to construct SAR models. This is 
especially important regarding non-quinoline chemotypes, since apparent differences 
between trends in the well-studied quinoline series and that of new series, are likely to 
elucidate further details of in vitro haemozoin inhibition and drug toxicity mechanisms as 
well as aspects of drug accumulation. For example, Egan et al.182 showed that quinoline 
analogues that inhibit βH formation but have low parasite activity, can be derivatised into 
potent antimalarials via the addition of basic side chains for pH trapping. However, it is not 
known whether this phenomenon is applicable to other chemotypes. In addition, several 
studies have reported correlations between βH inhibition activity and parasite growth 
inhibition activity for quinoline and related compounds, yet few series of non-quinoline βH 
inhibitors have been analysed using this method. Combrinck et al.113 reported an increase in 
free haem in whole-cell parasites with several quinoline antimalarials, CQ, AQ, QN and MF 
(Section 1.7.3), whereas the extent of free haem accumulation in parasites inoculated with 
diverse, non-quinoline, βH inhibiting scaffolds has not been investigated.  
Another advantage of βH inhibitors is their inherent structural suitability for short-sequence 
synthesis. This has favourable implications, not only for efficient production of analogues, 
but also for the potential future of these compounds as antimalarials. Because 90% of 
malaria-related deaths occur in sub-Saharan Africa, where most regions are burdened with 
poverty and low-levels of education,10 designing drugs which can be quickly and 
inexpensively manufactured is a rational priority. In 2013, 69 million children with malaria 
did not receive ACTs, which are currently the most effective way of preventing malaria 
caused by Plasmodium parasites.183 Unfortunately, artemisinin, the key ingredient of ACTs, 
costs $2.40 per dose, which is prohibitively expensive in most of the malaria-prevalent 
areas.184 On an industrial scale, the natural product artemisinin is extracted from the 




wormwood plant, Artemesia annua, and ACT supply depends heavily on the agricultural 
production of artemisinin.185,186 However, problems relating to crop quantities, often as a 
result of unpredictable climates or natural disasters, have led to shortages and price 
fluctuations. Despite a decade’s worth of research to solve these problems, no impact on 
the global supply chain has been achieved and little focus has been given to developing a de 
novo total synthesis of artemisinin.183 At best, an enantioselective five-pot process has been 
achieved that still demands five purifications as well as toxic, hazardous and 
environmentally unfriendly reagents. Although this is a cost-effective synthesis, large-scale 
production of artemisinin via synthesis is still under investigation.183,187 As such, natural 
product cultivation and extraction remain essential to meet world-wide antimalarial 
demands.188 
The complex chemical structure of artemisinin, which has resulted in long and difficult 
enantioselective syntheses, has been a liability for investigation into cost-reducing 
approaches.187 On the other hand, many βH inhibiting compounds can be synthesised via 
rapid, simple routes which do not require stereo-selectivity. This is due to the nature of their 
planar aromatic rings, which appear to be optimal for π-π stacking with haem. Antimalarials 
that can be synthesised from readily available starting materials using cheap and safe 
reagents would logically result in improved distribution of drugs to poverty-stricken areas. 
This would be particularly relevant when combined with a synthetic peroxide antimalarial, 
such as the ozonide OZ439 drug candidate currently in phase IIb clinical trials with 
Medicines for Malaria Venture (MMV).189 
Virtual screening has become an important technique for drug discovery but in malaria, is 
hindered by the lack of well-validated targets and as a result, few successful examples of 
this approach exist.178 An in silico technique using Bayesian statistics to create models, 
involving both active and inactive HTS data, has been utilised in recent literature to enrich 
hit rates in subsequent screens. Software is now available with a built-in Bayesian classifier, 
based on Bayes’ theorem, which has aided in efficient identification of new actives.190,191 
Since 2004, this method has been applied for modelling kinase inhibitors,192,193,194 
Escherichia coli dihydrofolate reductase inhibitors,195 G protein-coupled receptor (GPCR) 
ligands,196 histidine H4 antagonists, phosphodiesterase (PDE) inhibitors, metabotropic 
glutamate receptor antagonists,197 oestrogen receptor inhibitors as well as 




metalloproteinase, nitric oxide synthase and other non-kinase enzyme inhibitors.194,198 
These are key targets for diseases such as cancer and Alzheimer’s.199 In addition, Ekins et 
al.200,201 have employed public whole-cell Mycobacterium tuberculosis (Mtb) HTS data to 
demonstrate a 10-fold enrichment on typical hit rates when compounds are prioritized 
using Bayesian models. Although they were able to apply Bayesian models to phenotypic 
data, the other literature reports applying this statistical method for drug discovery, appear 
to include data for specific drug targets. Indeed, Bayesian models have not been applied to 
antimalarial HTS data, most likely as a result of the lack of sufficient target-defined activity 
data.  
With the recent developments of improved assays for identifying βH inhibitors, haemozoin 
target-based HTS of large diverse libraries offers a unique and compelling opportunity to 
acquire urgently needed data for further insight into the problem of malaria. 
 
  




1.10 Aims and Objectives 
1.10.1 Aims 
Given the desperate need for alternative antimalarial drug scaffolds, particularly for probing 
mechanisms aimed at improving activity and overcoming resistance, together with the 
suitability and convenience of haemozoin formation as a drug target, the aims of the project 
were to identify novel βH inhibiting compounds via HTS and to select appropriate 
chemotypes for investigation. The molecular scaffolds were chosen to be amenable to 
efficient synthesis of a small library of analogues in order to probe mechanistic aspects of 
activity and to uncover any possible SARs for each scaffold. 
 
1.10.2 Objectives 
Comprehensive lists of the specific goals for each component of this project are shown in 
the introduction to each respective chapter, however a summary of objectives is provided 
here.  
To accomplish the aims highlighted in Section 1.10.1, the specific objectives of this project 
were: 
1) To perform HTS on the Vanderbilt University Institute of Chemical Biology compound 
collection. This required carrying out the detergent-mediated assay on approximately 
40,000 compounds, after which, hits were screened in a secondary assay to identify 
those which inhibit P. falciparum growth.  
2) To analyse and investigate novel βH inhibiting scaffolds, particularly where some of the 
derivatives exhibited promising parasite inhibition potency, in order to select 
chemotypes for further exploration. 
3) To identify the minimum pharmacophore for βH and parasite growth inhibition within 
each selected chemotype, via synthesis or purchase of deconstructed analogues. 
4) To synthesise a small library of derivatives for each selected chemotype, in order to 
determine the βH and parasite growth inhibition activities. 




5) Where appropriate, to evaluate the effect of attaching basic side chains believed to cause 
pH trapping and then to determine CARs.  
6) To investigate structure-activity relationships (SARs) to determine the likelihood of future 
potential for the chosen scaffolds, either as mechanistic probes or as antimalarial drugs. 
7)  To create and evaluate a predictive model based on Bayesian probability using the 
combined structure-activity data, including all available HTS data as well as evidence 
from the synthetic libraries, to aid in silico HTS screening in the future. 









In an effort to discover novel βH inhibiting scaffolds active against P. falciparum, HTS was 
conducted on 43,520 compounds, a subset of the Vanderbilt University Institute of Chemical 
Biology (VU) chemical library. Validation of the βH inhibition assay for use in high 
throughput experiments was essential to the success of this project and hence, a number of 
quality-control analyses and a pilot screen were carried out prior to HTS. 
 
2.1.1 Drift, Z’ and edge effects in plate-based assays  
Assays can be powerful tools for drug discovery, owing to their ability to mimic the intricacy 
of biological systems on a suitably fundamental level. They also have the potential to be 
scaled up for HTS. Unfortunately, the chemical complexity gained from this technique can 
be the unwanted cause of noise and variability, leading to errors that affect assay 
performance. The factors that can cause uncertainties include errors in addition of reagents 
to the plate, differential reaction rates due to uneven response across the plate, plate-to-
plate variability, run-to-run variability, and edge effects.202 Since compounds are usually 
tested only once in primary screens, accuracy and sensitivity is vital for identifying hits.175 
In light of this, Carter et al.160 validated the βH assay in a 96-well plate for performance and 
plate uniformity with checkerboard positive and negative controls. Using the NP-40 
detergent, a drift response of <12%, significantly below the accepted threshold of 20%, was 
calculated.203  The drift response is calculated via Eq. 2.1. 
 
𝐷𝑟𝑖𝑓𝑡 =
(𝑚𝑒𝑎𝑛 𝑎𝑏𝑠.  𝑜𝑓 𝑐𝑜𝑙𝑢𝑚𝑛 1) − (𝑚𝑒𝑎𝑛 𝑎𝑏𝑠.  𝑜𝑓 𝑐𝑜𝑙𝑢𝑚𝑛 2)
𝑜𝑣𝑒𝑟𝑎𝑙𝑙 𝑚𝑒𝑎𝑛
    Eq. 2.1 




This favourable drift response of <12% indicated that there was uniformity across the plate. 
Furthermore, linear regression of the negative and positive control resulted in slopes  
<2.5 × 10−3, confirming negligible edge effects on the plate (Figure 2.1). In addition, Sandlin 
et al.161 reported a favourable Z’ value for the NP-40 mediated βH inhibition assay of 0.82, 
well above the 0.5 threshold value. This Z’ is based on Eq. 2.2 and indicates the degree of 
UV-vis absorbance error within repetitions of the controls. 
𝑍′ = 1 − 
3(𝜎𝑝+𝜎𝑛)
µ𝑝−µ𝑛
         Eq. 2.2 
Where σp and σn refer to the standard deviation in the absorbance of the positive and 
negative controls respectively and µp and µn are the mean absorbance values for the positive 




Figure 2.1 Absorbance data for the negative and positive controls in a checkerboard 
arrangement. Linear regression gave negligible slopes of <2.5 × 10−3 showing uniformity in 
the data across the plate. Copyright © 2014 Bentham Science, Carter et al.160  
 
  




2.1.2 Pilot screen for βH inhibitors and antimalarials 
In 2010, a pilot screen using the NP-40 assay was carried out at Vanderbilt University.161 A 
total of 38,400 compounds at a concentration of 19.3 µM were tested for their ability to 
inhibit βH formation. This resulted in the discovery of 161 novel hits, none of which were 
previously identified as βH inhibitors. The hits were defined as those compounds which had 
a measured UV-vis absorbance at 405 nm above 3 standard deviations of the negative 
DMSO control on that plate. These hits were then screened against P. falciparum in a 
phenotypic assay utilising SYBR-Green I fluorescence dye to bind to parasite DNA, based on 
modification of methods published in the literature.84 Of the 161 βH inhibitors identified, 48 
also inhibited ≥90% of parasite growth at 23 µM, with eight showing nanomolar IC50s. The 
success of this pilot screen prompted the HTS of the remaining 144,330 compounds in the 
library using a similar approach. 
 
2.1.3 Specific goals 
The specific goals for Chapter 2 were to: 
1) Carry out HTS using the NP-40 based assay for βH inhibition on 43,520 compounds, a 
subset of the VU HTS library.  
2) Perform data analysis using pre-defined cut-offs to identify hits.  
3) Cherry-pick βH inhibitors from compound library source-plates and test them in a 
dose-response assay to measure activities and detect false positives. 
4) Culture CQ sensitive D6 and multi-drug resistant C235 strains of Plasmodium 
falciparum in whole red blood cells for the phenotypic whole cell assay and identify 
compounds which show in vitro activity. 
5) Analyse hit scaffolds for further lead-probe optimisation. 
  




2.2 Results and discussion 
2.2.1 Assay validation 
A standard plate containing positive (AQ at IC100) and negative control wells was analysed to 
assess the quality and reproducibility of the NP-40 assay (Figure 2.2). The mean positive 
control UV-vis absorbance value was 3.332 ± 0.043 and that of the negative control was 
0.567 ± 0.096. Linear regression of the data confirmed negligible drift with slopes of 5x10-5 
and 7x10-5 for the negative and positive data sets respectively and a drift response across 
the 24 microplate columns of 2.3%, well below the 20% threshold. These data also resulted 
in an affirmatory Z’ value of 0.85, in good agreement with the 0.82 value determined by 
Sandlin et al.161  














Figure 2.2 Positive and negative control wells on a 384-well microplate, arranged in an 
alternating checkerboard, revealed a favourable Z’ value of 0.85 and low drift response of 
2.3%. 
 
Inhibitory concentrations, determined via dose response curves for both AQ and CQ were 
calculated to be 23.1 ± 2.6 µM and 66.3 ± 3.5 µM respectively (Figure 2.3). These IC50 values 
were within an acceptable range relative to previous literature which reported 21.0 and 
53.0 µM for AQ and CQ respectively.161  


















Figure 2.3 Standard antimalarials AQ and CQ inhibited βH formation in a dose-response 
manner.  
 
2.2.2 Compound screening for βH inhibitors 
The NP-40 assay for βH inhibition was performed on 43,520 compounds as part of a larger 
screen of 144,330 commercially available drug-like compounds from the Vanderbilt 
compound library.204  Test compounds were screened at a rate of 320 per microplate and 
20-30 microplates per week. Hits were considered to be those which, relative to the 
controls, inhibited βH formation above 50% at 19.3 µM, approximately the IC50 of AQ in this 
assay. The workflow for the HTS is shown in Figure 2.4 where a plot of the absorbance data 
for a typical 384-well microplate highlights the 50% inhibition cut-off and identification of a 
hit (red circle). A total of 136 microplates were screened and the Z’ score was calculated for 
each plate based on the first and last two columns containing controls. The average Z’ 
across all the plates was calculated to be 0.51 ± 0.08, showing acceptable accuracy relative 
to the negative and positive controls. For this subset of the library, 758 compounds were 
classified as hits, resulting in a hit rate of 1.7%. The chemical scaffolds from this subset are 
shown in Figure 2.5. The most common chemotype found (35% of hits) belonged to the 
quinoline family, which includes quinolones, quinazolines and quinoxalines. The second 
most frequently occurring group (16% of hits) were the fused five-membered to six-
membered rings containing nitrogen, oxygen and sulfur, namely the benzimidazoles, 
benzoxazoles, benzothiazoles and indoles, followed by the benzamide chemotype (10%). 




These were of particular interest since there was little known of the βH inhibiting properties 
of these classes of compounds.  
 
Figure 2.4 The HTS workflow for identification of compounds which inhibit βH formation in 
the NP-40 detergent (structure shown) assay. Hits were determined by measuring the 
absorbance of the haem-pyridyl complex shown in the figure, where inhibition values above 
50% or 80% at 19.3 µM were chosen as the criteria for hit identification. The higher cut-off 
was used when analysing the entire library of 144,330 compounds. 
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Upon completion of the entire HTS project, where all 144,330 compounds were tested, the 
criterion for hit identification was raised to ≥80% inhibition. This cut-off was chosen so that 
only potent inhibitors were advanced to the next stage of the screening in order to better 
manage the numbers of compounds tested for their dose-response with respect to βH 
formation and eventually against the parasite. In order to ensure that comprehensive 
results are reported and because the entire database of compounds was analysed to 
determine appropriate scaffolds for synthesis, the following discussion refers to the ≥80% 
cut-off for the whole library.  
Of the 144,330 compounds screened, 729 inhibited ≥80% of βH formation at 19.3 µM, 
resulting in a hit rate of 0.51%. In this preliminary screen, each compound was tested only 
once and as a result, false positives were expected to occur. It is important in any HTS 
project to confirm the validity of the active compounds, since errors are statistically likely to 
occur when dealing with such large numbers of compounds.194 In light of this, these hits 
were selected and their IC50 values determined in a dose-response assay. This process 
allowed the false positives to be found and the potency of the true actives to be measured. 
A total of 530 compounds were confirmed hits (0.37% hit rate) with IC50 values ≤27 µM, 
indicating a false positive rate of 0.14%. Although this was ten-fold higher than the 0.016% 
false positive rate determined in the pilot screen by Sandlin et al.,161 the overall hit rate of 
0.37% was similar to the hit rate of 0.40% reported previously. Furthermore, 416 were more 
potent than AQ, with IC50 values <23 µM and all 530 compounds had IC50 values below that 
of CQ (66.3 µM). The IC50 values of the hits ranged from 0.17 to 26.97 µM with most 
compounds displaying IC50s between 15 and 18 µM.  Figure 2.6 shows typical IC50 curves 
from the dose-response assay as well as the activity distribution. 
  















































Figure 2.6 a) Dose-response curves for randomly chosen hit compounds from different 
plates, performed on different days and b) the distribution of βH inhibition activities for the 
530 hit compounds. 
 
Analysis of SARs for the hit compounds did not reveal any one-variable correlations between 
the βH IC50 and logP, molecular weight (MW), number of aromatic rings (#AR), number of H 
bond acceptors (#HBA), number of H bond donors (#HBD), number of rings (#R), number of 
rotatable bonds (#RB) or fractional polar surface area (FPSA). There was generally a wide 
range represented for each property within the βH hits (Table 2.1), however, the majority of 
the hits preferred a greater logP, MW, #AR, #HBA, #HBD, #R and FPSA, while also favouring 
fewer RB. This observation suggests that compounds may be less likely to interact with 
haem to inhibit haemozoin formation when they have large numbers of rotatable bonds. 
Having fewer rotatable bonds is believed to help with π-π interactions, which has been 
reported as one of the primary interactions between haem and quinoline containing 
antimalarials. This was shown from the crystal structure of the complexes of QD or QN with 
iron(III) protoporphyrin IX (Fe(III)PPIX), where the closest distance between the quinoline 




ring and the the porphyrin pyrroles was  calculated to be 3.3 Å, a characteristic indication of 
π-π interactions.158 
 
Table 2.1 Ranges of physical properties for the βH inhibitors identified. The column on the 
right indicates that, for example, 75% of the compounds had a logP greater than 3.  
Property Range 
% of βH inhibitors 
greater or smaller  
than a value 
logP -0.29 – 6.97 75% ≥ 3 
Molecular weight 159.19 – 607.61 88% ≥ 300 
Number of aromatic rings 0 –  5 95% ≥ 2 
Number of H bond acceptors 0 – 10 92% ≥ 3 
Number of H bond donors 0 – 4 60% ≥ 2 
Number of rings 1 – 7 90% ≥ 3 
Number of rotatable bonds 0 – 12 66% ≤ 6 
Fractional polar surface area 0.03 – 0.56 68% ≥ 0.2 
 
 
The hits were also analysed using Scaffold Hunter,205 a program for interactive exploration 
of chemical space and visual analysis of biological activity data. The scaffold tree (Figure 2.7) 
showed 78 unique single rings which formed the most basic scaffolds of the 530 hits, 
emphasising the diversity of βH inhibitors.  The six parent rings which comprised the largest 
number of child scaffolds, from most to least active on average, were imidazole, pyridyl, 2,3-
dihydropyridin-4(1H)-one, pyrrole, phenyl and thiazole as shown enlarged in Figure 2.7. 
These represent a range of π-deficient and π-excessive rings. Interestingly, they were also 
reported to be amongst the most common aromatic scaffolds present in bioactive 
molecules.206  
 





Figure 2.7 Diagram from Scaffold Hunter showing the diverse scaffold tree for βH hits 
arranged by increasing average IC50 value anticlockwise from 2.61 to 26.9 µM. The root of 
the tree starts as a single aromatic ring. The six scaffolds which led to the largest number of 
child scaffolds are highlighted. 
 
The top ten most active parent scaffolds, which involved other N, O or S-containing five or 
six membered heteroaromatic rings, were linearly expanded to single structures on the 
scaffold tree. These structures are included in Table 2.2, which highlights the variety of 
chemotypes within the top 20 most potent βH inhibitors identified in the screening process. 
Interestingly, almost all the structures contained aromatic or heteroaromatic rings, with 
minimal saturated or freely rotatable bonds. Exceptions were VU0020967 and VU0013068, 
with a cyclohexane ring and hexane moiety respectively.  




Table 2.2 The 20 most potent βH inhibitors. 
Code Structure logP βH IC50 (µM) D6 IC50 (µM) 
VU0014379 
 
4.52 0.168 Inactive 
VU0014981 
 
4.03 0.4 Inactive 
VU0063871 
 
5.19 0.4 Inactive 
VU0015078 
 
3.95 1.1 0.81 
VU0020967 
 
4.19 1.5 Inactive 
VU0042031 
 
3.65 1.7 3.515 
VU0000264 
 
2.34 2.0 0.59 
VU0099210 
 
3.54 2.2 Inactive 
VU0123869 
 
4.57 2.4 Inactive 
VU0358176 
 
5.46 2.4 1.72 
 
  




Table 2.2 (Continued) 
Code Structure logP βH IC50 (µM) D6 IC50 (µM) 
VU0094619 
 
5.33 2.4 0.70 
VU0001216 
 
4.71 2.607 Inactive 
VU0073706 
 
5.61 2.911 4.313 
VU0013068 
 
2.81 2.948 Inactive 
VU0112751 
 
4.82 3.049 Inactive 
VU0000817 
 
5.51 3.147 Inactive 
VU0357956 
 
3.98 3.151 Inactive 
VU0009045 
 
1.82 3.181 Inactive 
VU0073726 
 
5.70 3.215 Inactive 
VU0358099 
 
4.22 3.353 Inactive 




2.2.3 Secondary screen of βH inhibitors for in vitro parasite activity 
The SYBR Green I fluorescence-based assay was used to evaluate the efficacy of the βH 
inhibitors against P. falciparum (0.3 % parasitemia, 2% haematocrit).84 This was achieved by 
first pre-screening the 530 compounds against the CQ-sensitive D6 strain, where hits were 
defined as those which inhibited ≥90% of parasite growth at a single concentration of 23 
µM. The percentage inhibition was calculated relative to the positive control which 
contained the IC100 (kill concentration) of CQ and the negative control (DMSO only). Here, 
171 compounds were identified as active against D6 parasite growth, giving a high hit rate of 
32.3% out of the 530 βH hits. This is in contrast to the relatively low hit rate of 3% published 
in 2009 by Rush et al.180 in their cell-free haem crystallization screen (CFHCS), which utilised 
an alternate method for βH formation. Their test compounds were incubated at 60 ˚C for 2 
h in the presence of haemin and 9.7 M sodium acetate, with no detergent present. It 
appears that this lack of lipid or lipid mimic produced a larger number of βH hits. Of the 
16,000 diverse compounds screened using their “acetate method”, 644 (3.96%) were 
reported active with >50% inhibition. This hit rate is more than twice that of the hit rate 
(1.7% at >50% cut-off) found using the NP-40 based assay. Therefore the acetate method 
identifies a much larger percentage of βH inhibitors which either cannot access the DV or do 
not inhibit βH in the parasite’s DV. It has been proposed that the latter is more likely owing 
to the less realistic mechanism of βH formation with an acetate mediator since high 
concentrations of acetate are known to solubilise free haem in a rate-limiting manner, 
which would not occur in the cell.152,161,207  In the case of the NP-40 assay however, the 
favourable percentage of βH inhibitors that are also able to prevent parasite growth 
indicates the relative reliability of the NP-40 based assay and its ability to more accurately 
mimic the parasite’s lipophilic environment through detergent micelles. The result also 
agrees with the pilot screen, which determined a hit rate of 30%.161 The parasite active hits 
were analysed for any QSAR correlations between D6 IC50 and physical properties including 
MW, surface area and volume, logP, PSA, #HBD, #HBA, H2O.Hyd and solubility. No 
statistically significant correlations were found when attempting linear regression with 
combinations of up to four variables. This result is not surprising given the diversity of 
scaffolds. Previously reported parasite activity correlations have only been identified within 
derivatives of a specific chemotype.101,107,108,208,209 This is also the case for 3D QSAR.210,211  




The relatively high single-point concentration of 23 µM chosen for the pre-screen (>1000 
times that of the CQ IC50) allowed for the maximum number of potentially interesting 
antiplasmodials to be detected. However, prioritisation of the scaffolds for further analysis 
towards antimalarial drug development was very dependent on the actual activities of the 
hits. To this end, the 171 compounds that inhibited parasite growth by ≥90% at 23 µM were 
selected and a dose response assay performed in duplicate. This resulted in 73 compounds 
showing activities below 5 µM of which 25 had nanomolar activities (< 1µM). These 25 were 
also tested against the multidrug resistant C235 strain of the parasite and their activities 
determined. In order to evaluate the potential for resistance predisposition, the resistance 
index (RI) of each compound was calculated (C235 IC50 / D6 IC50). By comparing the activities 
of the resistant versus sensitive strains, the level of cross resistance can be assessed.212 In 
this case only four compounds had RIs above 3 (16%), leaving 21 compounds which showed 
very low levels of cross resistance, including 15 compounds with RIs <2. This revealed that 
most of the novel chemotypes identified are roughly as effective against resistant strains as 
they are against sensitive strains, a property which gives them good potential for further 
optimization. Table 2.3 displays the most potent 25 compounds exhibiting IC50s ranging 
from 0.11 µM to 0.99 µM which show no apparent correlation with their βH activities. Of 
these eleven were derivatives of quinolines (including quinazolines and quinoliniums) and 
nine contained amide moieties.  
  















12.6 0.11 0.13 1.2 
VU0073687 
 
6.3 0.18 0.55 2.9 
VU0001281 
 
5.9 0.19 0.17 0.9 
VU0065708 
 
16.2 0.20 0.18 0.9 
VU0096505 
 
8.8 0.24 0.22 0.9 
VU0107282 
 
17.0 0.29 0.54 1.9 















13.4 0.35 4.82 13.9 
VU0002101 
 
14.3 0.35 0.41 1.2 
VU0028177 
 
13.3 0.35 0.46 1.3 
VU0063971 
 
8.9 0.38 0.83 2.2 
VU0129813 
 
26.78 0.396 0.294 0.7 
VU0114734 
 
22.08 0.461 1.138 2.5 
  















24.54 0.5503 0.8998 1.6 
VU0000264 
 
2.043 0.59 0.248 0.4 
VU0065892 
 
6.194 0.611 0.693 1.1 
VU0010690 
 
25.03 0.673 1.52 2.3 
VU0094619 
 
2.394 0.70 0.2842 0.4 
VU0012464 
 
7.288 0.708 0.923 1.3 
VU0008057 
 
9.567 0.73 1.497 2.1 
VU0358149 
 
8.339 0.7782 19.1 24.5 















1.121 0.81 5.744 7.1 
VU0119324 
 
21.47 0.8453 0.1864 0.2 
VU0078364 
 
5.299 0.922 1.971 2.1 
VU0107278 
 
11.77 0.951 3.896 4.1 
VU0064165 
 
15.36 0.9926 1.008 1.0 
CQ 53.0 0.016 0.226 14.1 
AQ 21.0 0.011 ND ND 
 
  




2.2.4 Scaffold analysis 
Discovering novel βH inhibiting chemotypes, particularly ones which maintain activity in 
vitro, was the primary motive for this HTS. Following the collection of all the activity data, 
the 530 βH hits were further analysed to assess the scaffolds in more detail, specifically in 
relation to the percentage of each class which are also biologically active. This process 
revealed that 246 of the hits belonged to a class containing at least seven derivatives (Figure 
2.8). These could further be traced back to the simpler structures, quinoline or quinazoline, 
benzamide and benzazole with the exception of scaffolds M and N. Interestingly, the parent 
scaffold a level up from these simpler structures was identified as an aminophenyl as shown 
in the scaffold tree diagram in Figure 2.8. The compounds from each class that were also 
active against the D6 strain of P. falciparum were considered in order to determine which 
chemotype holds the most promise for further hit to lead optimisation. Here, the 
triarylimidazoles (scaffold N) performed the best, with six of seven compounds (86%) 
maintaining parasite activity while the diarylpyrrolones (scaffold M) exhibited no 
compounds active in vitro. Approximately 50% of the quinoline and benzamide-based hits 
were also parasite actives, with the exception of scaffold C with a significantly lower value of 
22%. However, these percentages must be treated with caution since the results are biased 
by the initial compounds available in the HTS library. The remaining 54% of the βH hits were 
not assigned a specific scaffold class, an affirmation of the diversity of the identified active 
compounds.  
 





Figure 2.8 Fourteen βH hit scaffolds (A to N containing at least seven derivatives each), 
twelve of which were linked back to simple parent scaffolds. Scaffolds E and H are each 
derived from two parent scaffolds. The values indicate the number of βH hits (≥80% 
inhibition) belonging to the scaffold followed by the number of compounds (red) which are 
also active against the D6 P. falciparum.   




2.2.4.1 Haemozoin target validation via cell fractionation 
In addition to analysing the percentage of compounds within each scaffold that prevent 
parasite growth, it was also important to validate the therapeutic target within P. 
falciparum. This is due to the fact that a compound need not necessarily inhibit haemozoin 
within the whole-cell, even though it is active in the NP-40 assay. One reason for this may be 
that the compound is unable to access or accumulate in the DV to inhibit haemozoin, while 
still being to act on an alternate parasite target, allowing for favourable in vitro activity.  
Alternatively, the compound may be able to access the DV but interacts with haem and the 
other cellular components differently in vitro to how it interacts with buffered haematin in 
the NP-40 mediated assay. If this were found to be the case, the reliability of the NP-40 
assay would be called into question. Fortunately this was not the case, as cell fractionation 
studies carried out at Vanderbilt University in collaboration with the University of Cape 
Town’s (UCT) pharmacology department revealed all twelve compounds tested were 
haemozoin inhibitors, in contrast to a negative control.204 The cell fractionation procedure 
was based on previously published methods developed at the UCT, where the negative 
control employed was the antifolate, sulfadoxine/ pyrimethamine.113 However, in this study 
all compounds were analysed relative to a different negative control, α-[(cyclohexylamino)
methyl]-9H-Carbazole-9-ethanol, which was inactive in the NP-40 assay but active in the 
parasite (D10 IC50 of 0.99 μM).204 The twelve compounds were selected in order to 
represent the majority of the different scaffolds, including VU0001281 (Table 2.4), a pyridyl 
analogue of the phenyl benzamide scaffold (F). The activity values for each compound found 
in the D6 parasite assay were used to give the required testing concentrations (0, 0.5, 1, 2 
and 3 times the IC50 value). Haemozoin inhibition was measured via the quantification of D6 
P. falciparum Hb, free haem and haemozoin remaining after incubation with the test 
compound. An active haemozoin inhibitor was one which resulted in a decrease in 
haemozoin with an increase in free haem. In addition, some compounds were shown to 
cause significantly larger levels of free haem at their respective IC50s. The negative controls 
did not display any increase in free haem relative to baseline levels, despite being able to 
cause parasite death, indicating an alternate mechanism of drug action.  
The cell fractionation study by Combrinck et al.113 indicated that CQ caused approximately a 
10% increase in free haem (5% at 0 nM to 15% at 2.5 times the IC50), as discussed in  




Section 1.7.3. Tested compounds from the HTS based on the quinoline scaffolds (B, C, D and 
E) showed a relatively low increase in free haem (8 to 14%) despite having moderate-high 
D6 activity. This was especially evident for the compound representing scaffold E which only 
produced a 14% increase in free haem while also having a very low IC50 value. In contrast, 
compounds from scaffolds G and I induce high levels of free haem but had relatively low 
activity. Scaffolds F (phenyl benzamide), F* (pyridyl benzamide) and N (triarylimidazole) 
contained compounds which caused the largest increase in free haem at their respective 
IC50s, despite that fact that they exhibited a wide range of activities from 0.19 – 9.06 µM. 
These compounds were particularly interesting from a mechanistic perspective, since 
haemozoin inhibition is almost certainly the primary target. All the compounds induced a 
significant increase in free haem relative to that of 0.4% for the negative control (Figure 
2.9). 


























Figure 2.9 The increase in free haem at the IC50 found for each compound belonging to the 
specified scaffold. F* represents the pyridyl derivative of scaffold F (phenyl benzamide). 
Scaffolds F, F* and N showed the largest increase in free haem at their IC50s. 
 
2.2.4.2 Phenyl and pyridyl benzamides (Scaffold 1) 
The phenylbenzamides have been reported for showing activity against the 3D7 strain of P. 
falciparum using the parasite lactate dehydrogenase as a measure of parasite growth. These 




data were as a result of the GSK P. falciparum screen published in 2012.178 The Novartis 
group went on to optimise the solubility and selectivity of a benzamide which led to 
enhanced P. falciparum activity. (Figure 2.10).213 Another study reported antimalarial 
activity for a series of benzamide-containing stilbene derivatives.214 However, it is not 
known whether these compounds are haemozoin inhibitors. 
 
Figure 2.10 The benzamide compound discovered via the GSK antimalarial screen and 
optimised by Wu et al.213 from the Novartis group. 
 
A list of the βH inhibiting benzamides were analysed by mining the 530 hits for the subset 
which contained scaffold F and F*. This was carried out using the Molecular Substructure 
Miner (MoSS) software, freely available online at http://www.borgelt.net/moss.html.215  
The twelve benzamides which were active against the D6 strain of the parasite and do not 
contain a quinoline ring are displayed in Table 2.4.  Six of the benzamides also contained a 
benzimidazole and one contained a benzoxazole moiety. Compound VU0001281 was 
particularly interesting given that it showed the best in vitro activity (and the third most 
potent out of the whole screen) and because of its large increase in free haem (about three 
times greater than the quinoline compounds). However, there were some structural alerts 
for this compound in terms of its potential drug profile. Firstly, the aromatic nitro group has 
been known to result in toxic metabolites via reduction to the carinogenic nitroso 
toxicophore. Sequential reduction forms further toxicophores, aromatic hydroxylamines 
(ArNHOH) and anilines (ArNH2).216,217 Compounds containing nitro groups can also lead to 
methaemoglobinemia, a blood disorder characterised by too much ferric [Fe3+] versus 
ferrous [Fe2+] Hb.218,219 Secondly, the 4-pyridyl moiety in VU0001281 is a potential 
cytochrome P450 (CYP) enzyme inhibitor which may result in oxidation to the pyridine-oxide 
by one or more CYP enzymes.216  




Table 2.4 Non-quinoline containing benzamides from the HTS (scaffold F and F*) which 
showed ≥90% parasite activity at 23 µM. Compounds are listed in order of decreasing D6 
activity and % free haem increases are shown in red where data are available. 





































Table 2.4 (Continued) 






















    
 




The potential toxicity linked to compound VU0001281 prompted some in silico modelling 
using MetaSite220,221 and VolSurf+ software.222 Structural alerts for potential metabolic 
instability were confirmed by MetaSite, which identified the reduction of the nitro group, N-
oxidation of the pyridyl moiety and amide hydroxylation as sites of possible metabolism in 
the liver. However, VolSurf+ predicted the benzamide derivatives from the HTS to have 
suitable metabolic stability (within the 95% confidence boundary) when mapped relative to 
the chemical space of known drugs (Figure 2.11). Furthermore, very successful drugs such as 
Lipitor, Lidoderm and paracetamol contain benzamide moieties and it was hypothesised 
that replacing the nitro and pyridyl moieties with other functionalities could overcome 
potential metabolic weaknesses. Other models within VolSurf+ predicted appropriate 
CACO2 permeation, protein binding, solubility and volume of distribution within 95% 
confidence boundary of known drug space. 
 
Figure 2.11 Metabolic stability space of known drugs forming the training set of model 
compounds (black circles), a range of pyridyl benzamides (coloured circles) and known 
antimalarials, CQ (white diamond), AQ (white triangle) and QD (white square). All the 
benzamides and known drugs were within the outer circle, representing a 95% confidence 
for the metabolic stability space. 




2.2.4.3 Triarylimidazoles (Scaffold 2) 
Scaffold N (triarylimidazoles) displayed a very high rate for parasite activity (six of seven βH 
inhibitors were active against in vitro). In addition to this, compound VU0099289 induced a 
large increase in free haem in the cell fractionation assay of 43% relative to the negative 
control. The identified compounds showed activities from 0.61 to 11.71 µM, with small 
structural changes having significant influence on the activity as evident when comparing 
VU0132562 (0.3 µM) VU0094619 (0.7 µM), VU0129734 (3.4 µM) and VU0099289 (9.0 µM). 
Imidazoles have a wide application owing to their range of biological activities, such as anti-
inflammatory,223 anti-allergic,224 anti-analgesic,225 anti-cancer226 and antibiotic.227 
Additionally, a series of 2,4,5-triarylimidazoles was shown to have antibacterial 
properties.228 Rathore et al.229 screened 110,000 drug-like, diverse heterocyclic compounds 
and identified 305 inhibitors of P. falciparum haem detoxification protein (HDP), one of 
them being the triarylimidazole, 4,4'-(4-phenyl-1H-imidazole-2,5-diyl)bis-phenol. However 
no follow-up reports of antimalarial activity could be found in the literature. Recently, 
several triarylimidazoles were discovered to have 3D7 parasite activity as a result of the 
phenotypic screens carried out by GSK and Novartis.171,181 Due to the scope of imidazole-
based compounds as biologically active agents, this scaffold was identified as a potentially 
interesting starting point for a series of derivatives to probe haemozoin inhibition. 
Moreover, an investigation into βH inhibition SARs for this class was attractive owing to the 
novelty of the chemotype as an antimalarial. The active triarylimidazoles are shown in Table 
2.5. 
  




Table 2.5 The seven βH inhibiting triarylimidazoles which were active against P. falciparum. 
Compounds are listed in order of decreasing D6 activity and % free haem increases are 
shown in red where data is available. 


































2.3 Summary and conclusions 
A total of 43,520 compounds were screened as a significant contribution to a larger HTS 
effort, involving a total of 144,330 compounds from the VU chemical compound library. Of 
the total screened 530 (0.37%) were identified and subsequently confirmed as βH inhibitors 
with potent IC50 values all below that of the CQ control. The structurally diverse hits 
generally possessed physicochemical properties, such as large #AR, #HBD and #HBA and low 
#RB, classifying them as planar, aromatic compounds capable of hydrogen bonding and π-π 
interactions with Fe(III)PPIX. Upon testing the hits from the primary screen against P. 
falciparum, 171 inhibited parasite growth by ≥90% at 23 μM, (32.3% of the 530 βH 
inhibitors) and 25 compounds exhibited favourable IC50 values below 1 μM. Furthermore, 
cell fractionation studies were able to successfully validate haemozoin formation as the 
mechanism of action in parasites for all tested compounds, representing twelve of the 
fourteen novel scaffolds identified. 
In this study HTS was successfully applied to the discovery of numerous yet diverse 
chemotypes, active against malaria parasites, the majority of which have not been reported 
as having this activity. Moreover, all the hit scaffolds were identified for the first time as 
haemozoin inhibitors, including those also found in previous phenotypic screens by St. 
Judes, GSK and Novartis, where the drug targets are unknown. Identifying the mechanism of 
action for newly validated hits from phenotypic screens remains a challenge. Historically, 
very low hit rates have been attained when attempting to select inhibitors of specific targets 
from various other sets of phenotypic hits. However, Pink et al.230 suggest that this is 
probably due to insufficient validation of the targets rather than to the methods 
themselves. Not only has this target-based screen allowed for 144,330 compounds to be 
evaluated for their βH inhibiting antimalarial activity in a more efficient, robust and cost-
effective manner than whole-cell screening, but a diverse range of compounds were proven 
to be haemozoin inhibitors in vitro. This, along with the unprecedented activity retention 
between the two utilized assays, shows the value and reliability of the initial NP-40 assay for 
accurately mimicking the haemozoin formation process within the parasite DV. While other 
large-scale screening efforts, such as the GSK screen have been very successful in finding 
thousands of antimalarial molecules, including one already in clinical trials, the failure rate 
for new antimalarials in phase 2 trials is 50%.230 Therefore it is crucial to utilise the potential 




of the existing antimalarial hits for maximum benefit in order to probe mechanistic aspects 
of activity.178 This can be achieved most successfully by having access to multiple hits which 
act on the same target in order to understand SARs. Improvements in public disclosure and 
sharing of data will also aid in bridging the gaps in the knowledge of potential starting points 
for antimalarials. Two hit scaffolds from this HTS, the benzamides and the triarylimidazoles, 
were particularly interesting since upon inoculation with representative compounds, much 
larger quantities of free haem were measured in the parasite, compared with the known 
quinoline antimalarials. Furthermore, their rates of βH inhibition hit occurrence were 
relatively high and parasite activities varied significantly between derivatives within each 
scaffold. These novel chemotypes were chosen for further investigation, requiring the 
purchase or synthesis of analogues to establish the minimum active pharmacophores and 
SARs in each case. 








In order to determine the potential of the benzamide and triarylimidazole scaffolds 
discovered via HTS (discussed in Section 2.2.4) for further hit-to-lead development, a more 
detailed understanding of the SARs of each pharmacophore was required. The promising 
initial parasite activities for at least one compound from each chemotype led to the 
prospect of improved analogues that could be efficiently synthesised from cheap starting 
materials. Investigating novel βH and antimalarial scaffolds requires a library of derivatives 
with different physical properties and functional groups. While these derivatives are not 
necessarily intended to become antimalarial drugs, they are required as probes for 
understanding the mechanism of action. Choosing chemotypes that do not require 
demanding, expensive and multi-step syntheses allows for more derivatives to be 
synthesised in a given time frame, and is a rational way of effectively probing haem-drug 
interactions and finding SARs. This is especially important for quantitative structure-activity 
analysis, since having more synthesised compounds for activity input data may lead to an 
improved statistical significance and more reliable relationships. 
 
3.1.1 Scaffold 1: Benzamides 
3.1.1.1 Amide bond formation  
Benzamides have been synthesised and extensively studied owing to their wide range of 
applications, which include pharmaceuticals and medicinal chemistry,231,232 polymer 
materials233 and supramolecular chemistry.234 As a result, many methods have been 
developed for their synthesis, most of which most focus on amide-bond formation. The 
amide functionality is present in proteins, which are involved in almost all biological 
processes and therefore ubiquitous in life.235 Moreover, the carboxamide functionality 
appears in 25% of all known drugs analysed from the Comprehensive Medicinal Chemistry 




database.236 This may be because they are neutral, stable and also have hydrogen-bond 
donating and accepting properties. The most prevalent method of synthesis involves 
condensation between an acid or its activated derivative and an amine, in which a whole 
host of methods are available.235,237 
Other examples of amide bond synthesis include the hydrolysis of aromatic nitriles,238 
aminocarbonylation between an aromatic halide, an amine and carbon monoxide with a 
palladium catalyst239,240 and the acid-induced rearrangement of oximes (Beckmann 
rearrangement).241-243 
Formally, amide bond formation between an acid and an amine is a condensation reaction, 
thereby liberating H2O. However, for this to take place, adverse thermodynamic factors 
need to be overcome, owing to the stable salt which forms upon mixing an acid with an 
amine (Scheme 3.1a). As a result, direct condensation of the salt can only take place at high 
temperatures exceeding 160 °C, which are generally incompatible with other 
functionalities.244 In order to overcome this, the traditional and easiest method, involving 
conversion of the hydroxyl into a good leaving group, can be employed. Here, the acid is 
activated after introducing the leaving group to the acyl carbon of the acid, allowing for 
amine attack by virtue of a lower activation energy and hence under milder conditions 
(Scheme 3.1b). A variety of coupling reagents exist for this purpose, enabling the generation 






Scheme 3.1. Aspects of amide bond synthesis. 
 
  




Owing to the plethora of methods and reagents for amide bond formation, it is sometimes 
necessary to screen a variety of different conditions for reaction optimisation. Several 
factors often need to be considered, which may include yield and selectivity improvement, 
or reduction of by-product formation. In other cases, the aim may be to facilitate the 
purification process or take advantage of more economical reagents.235 Amide bond 
formation during peptide synthesis can be more complicated as a result of possible 
epimerisation, usually through an oxazoline intermediate. In this circumstance, peptide 
coupling reagents such as dicyclohexylcarbodiimide (DCC) are generally used, in which an 
activated intermediate O-acylurea is formed in situ.245 Other popular peptide coupling 
reagents include 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxidhexafluoro 
phosphate (HATU). 
For amide bond formation which does not involving peptides and where there is no danger 
of hydrolysis, racemisation or cleavage of protecting groups; acyl chlorides or acid chlorides 
are one of the most popular and easiest to prepare of the activated intermediates. They can 
be readily made from the acid using a host of reagents such as thionyl chloride (SOCl2),246,247 
oxalyl chloride (COCl2),248,249 phosphorus trichloride (PCl3),250 phosphorus oxychloride 
(POCl3),251 or phosphorus pentachloride (PCl5)250. The sulphur, carbon or phosphorus in 
these reagents is necessary for removing the oxygen from the acid, and therefore acid 
chlorides cannot be formed from HCl alone.252 Oxalyl chloride is potentially hazardous due 
to the stoichiometric production of three gases, HCl, carbon dioxide and carbon monoxide 
and therefore care needs to be taken when considering this reaction. Generally, the 
phosphorus-containing reagents are employed in cases where the acid does not react 
readily with SOCl2, which produces sulphur dioxide and HCl as by-products.235 The attack of 
the acid oxygen on the electrophilic SOCl2 sulphur results in an unstable, highly electrophilic 
chlorosulfite ester intermediate, which is then protonated by expelled HCl. This increases 
the electrophilicity of the carbonyl carbon resulting in addition of the choride ion to form a 
tetrahedral intermediate, which collapses irreversibly to the acyl chloride with release of 
sulphur dioxide (SO2) and HCl as shown in Scheme 3.2.252 The production of HCl may, in 
some cases be problematic, especially in acid sensitive reactions such as those involving 
Boc-protected amines. In this instance, cyanuric chloride (2,4,6-trichloro-1,3,5-triazine), 




which maintains basic pH conditions, can be used to form the acid chloride in the presence 
of triethylamine (Et3N).253  
 
Scheme 3.2. Mechanism for the formation of the acid chloride using thionyl chloride. 
Once the acid chloride has been formed, a simple coupling reaction with the appropriate 
amine is carried out to form the amide. Once again, this reaction liberates HCl, and a base is 
necessary to avoid protonation of the amine to form an unreactive ammonium chloride salt. 
Furthermore, other basic groups on the acid or amine substrates may become protonated 
under these conditions. For this reason, reactions are generally carried out in the presence 
of non-nucleophilic tertiary amines, such as Et3N or Hünig’s base (i-Pr2NEt), in inert dry 
solvents.254 In order to decrease reaction times and improve solubility in some cases, 
pyridine can be used as a solvent. Pyridine acts as an acyl-transfer catalyst in the aminolysis 
by undergoing a nucleophilic acyl substitution (SNAc) reaction with the acid chloride faster 
than with the primary amine to generate an intermediate acyl-pyridinium salt.235 This is due 
to the pyridine nitrogen’s relatively soft and strongly Lewis basic character. The ionic species 
formed is more electrophilic than the acid chloride, and attack by the amine is driven by the 
positive charge on the pyridine nitrogen (Scheme 3.3). N,N-dimethylaminopyridine (DMAP) 
can also be used for this purpose.255 
 
Scheme 3.3. Mechanism of acyl-transfer with pyridine in the aminolysis.  




3.1.1.2 Synthetic targets for the benzamide scaffold 
The benzamide that showed the highest activity in the HTS against the D6 strain of the P. 
falciparum parasite was a di-pyridylbenzamide (VU0001281) with an IC50 of 0.194 µM 
(Figure 3.1a). Cell fractionation studies showed that this βH inhibitor also induced a large 
increase in free haem in the parasite, supporting haemozoin as the therapeutic target (Table 
2.4). Related to the dibenzamide compound was the mono-pyridylbenzamide (VU0358764) 
containing a nitro group in place of the second N-pyridyl amide (Figure 3.1b). While this 
compound showed similarly potent activity against βH formation, it was significantly less 
active towards the parasite in the D6 strain relative to VU0001281, with an IC50 of 4.76 µM. 
These results prompted a study into the structure-activity relationships (SARs) of this 
scaffold.  
 
a)  b) 
  
Figure 3.1 The mono- and di-pyridylbenzamide identified in the HTS. 
 In order to generate a library of mono- and di-benzamide derivatives, several structural 
aspects were chosen for variation in order to probe the effect of varying the electronic and 
spatial properties of the substituents on both βH and parasite activity, and to address 
improving the toxicity profile of the compound. Figure 3.2 shows the parts of the mono- or 
di-benzamide scaffolds which were varied either by purchase (indicated by the *) or 
synthesis in order to probe SARs.  Several mono-benzamides were purchased according to 
information that emerged from the Topliss decision tree, a method designed to aid in the 
selection of new analogues, based on maximising the chances of improving activity. It also 
allowed for the maximum discrimination between substituent properties such as resonance 
vs inductive effects as well as substituent size and hydrophilicity.256 In the case of the di-




benzamides, all derivatives were symmetrical except for the benzimidazole ring (**), which 





Figure 3.2 Derivatives of the mono- and di-benzamides obtained from commercial sources 
or via synthesis.  
  




3.1.2 Scaffold 2: Triarylimidazoles  
3.1.2.1 Literature methods for the synthesis of triarylimidazoles 
Many synthetic routes to 2,4,5-triarylimidazoles have been reported in the literature, most 
often in conjunction with probing their biological activities,228,257 fungicidal or herbicidal 
properties258,259 or their potential usage in carbon-based materials.260 The standard 
procedure for accessing a 2,4,5-triphenylimidazole core involves the condensation reaction 
of benzaldehyde, benzil, and ammonium acetate. This can be performed in a variety of 
organic solvents,259,261 glacial acetic acid260 or under solvent-free conditions.257,262 In 
addition, Chauveau et al.263 have shown that the reaction can be carried out in water under 
microwave irradiation, achieving yields over 70%. Some studies have also involved the use 
of catalysts, such as Brønsted acidic ionic liquids, to increase yields and reaction rates or to 
avoid the use of organic solvents.228,257,261,262,264 The general mechanism for the formation of 
triarylimidazoles in this way is shown in Scheme 3.4. 
 
Scheme 3.4 Mechanism of the condensation reaction between benzaldehyde, benzil and 
ammonium acetate. 




Azizi et al.259 optimised the catalyst-free reaction conditions by varying the organic solvent 
and type of amine or ammonium. Ethanol (EtOH) and methanol (MeOH) were found to give 
the highest yields of 70% and 97% respectively with ammonium acetate (NH4OAc) at 60 °C 
for 4 h. Another catalyst-free study used glacial acetic acid, by refluxing the reaction at 118 
°C for 4 h to give a p-nitro-substituted analogue in 92% yield. The product was then reduced 
to the amine using iron powder and 2 drops of 38% HCl, which required heating at 80 °C for 
6 h.260 The advantages of these methods were the efficient work-ups and simple procedures 
for product isolations, requiring no catalyst removal. As a result, these were the methods 
followed in the synthesis of the selected analogues. 
 
3.1.2.2 Synthetic targets for the triarylimidazole scaffold 
Seven βH-inhibiting triarylimidazoles were identified as active against the D6 strain of P. 
falciparum in the HTS. The three compounds with the greatest activity (<1 µM) against the 
parasite contained the same substitution pattern on the 2-phenylimidazole (ring A), 
specifically p-hydroxy and m,m-dimethoxy groups. Interestingly, removal of the dimethoxy 
groups in VU0132562 to give VU0099289 resulted in an increase in βH activity as indicated 
by a drop in the IC50 from 12.6 to 5.7 µM, but with a large decrease in parasite activity from 
0.31 to 9.1 µM. The substituents on the 4,5-phenylimidazole (rings B and C) also influenced 
activity with the p-bromo derivative (VU0132562 – Figure 3.3a) showing a 2-fold better 
activity than the p-hydroxy (VU0094619 – Figure 3.3c). These compounds are shown in 
Figure 3.3.  
 
a)                           b)            c)       d) 
              
Figure 3.3 Examples of triarylimidazoles found in the HTS showing D6 parasite activities.   




These intriguing structure-activity relationships encouraged the synthesis of a small library 
in order to firstly discover the structural requirements for βH inhibition, and secondly, to 
probe the influence of the substituents of ring A, specifically to determine whether other 
functionalities could maintain activity. Figure 3.4 displays the proposed variations of the 
triarylimidazole scaffold, including the removal of the B and C phenyl rings to give 2-
phenylimidazole, which was commercially available. 
 
 
Figure 3.4 Derivatives of the triarylimidazoles obtained from commercial sources or via 
synthesis.  
 
3.1.3 Specific goals 
The specific goals for Chapter 3 were to: 
 Synthesise and characterise a series of mono-, di- and tri-benzamide derivatives. 
 Synthesise and characterise a series of triarylimidazole derivatives.  




3.2 Results and discussion 
3.2.1 Scaffold 1: Benzamides 
3.2.1.1 Synthesis of the monobenzamides 
Synthesis was initially directed at generating benzamide derivatives of scaffold 1 in which 
the synthetic procedure for amide formation was optimised on the simplest target 
molecule, 2-nitro-N-phenylbenzamide (2a). The general method in the literature, whereby 
aniline and 2-nitrobenzoyl chloride (1:1) are stirred in dichloromethane (DCM) with Et3N (1 
eq.) for 2 h at RT, was used as a guideline.265,266 However, pyridine was chosen as a solvent 
instead of, or in addition to DCM. This variation allowed for faster, cleaner reactions owing 
to the improved solubility of the starting materials and the ability of pyridine to act as an 
acyl-transfer catalyst. Furthermore, pyridine provided the base to consume the expelled HCl 
and therefore the addition of Et3N was unnecessary for reactions with aniline as the amine. 
 A work-up of the pyridine-stirred reaction with ethyl acetate (EtOAc) and 1 M HCl enabled 
isolation of the product in the organic layer, eliminating the pyridine as a pyridinium salt 
dissolved into the aqueous layer. However, several washings of the EtOAc layer with 1 M 
HCl were required, otherwise a fraction of pyridine remained in the organic layer and had to 
be removed later under reduced pressure. 
The reaction product did not require purification by column chromatography but the 
product could be crystallised directly to give an excellent yield of 99%. The synthesis of 2a 
was confirmed by nuclear magnetic resonance (NMR) analysis (Figure 3.5) in 
deuterodimethyl sulfoxide (DMSO-d6). All NMR analyses of the benzamides were carried out 
in this solvent, since it allowed for the NH peaks to be detected, an important indicator of 
amide bond formation, and was able to dissolve all the derivatives, many of which were too 
polar for dissolution in deuterochloroform (CDCl3). Peak assignments were confirmed with 
correlation spectroscopy (COSY) and heteronuclear single-quantum correlation (HSQC) 
spectroscopy (Figure 3.6). The aromatic protons were observed in two distinct coupling 
systems with those on the nitro-substituted ring more downfield owing to the resonance-
based electron-withdrawing character and deshielding effect of a nitro group. The ortho-
proton adjacent to the nitro (H-6) group was assigned as the most deshielded on the basis 
of a nitro substituent being more electron-withdrawing than a carboxamide. Assignment of 
H-3 as the triplet at 7.87 ppm and H-5 as the triplet at 7.80 ppm was based on the lack of 




coupling in the COSY spectrum of H-3 to H-6, the latter resonating at 8.15 ppm, while H-5, 
adjacent to H-6, did show a cross-peak to indicate coupling. The downfield NH proton peak 
and C=O carbon peak supported the successful formation of the amide bond. The fully 
assigned spectra are shown below. 
  








Figure 3.5 The assigned a) 1H and b) 13C NMR spectra for 2a in d6-DMSO.  
 








Figure 3.6 The assigned a) COSY and b) HSQC spectra showing the correlation of 13C and 1H 
peaks for assignment of compound 2a. 
The remaining phenyl and pyridyl monobenzamides (2b-e) were synthesised from the 
relevant commercially available acid chlorides (1b-e) as per Scheme 3.5. Et3N (*) was only 
used in the case of the pyridyl derivatives to ensure that the neutral species of the product 
was obtained. These derivatives were fully characterised by 1H and 13C NMR spectroscopy, 
where the correct multiplicity and number of resonances supported structural identity. 
Furthermore, all compounds were sent for high resolution mass spectrometry (HRMS) in 
which observed [M-H]+ ions corresponded to calculated theoretical masses within 5 ppm. 
Purity was assessed by melting point and high pressure liquid chromatography (HPLC) 
analysis. All the compounds had melting point ranges of ≤3 °C and HPLC purities of >95.0%. 






Scheme 3.5 Synthesised derivatives of the monobenzamides.  
In some of the targets, particularly those containing a pyridyl ring, removal of pyridine using 
1 M HCl in the work-up was inappropriate. This was due to the similarity in pKa of the 
molecule’s conjugate acid to that of the pyridinium ion.  A higher value for the conjugate 
acid pKa indicates a stronger base since the concentration of protonated base (BH+) in the 
equilibrium equation increases (Eq. 3.1). 
𝐁𝐇+ + 𝐇𝟐𝐎              𝐁 + 𝐇𝟑𝐎
+     Eq. 3.1 









In this case, azeotropic removal of the pyridine with toluene on the rotary evaporator at ≥60 
°C could be employed to remove the majority of the pyridine. Toluene and pyridine form a 
positive azeotrope whereby the boiling point of the mixture is lower than that of either 
constituent. For example, at atmospheric pressure, toluene and pyridine boil at 110.63 °C 
and 115.3 °C respectively, while the mixture boils at 110.0 °C with a composition of 78% and 
22% respectively.267,268 When the pressure is reduced, the boiling point decreases allowing 
toluene and pyridine to be removed together at a lower temperature than pyridine alone.  
This method was tested for 3,5-dinitro-N-phenylbenzamide (2b), which achieved complete 
removal of the pyridine under reduced pressure with toluene without using an acidic work-
Ka 




up. This was important for the synthesis of the pyridyl derivatives, in view of the similarity of 
the two pKa’s (5.12 for pyridine; 5.62 for 3,5-dinitro-N-(pyridin-4-yl)benzamide (2c)).269 
In the cases where 4-aminopyridine was the starting material, the reaction proceeded via 
the benzoylpyridin-4(1H)-iminium chloride salt (Scheme 3.6). This is because the nitrogen of 
4-aminopyridine (predicted conjugate acid pKa of 8.95) is almost 10,000 times more basic 
than that of pyridine (predicted conjugate acid pKa of 5.12) and much more nucleophilic as a 
result of resonance from the amine into the pyridyl ring. Therefore it is preferentially this 
nitrogen that reacts with the acyl chloride carbonyl to form an acyl-pyridinium ion 
intermediate which is then irreversibly converted to the product by transfer to the amino 
group of an unacylated 4-aminopyridine molecule. This process is slower since the pyridyl 
amine is less nucleophilic than the pyridyl nitrogen, but is driven by the charge on the 
iminium ion.  
The reaction to form 2d, the 3-pyridyl derivative, involved 3-aminopyridine as the reactant, 
which has a conjugate acid pKa of 5.75, comparable to that of pyridine. The amino group 
nitrogen lone pair is not able to resonate onto the pyridyl nitrogen, increasing the 
nucleophilicity of the amino group nitrogen but decreasing that of the ring nitrogen, relative 
to those in 4-aminopyridine. In this case, it is most likely that pyridine, being in a large 
excess, acts as the transfer agent. This is likely also the case for the synthesis of 2e with 2-
aminopyridyl (conjugate pKa of 6.84), where although resonance communication can occur, 
steric factors decrease the nucleophilicity of the ring nitrogen relative to that of 4-
aminopyridine. There did not appear to be a significant difference in reaction times between 
reactions forming 3-, 4- and 2-pyridyl compounds when pyridine was used as a solvent. 
Scheme 3.6 summarises these ideas and shows the mechanism for the reaction with 4-
aminopyridine, which possesses the largest conjugate acid pKa and the most nucleophilic 
ring nitrogen. This was the only aminopyridine starting material that was likely to act as the 
acyl transfer catalyst, rather than pyridine. 
 





Scheme 3.6 The mechanism for the formation of pyridylbenzamides 2c-e. 
 
3.2.1.2 Synthesis of the dibenzamides 
As with the mono-benzamides, the di and tri-benzamides were also synthesised via N-
acylation using the acid chloride. However, in the case of the dibenzamides, the relevant 
isophthalic dichloride had to be prepared fresh using SOCl2, as they were unstable or not 
commercially available. Once prepared, the acid chlorides were not isolated but kept under 
vacuum or under N2 and then dissolved in pyridine within the same reaction flask.  
 
3.2.1.2.1 Symmetrical dibenzamides 
The pyridyl derivatives 5a, 5b, 5d, 5f, 5h, 5i, 5k, 5m and 5o (Scheme 3.7) were synthesised 
from the appropriate freshly prepared isophthaloyl dichlorides and the appropriate amine 
as in 2c but with 2 equivalents (eq.) of Et3N. In some cases, the reactions were slower than 
that of the monobenzamides and were left overnight to insure that both amide bonds were 
formed and that purification by column chromatography was not necessary. In general the 
5-nitro (5a and 5b), 5-cyano (5d) and 5-methoxy (5m) derivatives needed longer to react 
than the 5-methyl (5f), 5-tert-butyl (5h and 5i) and the unsubstituted (5k and 5o) 




derivatives. The reasons for these differences are not known but may involve factors such as 
solubility or differences in quantities synthesised. The reaction times did not correlate with 
electron-withdrawing versus releasing capabilities of the substituents since the derivatives 
with the electron-withdrawing nitro and cyano substituents did not react faster than the 
electron releasing methoxy substituent. This is possibly due to the meta relationship 
between the acyl groups and the position-5 substituents of target molecule 5, which are not 
in direct electronic contact through resonance. Basic workups with sodium carbonate 
ensured that the pyridyl product was neutralised and could be extracted in EtOAc. Pyridine 
was then completely removed with toluene via azeotropic evaporation.    
The phenyl derivatives 5c, 5e, 5g, 5j, 5l, 5n, 5p (Scheme 3.7) were also synthesised from the 
appropriate freshly prepared isophthaloyl dichlorides but with aniline instead of the 
aminopyridine. The reactions were faster and cleaner than those of the pyridyl derivatives, 
partly owing to the fact that aniline, in contrast to 2-, 3- or 4-aminopyridine, is a liquid which 
assisted with solubility. Another reason for the shorter reaction times was the better 
nucleophilicity of the aniline amine relative to the pyridyl amines, where the amine 
electrons are delocalised onto the ring nitrogen. In order to accurately deliver the aniline, a 
micropipette was used, however, any excess aniline was removed in the workup with 1 M 
HCl, since the predicted pKa of the conjugate acid of aniline is 4.64. The pyridine was also 
removed in this way, allowing for efficient isolation of the products in good to excellent 
yields.  
 
 Scheme 3.7 Synthesised derivatives of symmetrical phenyl and pyridyl dibenzamides.  




Many studies have suggested that increased accumulation of compounds in the parasite has 
a large influence on their activity in vitro.98,58,99,101,108 For the 4-amino quinoline compounds, 
this is believed to be as a result of pH trapping in the acidic DV, owing to the basic amine 
side chains in the known antimalarials CQ, AQ, QN and QD.182 In this case, derivatives with 
basic side chains that can be protonated at pH 4.8, may be more active owing to larger 
VARs. This is discussed in detail from Sections 4.2.3.   
Synthesis of a derivative of the hit compound from the HTS (5a) with basic amino side chains 
in the form of target molecule 7 (Scheme 3.8), was attempted in several different ways. 
Initially this involved the formation of Boc-protected intermediate 6a and 6h from the 
relevant acid chloride and 4-[(N-Boc)aminomethyl]aniline. Although 6a was intended as the 
appropriate intermediate to target molecule 7, trial reactions were performed using 6h, the 
t-butyl analogue, owing to the availability of larger quantities of the starting material 3h 
than 3a. The protecting group on the amine was necessary since the aliphatic methylamine 
is more nucleophilic than the aromatic amine, which releases electron density into the ring 
via resonance.  
 
 
Scheme 3.8 Formation of target molecule 7 from the Boc-protected intermediate 6. 
  




Formation of 6h was supported by TLC analysis and confirmed by 1H NMR analysis in MeOD 
(Figure 3.7). Aromatic peaks corresponding to all three phenyl rings were observed, along 
with the 4.34 ppm resonance, integrating for the four aminomethyl protons corresponding 
to H-20 and H-28. In addition, the two magnetically equivalent Boc t-butyl functionalities 
and the one t-butyl at R1 were observed upfield in the spectrum at 1.58 and 1.56 ppm 
respectively. The amide and carbamate NH protons were not observed in the spectrum 




Figure 3.7 The 1H NMR spectrum of intermediate 6h in MeOD. 
In the next step, the Boc group of 6h was deprotected using trifluoroacetic acid (TFA) in dry 
DCM. This acid is particularly strong, owing to the electronegativity of the fluorine atoms, 
which not only destabilise the O-H bond, but also stabilise the anion of the conjugate base. 
As a result, the deprotection was carried out at 0 °C to ensure that the amide was not 




hydrolysed by the TFA. Deprotection proceeded via protonation of the carbamate followed 
by the entropy-driven loss of isobutylene and then the liberation of carbon dioxide to form 
the ammonium trifluoroacetate salt (Scheme 3.9).  
 
 
Scheme 3.9 Boc deprotection of 6 with TFA. 
 
The low boiling DCM and excess TFA could be easily removed under reduced pressure after 
which the free amine was isolated by stirring the product with potassium carbonate (K2CO3) 
in MeOH. This step resulted in an ion exchange to give the free amine 6, potassium 
trifluoroacetate and potassium bicarbonate. The differential solubility of these species in 
MeOH, in which only the free amine remained dissolved, enabled separation by filtration 
through Celite. The Boc-deprotection was confirmed by the disappearance of the Boc t-butyl 
groups and the upfield shift of the methylamine protons in the 1H NMR spectrum of 6h after 
deprotection (Figure 3.8). As in the spectrum of 6h before deprotection (Figure 3.7), NH 
protons were not observed in the solvent, MeOD. 





Figure 3.8 The 1H NMR spectrum in MeOD of the 6h after Boc deprotection.  
 
Following deprotection, methylation was first attempted with dimethylsulfate (DMS), a 
relatively hard electrophilic methylating agent. Trimethylamine (Et3N), as an external base, 
was needed to neutralize the MeHSO4 species from the methylation. However, adding the 
Et3N prior to the DMS resulted in a possible intramolecular rearrangement of the 
deprotected 6h to a N-(4-aminobenzyl)acetamide within 15 mins, most likely as a result of a 
base-catalysed rearrangement involving the nucleophilic primary amine. Evidence of this 
was indicated by TLC analysis, in which less polar UV active spots that stained dark purple 
with ninhydrin spray were observed before the addition of DMS.  
TLC evidence of the reaction with 5 eq. DMS, followed by 7 eq. of Et3N, gave evidence of 
quaternisation to the ammonium salt, visualised as a polar UV-active spot on the TLC 
baseline. This can be explained by the increase in nucleophilicity due to inductive effects of 
going from secondary (2°) to tertiary (3°) amine status. Scheme 3.10 outlines the 
mechanism of formation of 2°, 3° and 4° amines via methylation of the primary amine with 








Scheme 3.10 Methylation to the quarternary amine with dimethylsulfate (DMS). 
 
Owing to the added complication of having two sides of the molecule to methylate, the 
second strategy that was pursued involved the methylation of 4-(aminomethyl)aniline using 
DMS, to form 4-((dimethylamino)methyl)aniline, before amide bond coupling. This reaction 
involved using 2 eq. of DMS followed by 3 eq. of Et3N. Unfortunately, TLC analysis of this 
reaction also gave evidence in support of quaternisation, and a mixture of inseparable 
amines was produced. This can be seen in an example of a 1H NMR spectrum of the crude 
reaction product, obtained in very low yield from one of the reactions after extraction into 
EtOAc (Figure 3.9). Here, the 2° and 3° amines were observed in approximately a 1:1.2 ratio, 
having removed the 4° product into the aqueous layer during the work-up.  
 





Figure 3.9 The 1H NMR spectrum in MeOD of the methylation reaction with DMS. 
Hence, as a result of not being able to control the chemoselectivity of N-alkylation, an 
alternative, more selective method was adopted, as reductive amination, which involves a 
different C-N bond-formation mechanism (Scheme 3.11).  
 
Scheme 3.11 Formation of 7 via reductive amination from 6a. 




Specifically, the primary amine from Boc deprotection was formylated with formaldehyde to 
produce the imine, which was reduced with sodium cyanoborohydride (NaBH3CN) in 
situ.270,271 The resultant secondary amine then participated in the sequence again resulting 
in formation of the tertiary amine ultimately, using an excess of formaldehyde (40 eq.) and 
NaBH3CN (6 eq.) The one-pot reaction allowed both sides of the dibenzamide to be 
alkylated and, importantly, avoided the formation of the quaternary ammonium ion, which 
was not possible via this mechanism. The reason for this is presented in Scheme 3.12, which 
shows the necessity of the nitrogen lone pair for elimination of water. Sodium 
cyanoborohydride was used since it is milder than sodium borohydride, owing to the 
electron-withdrawing nature of the cyano group. This helps to stabilise the negative charge 
on the boron so that the hydride anion is less nucleophilic, resulting in a reducing agent 
which is selective for imines. Furthermore, the cyano derivative is stable in water, which was 




Scheme 3.12 The mechanism for the formation of the tertiary amine via reductive 
amination of the imine with sodium cyanoborohydride. 
 
  




The reaction was carried out with aqueous formaldehyde in DMF, a solvent known to assist 
reactions that proceed via a polar mechanism,252 such as the assisted E1-like elimination of 
water in this reaction (Scheme 3.12). This high-boiling solvent was partly removed in an 
aqueous work-up with EtOAc and then by evaporation under reduced pressure with heating. 
The NMR spectrum (Figure 3.10) of the purified product shows the assignment of the peaks 
for the target compound 7, whose relative simplicity bears testimony to its C-2 symmetry. 





Figure 3.10 The 1H NMR spectrum of 7 in DMSO-d6. 
 
  




3.2.1.2.2 Unsymmetrical dibenzamide (8) 
In order to evaluate the effect of increasing the aromatic molecular surface area available 
for haem association, a fused ring system, in the form of a benzimidazole, was selected for 
the R2 position in place of pyridyl or phenyl. This is discussed in detail in Section 4.2.4. 
The dibenzamides discussed in Section 3.2.1.2.1 were all symmetrical with respect to amide 
N-substituents and could therefore be synthesised easily with 2 eq. of the amine. 
Compound 8, as the only unsymmetrical compound, was synthesised owing to the fact that 
having two benzimidazoles resulted in an insoluble compound, which made isolation and 
purification essentially impossible. Since this type of molecule was undesirable for further 
assaying and analysis, a monobenzimidazole as a mixed derivative 8 was synthesised via 
sequential addition of two different amines instead (Scheme 3.13).  
 
Scheme 3.13 Formation of the unsymmetrical benzamide 8. 
The first attempt to achieve this involved reaction of the acid chloride with 1 eq. of aniline in 
an acetonitrile/liquid nitrogen cooling bath at -40 °C by slow addition. The lower 
temperature was chosen in order to slow down the rate of the reaction, with the intention 
of optimizing formation of the mono-phenylbenzamide. However, TLC analysis revealed 
remaining starting material together with two spots, most likely corresponding to the mono- 
and di-phenylbenzamide. Realising the inefficiency of this method, an alternative route was 
found, whereby the 5-nitroisophthaloyl dichloride was reacted with the less nucleophilic 2-
aminobenzimidazole first before addition of the more nucleophilic aniline. The resonance of 
the aminobenzimidazole vs aniline amines into the aromatic ring are shown in Figure 3.11. 
The stabilising ability of the nitrogen in the benzimidazole results in a less nucleophilic 
amine than that of the aniline. 





Figure 3.11 Resonance structures for the benzimidazole and aniline nucleophiles. 
To this end, one third of 1 eq. of the 2-aminobenzimidazole was slowly added to the 5-
nitroisophthaloyl dichloride in DCM without pyridine at -40°C. These conditions enabled the 
reaction to be maximally controllable since the solubility of the nucleophile in DCM was 
poor. After warming to RT, two drops of pyridine were added which assisted with the 
solubility and catalysed the amide bond formation. The remaining portion of the 
aminobenzimidazole as the limiting reactant was then also added slowly at  
-40°C before warming the solution and heating at 40°C to enable adequate solubility of the 
starting materials. Once TLC indicated that the amine had been consumed, aniline in excess 
was added to form the second amide bond, and a major product spot on the TLC, which did 
not correspond to that of the diphenylbenzamide product, was observed. After extraction 
into EtOAc, and hot filtrations to remove the impurities, 1H NMR analysis confirmed the 
successful synthesis of the unsymmetrical dibenzamide, 8 (Figure 3.12). As a result of the 
insolubility of compound 8 in many organic solvents, further purification by recrystallisation 
was only possible in hot pyridine, resulting in traces of pyridine in the 13C NMR spectrum 
after drying under reduced pressure. The peaks were characterised from HSQC NMR 
analysis (Figure 3.13). As for the other dibenzamides, HRMS confirmed structural identity in 
addition to NMR techniques. However, compound 8 had the lowest HPLC purity of all of the 
compounds synthesised of 93.2%, with UV-active trace amounts of pyridine, and a melting 
point range of 3°C. The remaining dibenzamides were all found to be >95% pure with a  
≤3 °C melting point range. 
  








Figure 3.12 The assigned a) 1H NMR (before recrystallisation in pyridine) and b) 13C NMR 
spectra (after recrystallisation in pyridine) for 8, confirming the successful synthesis. 
Recrystallisation resulted in trace amounts of pyridine observed in the spectra (1H ppm 9.7, 
8.8, 8.4; 13C ppm 148.8, 146.1, 128.7). 





Figure 3.13 The assigned HSQC spectrum showing the correlation of 13C and 1H peaks for 
assignment of compound 8. 
 
3.2.1.3 Synthesis of the tribenzamide 
Having synthesised a range of mono- and di-benzamides, access to a tri-benzamide was the 
next rational step in order to enrich the SAR analysis. Hence, symmetrical 
triphenylbenzamide 10 was synthesised which was easily achieved from the commercially 
available benzene-1,3,5-tricarbonyl trichloride with aniline and a 4:1 mixture of dry DCM 
and pyridine in 55% yield (Scheme 3.14). 
 
Scheme 3.14 Formation of tribenzamide 10. 
  




3.2.2 Scaffold 2: Triarylimidazoles 
3.2.2.1 Synthesis of triarylimidazoles with unsubstituted B and C rings 
The standard method available in the literature was used to prepare triarylimidazoles 15a-d 
by refluxing the appropriate aldehyde, benzil and sodium acetate in MeOH, according to 
Scheme 3.15. Benzil, being unsubstituted in the phenyl rings, resulted in products containing 
unsubstituted B and C rings, while substitution could be readily introduced into the A-ring 
by appropriate choice of aldehyde.  
High temperatures were preferred owing the release of water in the reaction mechanism, 
which is entropically favoured. The Gibbs free energy of reaction, which is related to the 
enthalpy (∆H), temperature (T) and entropy (∆S) by ∆G = ∆H - T∆S, is more negative with 
higher temperatures since ∆S is positive for entropically favoured reactions. The decrease in 
∆G typically results in a higher shift in the reaction equilibrium to the product side.273 
 
Scheme 3.15 Preparation of the triarylimidazole derivatives 15a-d. 
The optimized conditions presented by Azizi et al.259 were followed, which gave good to 
excellent yields for 15a-d. NMR data or melting points correlated with that of the literature 
for 15a274, 15b264 and 15c275 although 15d was a new, previously unreported compound, 
with a similar reaction time to that of 15a-c. There was no apparent trend observed 
between the electron donating ability of the aldehyde substituent and the reaction time, 
despite the expectation from a mechanistic standpoint that an electron-withdrawing 
substituent would increase the reaction rate, due to the greater electrophilicity of the 




aldehyde carbonyl carbon. Figure 3.14 shows confirmation of the synthesis of 15d, via 1H 
and 13C NMR analysis in deuterated acetone (acetone-d6) and DMSO-d6, respectively. The 
downfield NH peak in the 1H spectrum (~11.8 ppm) confirmed the formation of the 
imidazole ring. The 13C peak corresponding to the trifluoromethoxy carbon was further 
downfield at ~129 ppm compared to a methoxy carbon (normally at 50-60 ppm)276 owing to 
the strong electron-withdrawing ability of the three adjacent fluorine atoms, and was 
observed as a relaxed quartet (J = 144.9 Hz) due to a large germinal C-F coupling (IF = 0.5). 
This quartet is indicated by the red asterisks in Figure 3.14.  
 
  






Figure 3.14 1H and 13C NMR spectra of 15d in DMSO-d6.  
 
3.2.2.2 Synthesis of triarylimidazoles with substituted B and C rings 
Target compounds 15e and 15f containing substituents in the B and C rings required 4-
chlorobenzil and 4,4’-dimethoxybenzil as the starting materials respectively (Scheme 3.16). 
Since these compounds were not commercially available at the time of synthesis, they were 
synthesised from the corresponding benzoins, 12e and 12f via oxidation of the hydroxyl to 
the carbonyl with sodium hydride (NaH). Here, oxidation proceeds via the anion in a process 
driven by conjugating the two carbonyl groups into resonance with both aromatic rings. 
CF3 





Scheme 3.16 Preparation of the triarylimidazole derivatives 15e and 15f. 
 
The proposed mechanism by Joo et al.277 first involves the deprotonation of the hydroxyl 
group. The resultant alkoxide then undergoes an interesting hydride elimination with 
transfer to molecular oxygen, which is reduced to hydroperoxide. This then reacts with a 
second eq. of NaH to produce 2 eq. of sodium hydroxide (NaOH). The driving force for this 
transfer is undoubtedly that of achieving full conjugation between both phenyl rings and the 
two carbonyl groups. A work-up with sodium bicarbonate (NaHCO3) helps to wash out the 
NaOH, allowing for negligible by-product formation (Scheme 3.17). The role of oxygen was 
investigated by carrying out the reaction under oxygen-free conditions, which resulted in a 
33% decrease in product yield, confirming the involvement of oxygen in the mechanism. 
  





Scheme 3.17 The proposed mechanism for the oxidation of benzoins to benzils using 
NaH.277  
The two oxidation reactions of 12e and 12f progressed at significantly different rates. The 
formation of 14e (R4 = Cl, R5 = H), was completed after only 15 mins of stirring from 0° C to 
RT. The rapid rate of oxidation for this chloro derivative agreed with the previously reported 
time of 6 mins at RT. This was in contrast to 14f (R4 = R5 = OMe), the 4,4’-dimethoxy 
derivative, which required stirring at RT for 3 h in order to completely consume the benzoin 
starting material. A likely reason for this difference in rate is the electronic effect of the 
chloro (Cl) vs methoxy (OMe) substitiuent. The reported reaction time for benzoin (R4 = R5 = 
H) is 1.5 h, significantly longer than the chloro derivatives, which show times ranging from 6 
to 15 mins. Since the order of electron donating ability is OMe > H > Cl and the 
corresponding reaction times were 3 h > 1.5 h > 15 mins, the electron density within the 
phenyl ring is likely to have an important effect on the degree of stabilisation of the 
developing carbonyl group. Here, presumably mesomeric electron release (OMe) or 
inductive withdrawal (Cl) destabilises or stabilises respectively, the developing carbanionic 
character of the benzylic position in the transition state (Figure 3.15). Although the 
oxidation of 4,4’-dimethoxybenzoin with NaH has not been reported, that for the 3,3’-
dimethoxy derivative meta to the C=O and C-OH, has been published. Interestingly, this 
reaction has a reported time of 9 mins, remarkably shorter than both the p-dimethoxy and 
the unsubstituted benzoin. This is in agreement with the proposed hypothesis since the m-
methoxy cannot conjugatively release electron density via resonance towards the carbonyl, 
although it does have an inductive withdrawing effect which may assist with α-hydride 
elimination. Alternatively, the negative charge adjacent to the hydroxyl carbon in the p-
methoxy derivative may decrease the rate of α-hydride elimination, since negative charge 
must flow from the sodium alkoxide oxygen to the adjacent carbon in order for this 




elimination to take place. The negative charge on the phenyl ring cannot assist with this 
elimination since it is part of the π-orbital framework and the α-hydride leaves with electron 
density through the sigma orbital framework. Figure 3.15 summarises these ideas for a p-
methoxy group. 
 
   
Figure 3.15 Resonance structures for 4,4’-dimethoxybenzoin. 
 
Formation of the required benzils 14e and 14f was confirmed by 1H NMR analysis, whose 
data corresponded to that of the literature,278 and the spectra of which are shown in Figures 
3.16 and 3.17, respectively. In both cases resonances in the aromatic region shifted 
downfield upon oxidation owing to the electron-withdrawing effect of the oxidised 
carbonyl. For 12e, coupling (J = 6.2 Hz) was observed between the hydroxyl and benzylic 
protons. This is due to the hydrogen bond accepting capability of the solvent used, acetone-
d6, which decreases the rate of hydroxyl proton exchange and results in doublets for each of 
these two resonances. However, this coupling was not observed for 12f, in CDCl3, since 
intermolecular exchange of the hydroxyl protons, leading to broadening of the signals, 
occurs in this solvent.279 The resonances corresponding to the hydroxyl and benzylic protons 
disappeared upon oxidation to 14e and 14f. The oxidation to 14f was particularly interesting 
as the molecule becomes symmetrised upon forming two carbonyls. This is very evident in 
the 1H NMR spectra (Figure 3.17) which shows the two methoxy peaks, initially in different 
chemical environments converging to one peak once they are chemically and magnetically 
equivalent.  
  







Figure 3.16 The 1H NMR spectra of 4-chlorobenzoin (12e; bottom) and 4-chlorobenzil (14e, 
top) in acetone-d6. 






Figure 3.17 The 1H NMR spectra of 4,4’-dimethoxybenzoin (12f; bottom) and 4,4’-
dimethoxybenzil (14f; top) in CDCl3. 
Following synthesis of the benzils (14e and 14f), the corresponding triarylimidazoles (15e 
and 15f) were formed in good yields using the procedure previously described for 15a-d.  
 
  




3.2.2.3 Synthesis of nitro- and amine-substituted triarylimidazoles 
Attempts to synthesise target compound 16 containing a para-amino group in the A-ring 
from p-aminobenzaldehyde were unsuccessful. The reason for this was not further 
investigated since multiple spots on the TLC were observed in which the reaction formed a 
dark, gummy mixture that could not be extracted into an organic solvent. It is likely that the 
aldehyde preferentially self-condenses under these conditions to give oligomeric products. 
An alternative route was followed whereby the nitro derivative (15g) was formed and then 
reduced to the amine using iron powder and a catalytic amount of HCl. The conditions 
reported by Wan et al.260 were followed for both 15g and 16, which involved a 4 hr glacial 
acetic acid reflux at 118 °C for 15g and then a 6 hr reflux at 80 °C reflux with Fe powder in 
an EtOH/water (2:1) mixture for 16 (Scheme 3.18).  
 
 
Scheme 3.18 Preparation of the triarylimidazole derivatives 15g and 16. 
  




The formation of 15g in acetic acid occurred at a similar rate to that of 15a-d in MeOH. 
Upon neutralisation of the acid with ammonia during the workup, the insoluble product, 
15g, could be extracted by filtration and then purified by recrystallisation resulting in an 
excellent yield of 93%. In the subsequent step, the nitro group was reduced with zero-valent 




Scheme 3.19 The reduction of an aromatic nitro functionality to a phenyl amine using 
elemental iron and a catalytic amount of HCl.  
 
The formation of the amine was supported in the 1H NMR spectrum by the appearance of 
two amine protons at ~5.3 ppm as well as an upfield shift of the four protons on ring A due 
to the electron-releasing influence of the newly introduced amino group. Figure 3.18 shows 
the overlaid spectra for the nitro (15g) and amine (16) derivatives respectively.  
 





Figure 3.18 Comparison of the spectra in DMSO-d6 for the nitro derivative (15g) and the 
amine derivative (16).  
 
All the triarylimidazoles (15a-g and 16) were characterised by both 1H and 13C NMR analysis 
as well as HRMS, which showed masses for the observed [M+H]+ ions within 5 ppm of the 
theoretical values. Furthermore, all compounds were found to be adequately pure with a 
melting point range of ≤2 °C and >95% purity as determined by HPLC analysis. 
 
3.3 Summary and conclusions 
The formation of the benzamide derivatives was carried out from the appropriate acid 
chloride, which was either purchased or freshly prepared, and either aniline, an 
aminopyridine, or 2-aminobenzimidazole or 4-[(N-Boc)aminomethyl]aniline. In the last, the 
desired product, derivative 7, was achieved via Boc-deprotection, formylation to the imine 
and reductive amination. All dibenzamides were symmetrical except for derivative 8, which 




was formed via the addition of the less reactive amine, the 2-aminobenzimidazole first, 
before the addition of aniline to the acid chloride. This involved lower temperatures and a 
catalytic amount of pyridine to carefully control the reaction, in contrast to the symmetrical 
derivatives which were conducted in neat pyridine for optimal reaction rates and yields. The 
addition of Et3N to the amide coupling reaction was not necessary in the case of the 
phenylbenzamide derivatives but aided in solubility of the starting materials in the case of 
the pyridylderivatives and also neutralised the formed HCl to ensure isolation of the 
unprotonated product. 
Synthesis of the triarylimidazoles via multiple condensation steps with benzil, an aldehyde 
and ammonium acetate was successfully performed using standard procedures, which 
required refluxing for optimal reaction times and product yields. The elimination of water in 
the reaction mechanism led to higher temperatures being favoured according to the Gibbs 
free energy equation since an increase in temperature resulted in a larger entropy term. 
Two of the benzils, 14e and 14f, were oxidised from the corresponding benzoins with the 
strong, hard base, sodium hydride. The reactions required diverse reaction times which 
agreed with the literature trends. Electron-withdrawing substituents increased the rate 
while electron releasing para substituents significantly decreased the rate of oxidation. The 
reaction with 4-aminobenzaldehyde was unsuccessful but the target compound could be 
synthesised via the nitro derivative, 15g, which was then reduced to yield the required 
amino derivative, 16. 
A total of 24 mono- or di-benzamides and 8 triarylimidazoles were synthesised in moderate 
to excellent yields using inexpensive starting materials. Most synthetic routes required no 
more than two steps and minimal time for isolation and purification. All the characterisation 
data confirmed compound identity and high purity. The synthesised derivatives comprised a 
variety of electron-withdrawing and donating groups as well as hydrophobic and hydrophilic 
moieties. In addition, they could all be dissolved in DMSO, making them suitable for testing 
in the required assays for SAR analysis. 






STRUCTURE-ACTIVITY RELATIONSHIPS FOR  
β-HAEMATIN INHIBITION AND PARASITE ACTIVITY 
 
4.1 Introduction 
One of the major challenges of drug development is identifying appropriate research routes 
after HTS, particularly when it comes to selecting potential leads. In this case, HTS revealed 
the pyridyl-dibenzamide, 5-nitro-N,N'-di(pyridin-4-yl)benzene-1,3-dicarboxamide (Figure 
4.1a), with nearly a ten times lower IC50 for βH inhibition than CQ and with a promising 
parasite activity of 0.19 µM against the D6 strain, the third most potent compound of all 171 
parasite-active hits. Furthermore, a mono-pyridylbenzamide, 3,5-dinitro-N-(pyridin-4-
yl)benzamide (Figure 4.1b) was also shown to have excellent potency against βH formation 
but a poorer potency against the parasite. A literature search revealed that the dibenzamide 
chemotype had not been previously published as an antimalarial, although other mono-
benzamides had been reported to prevent parasite growth, supposedly via kinase 
inhibition.213 Besides potent activity, the benzamides were attractive from a synthetic point 
of view, owing to the ease with which derivatives could be synthesised. Indeed, almost all 
the required derivatives were efficiently synthesised in short sequences from cost-effective 
reagents. In addition, the structural difference of the benzamides from many of the 
haemozoin-inhibiting antimalarials that contain fused ring systems such as the quinolines 
and neocryptolepines, made them attractive for probing mechanisms of action.107-109,282 In 
the discussion which follows, ring A is defined as the aromatic substituent that is attached to 
the carbonyl of the amide and ring B to the amine of the amide. 
  









     VU0001281, IC50 of 0.19 µM VU0358764, IC50 of 4.76 µM 
 
Figure 4.1 Examples of parasite-active hits found in the HTS; a) The di-pyridylbenzamide, 5-
nitro-N,N'-di(pyridin-4-yl)benzene-1,3-dicarboxamide and b) the mono-pyridyl-benzamide, 
3,5-dinitro-N-(pyridin-4-yl)benzamide.  
 
4.1.1 Specific goals 
The specific goals for Chapter 4 were to: 
 Test the purchased or synthesised simple benzamide derivatives in the NP-40 assay 
for βH inhibition to determine the minimum structural requirements for activity. 
 Employ the synthesised analogues possessing substituents with varying electronic, 
lipophilic and spatial properties for SAR analysis by evaluating the βH inhibition 
activity of these analogues in the NP-40 assay and investigating mechanistic aspects 
of the inhibition process. 
 Determine the inhibition of parasite growth activity using the LDH malaria parasite 
growth assay. 
 Attempt to validate the biological target within parasitised red blood cells. 
 Perform other relevant experiments to determine cellular accumulation or strength 
of haem association. 
  




4.2 Results and discussion 
4.2.1 β-haematin inhibitory activity of the benzamides 
4.2.1.1 βH inhibition assay in 96-well plates 
The NP40 assay for βH inhibitors employed in the HTS at Vanderbilt University (VU) was 
modified for use in 96-well plates at the University of Cape Town (UCT). At VU, compounds 
were added to a 384-well plate automatically using acoustic delivery from source plates 
which contained the HTS library compounds. At UCT, however, compounds and reagents 
had to be added manually. As a result, the use of 384-well plates became problematic, since 
they required very low µL volume additions. Instead, compounds were added using single 
channel micro pipettes. For concentration dose response experiments, this was initially 
carried out by preparing several stock solutions of the test compound and pipetting the 
relevant quantity into the well for the desired concentration. However, efficiency and 
accuracy was greatly improved after adopting a serial-dilution technique to achieve the 
required test sample concentration. Reagents were added using multichannel pipettes and 
incubated in either a closed water bath or a thermally controlled incubator without shaking. 
The IC50s were consistently slightly lower than the 384-well experiment, but relatively 
comparable. Reproducible values were obtained (Figure 4.2).  
 

















Figure 4.2 Concentration dose response curves generated from four replicates using the 
serial dilution technique for the NP40 assay in 96-well plates for CQ and AQ, with IC50s of 
31.5 ± 0.5 µM and 12.7 ± 0.3 µM respectively. 
  





4.2.1.2 Evaluation of βH inhibition for the purchased benzamides  
N-phenylbenzamide, the core structure of the hit compounds VU0001281 and VU0358764 
(Figure 4.1a, b), as well as simple derivatives were purchased in order to ascertain the 
smallest fragment for which βH inhibition activity is obtained by varying substituents on the 
phenyl ring. Selection of the compounds was guided by the Topliss decision tree, which aids 
in deciding which substituents to employ for improved activity.256 The idea behind the 
diagram in Figure 4.3 is to start from a derivative with an unsubstituted ring and to evaluate 
the activity relative to the hit compound, which in this case contained 3,5-dinitro 
substituents. The branch corresponding to either less (L), equally (E) or more (M) active than 
the previous compound is then followed and the next substituent is evaluated. Following 
the guidelines for substituents within the relevant branch of the Topliss decision tree should 
theoretically lead rapidly to the substituents which are electronically, hydrophobically and 
sterically favoured for activity. In this study, the branches of the tree were not followed 
sequentially in the interest of time, but rather, compounds were purchased in order to 
cover a range of substituents throughout the tree so that SARs could be constructed using 
diverse derivatives. This is because the substituents selected using the Topliss scheme cover 
a wide range of electronic, hydrophobic and steric properties. In some cases, compounds 
were not commercially available, but ten were obtained (P1 - P10) for βH activity 
measurement, as shown in Figure 4.3 and Table 4.1. 
  






Figure 4.3 The Topliss decision tree showing aromatic substituents of purchased compounds 
P1 - P10 to evaluate SARs (L = less active, E = equally active and M = more active).256 
Numbered boxes indicate substituents of compounds purchased. Copyright © 2001, Oxford 
University Press.283 
 
Table 4.1 Purchased benzamides for core structure analysis. All the compounds were 
inactive and benzamides P7-P10 formed a pink precipitate at the indicated concentration 
range when added to a solution of haem and NP40 at pH 4.8.  
 
Code 
Concentration range at which 
precipitate forms (µM) 











Unexpectedly, the purchased compounds P1 – P10 did not display activity against βH 
formation (IC50 > 5500 µM). Compounds P1 - P6 contained either an unsubstituted phenyl 
moiety as ring A and a pyridyl as ring B, or a substituent in the para position of the phenyl 
ring and a phenyl or pyridyl as ring B (Table 4.1). These compounds showed no specific 
interaction with haematin. However, purchased compounds P7 – P10, all possessing a 
halogen substituent in the meta and para positions, demonstrated an interesting 
phenomenon whereby, upon addition of haem, a pink precipitate rapidly formed, indicative 
of low spin Fe(III)PPIX complex formation in a similar manner to that of pyridine 
coordination to unconverted Fe(III)PPIX in the βH assay. Coordination of these compounds 
to the central Fe atom of haem was believed to be via the nitrogen of their pyridyl 
substituent, which has added nucleophilicity over that of pyridine due to resonance from 
the amide N atom to the 4-pyridyl N atom. The precipitation of this complex was likely 
caused by the lipophilic influence of the halogen(s) with P9, containing two chloro 
substituents, showing the effect at the lowest compound concentration and P7, with only 
one 4-chloro atom, showing the effect at five times higher concentration.  In summary, this 
precipitation occurred at a lower concentration for meta substituents as opposed to para 
and for two substituents as opposed to one.  
 
4.2.1.3 Evaluation of βH inhibition for the synthesised monobenzamides 
The results for the purchased compounds showed that the Topliss decision tree was not a 
suitable method for selecting derivatives for SAR analysis. This was because the activity of 
the monobenzamides could not be “switched on” by the halogen substituents or by para 
substituents. In contrast, the hit compound with two meta-nitro substituents showed 
excellent βH inhibition activity (Figure 4.1b). This compound was resynthesised so that the 
results of the HTS could be confirmed (compound 2c). Since both compounds P3 (4-nitro 
substituent) and P4 (2,4-dinitro substituents) were not βH inhibitors, the influence of the 
para nitro group was probed by synthesising and evaluating a derivative with only an ortho 
nitro substituent (2a). Additionally, the type of ring B (defined here as R2) was varied in 
order to probe the effect of the pyridyl nitrogen. Figure 4.4 shows the five synthesised 
monobenzamides. 
 





Figure 4.4 The synthesised mono-benzamide derivatives. 
 
Activities for the monobenzamides are shown in Table 4.2. Compound 2a did not show 
activity against βH formation up to 1000 µM, as compared to the CQ standard of 30 µM. 
This result led to the conclusion that mono phenyl benzamides with 2-nitro, 4-nitro or 2,6-
dinitro substituents were incapable of inhibiting βH formation. However, the 
phenylbenzamide, 2b, with 3,5-dinitro substituents, showed a good activity of 22 ± 1 µM, 
which was slightly better than the CQ standard and about half as active as AQ. Compounds 
2c and 2d, N-pyridyl analogues of 2b, showed even better activity with IC50 values of 10.9 ± 
0.3 µM and 13 ± 1 µM respectively.  The dramatic increase in activity for 2b, 2c and 2d 
compared with 2a showed that the meta nitro substituents were required for βH activity in 
which variation of the R2 ring had less influence. This proved that the nitrogen in the pyridyl 
ring was not required for activity and therefore also demonstrated that it was unlikely that 
this series inhibited βH formation via coordination of the pyridyl nitrogen to the haem iron 
centre. Compound 2e, containing a 2-pyridyl at R2 also displayed some activity (IC50 of 134 ± 
8 µM), although it was 10 fold weaker than the 3-pyridyl and 4-pyridyl analogues. Since the 
derivative with no nitrogen atom in the R2 ring (2b) was active, the decrease in activity of 2e 
was presumably not due to the loss of the nitrogen in the 3 or 4-position, but rather 
because of the added nitrogen in the 2-position of the ring. Estimation of the pKa values of 
2c-e using MarvinSketch software269 showed a decrease in basicity of the nitrogen in 4-
pyridyl, 3-pyridyl and 2-pyridyl groups with predicted pKas of 5.62, 4.37 and 2.69 
respectively. The relative basicity of the derivative influences the ratio of protonated to 
unprotonated species present in the assay well or in the DV. At pH 4.8, using the predicted 
pKas, 2c was 87% protonated while that of 2d was only 27%. Owing to the much weaker 
basicity of 2e, more than 99% was neutral at the pH of the DV. This weaker basicity is partly 




due to the inductively withdrawing effect of the ortho amide substituent, which has been 
shown to have a larger inductive effect than a resonance releasing one, for the 2-position.284 
As a result, the conjugate acid of 2e is destabilised. This is in contrast to the 4-position, 
where the resonance releasing ability of the amide is much greater than its inductive 
withdrawing ability, leading to increased 4-pyridyl basicity or greater conjugate acid 
stability. Another reason for the weaker basicity for the ortho substituted pyridine is the 
steric hindrance factor which destabilises protonation on the ortho-nitrogen. However, the 
relative basicity did not appear to be the sole reason for activity differences, since both 2c 
and 2d displayed equally potent activity. Furthermore, basic groups are not required for 
activity since 2b, the phenyl derivative, was also active. 
 
Table 4.2 βH inhibition activity for the synthesised monobenzamides 
Compound βH inhibition IC50 (µM) 
2a >1000 
2b 22 ± 1 
2c 10.9 ± 0.3 
2d 13 ± 1 
2e 134 ± 8 
CQ 31.5 ± 0.5 
 
4.2.1.4 Factors influencing βH inhibition of mono-benzamides.  
The exact mechanism by which βH inhibitors block crystal growth is still under debate. Over 
the past two decades it has been proposed that inhibition by quinoline antimalarials is via 
direct drug complexation to haematin in solution,139,285,141 by binding to the fastest growing 
faces of the βH crystal,154,207,136 or via a drug-haem complex capping the haemozoin crystal 
to block sites of further crystal growth.137 Nevertheless, all the proposed mechanisms 
involve an interaction between the drug compound and Fe(III)PPIX. Recently, de Villiers et 
al.158 have reported crystal structures of QD-Fe(III)PPIX and QN-Fe(III)PPIX, which 
demonstrate that three key interactions are involved in haem binding by these drugs, 
namely coordination, hydrogen bonding and π-π stacking. For QD and QN, hydrogen 
bonding occurs between the protonated quinuclidine nitrogen and the propionate group of 
haem. Another study showed that dihydroxyxanthones hydrogen bond via their hydroxyl 
groups, as well as π-π stack with Fe(III)PPIX.286  Most of the benzamides possess features 




which are capable of binding to Fe(III)PPIX via all three of these interactions, specifically, a 
pyridyl N for coordination, an amide for hydrogen bonding and aromatic rings for π-π 
stacking. However, 2b does not possess a pyridyl moiety for coordination to the Fe(III)PPIX 
centre and yet retains a low IC50, ruling out coordination as a key interaction for βH activity. 
Furthermore, the lack of hydrogen bonding substituents in 2b-e suggests that this 
interaction can only occur via the amide. Since many of the compounds with amides, 
including all the purchased benzamides, were inactive, an amide hydrogen bonding 
interaction was considered very unlikely to be the crucial determinant of βH inhibition 
activity. By a logical process of elimination, π-π stacking was left as the major interaction 
leading to inhibitory activity. Although the exact requirements for π-π stacking are still not 
clear, it was hypothesised that having larger, aromatic, planar molecular surfaces would 
increase the strength of the interaction with either haematin or haemozoin. The ability of 
the molecule to lie flat would therefore be expected to influence the βH inhibition activity. 
This hypothesis was considered to be the only feasible explanation for the observed SARs.  
The π-π stacking mechanism was consistent with the structure-activity data for pyridyl 
derivatives P4 with 2,4-dinitro groups (inactive) vs 2c with 3,3-dinitro substituents (active) 
and phenyl derivatives, 2a with 2-nitro groups (inactive) vs 2b with 3,3-dinitro substituents 
(active). In silico internal energy calculations carried out using Gaussian software287 
demonstrated that the barrier to rotation around the bond linking the carbonyl to the 
phenyl for P4 (Figure 4.5a) possesses minimum energy conformers with torsion angles 
about the C=C-C=O bond of 70° and -110°. For the molecule to be planar, the torsional angle 
would be 0° or ±180°. The steric strain energies of these flat conformers are far greater than 
the thermally accessible energy 3kT indicted in Figure 4.5a. If the molecule is only able to 
bind to Fe(III)PPIX when in the planar conformation, this hypothesis would explain the lack 
of βH inhibition activity for P4. This hypothesis is also consistent with the positive activity 
data for 2c which is able exist in a planar conformation (±180°) below 3kT (Figure 4.5b) 
owing to the low steric strain caused by meta as opposed to ortho-nitro substituents. It may 
also explain why 2e with a 2-pyridyl group had lower activity than the 3-pyridyl and 4-pyridyl 
analogues due to the close proximity of the negative ortho nitrogen lone pair to the electron 
cloud on the carbonyl oxygen, which is likely to affect the conformational preference of 2e.  
 





Figure 4.5 Free energy diagrams for rotation around the indicated bond where 0° or ±180° 
represents the flat conformation for (a) purchased compound P4 (βH inactive) and (b) 
synthesised compound 2c (βH active). The value 3kT represents the thermally accessible 
energy value at 37 °C. Note the difference in scale of the y-axes (a) and (b). 
 
A summary of the SARs for the monobenzamides is given in Figure 4.6. These results 
demonstrate the minimum requirements for βH activity of the benzamides, which were 
later applied in the synthesis of di- and tri-benzamide derivatives (Section 4.2.1.5). Most 
importantly, only compounds with substituents in the meta position on ring A were chosen 
for further analysis, since substituents in the ortho and para positions were not tolerated for 
βH inhibitory activity. Furthermore, 2-pyridyl was excluded for the R2 substituent since the 
results for the monobenzamides suggested that the βH inhibition activity was substantially 
lower in this analogue. The effect of different R2 substituents on the SARs is further 
investigated for the dibenzamides in Section 4.2.1.5.  





Figure 4.6 βH inhibitory SARs for the monobenzamides.  
 
4.2.1.5 Evaluation of βH inhibition for the synthesised di- and tri-benzamides 
Although two of the monobenzamides were able to inhibit βH inhibition with comparable 
activity to AQ, the parasite data from the HTS indicated that dibenzamides were more 
effective at preventing parasite growth than the monobenzamides. For this reason, a 
focused library of dibenzamides was synthesised and tested. In addition, the 4-pyridyl 
parent compound was resynthesised (5a) along with 3-pyridyl (5b) and phenyl (5c) 
derivatives. A 2-pyridyl derivative was not synthesised since the monobenzamides indicated 
that the 4-pyridyl and 3-pyridyl analogues were better βH inhibitors (Table 4.2). In addition 
to varying the type of ring B (R2 substituent), the substituent on ring A (R1) was also varied 
from the parent nitro to cyano, methyl, t-butyl, hydrogen or methoxy, resulting in 
derivatives 5b - 5n. These substituents were chosen for their range of electron-withdrawing 
vs releasing as well as hydrophobic vs hydrophilic properties, which excluded the halogens, 
since the chloro derivative was shown to be inactive in the purchased mono-benzamides. In 
addition, substituting X = CH for X = N resulted in derivatives with a pyridyl central ring as 
opposed to a phenyl (5o and 5p) all of which are defined in Figure 4.7, along with the 
tribenzamide 10.  
  







Figure 4.7 The synthesised dibenzamides, analogues of the hit compound 5a, and the 
tribenzamide 10. 
 
Table 4.3 shows the βH inhibition values for the compounds 5a - 5p and 10. Dibenzamides 
5a, 5b and 5c displayed similarly potent βH IC50 values (2.9-7.0 µM), four to ten times more 
active than CQ and at least three times the activity of the monobenzamide analogues. This 
improved activity is in agreement with the hypothesis that larger planar surfaces result in 
improved βH inhibition due to increased π-π stacking ability. The cyano derivatives (5d and 
5e) maintained excellent βH activity about six times that of CQ for both the pyridyl and 
phenyl rings. However, for the methyl (5f and 5g), t-butyl (5h-j), hydrogen (5k and 5l) and 
methoxy derivatives (5m and 5n), only those with pyridyl rings at R2 showed activity, while 
those with a phenyl ring displayed no activity below 1000 µM. Compounds 5o and 5p with a 
central unsubstituted pyridyl ring and R1 = H showed weak activity for the pyridyl derivative 
and no activity below 1000 µM for the phenyl derivative. The tribenzamide 10 showed good 
activity, slighter better than that of CQ. 
  




Table 4.3 βH inhibition activities for the di-benzamides 5a-5p and tri-benzamide 10. 
Compound R1 substituent βH inhibition IC50 (µM) 
5a 
Nitro 
4.3 ± 0.1 
5b 4.7 ± 0.7 
5c 7.0 ± 0.2 
5d 
Cyano 
6.34 ± 0.09 
5e 4.4 ± 0.2 
5f 
Methyl 




13.3 ±  0.7 








22 ±  1 
5n > 1000 
5o 
H (X = N) 
260 ± 7 
5p >1000 
10 N/A 21 ± 1 
CQ N/A 31.5 ± 0.5 
 
In general, a compound with a spatially flat, hydrophilic, electron withdrawing group such as 
NO2 (5a-c), CN (5d,e) or benzamide (10)) at R1 was able to maintain activity with either a 
pyridyl or phenyl ring at R2. Conversely, when R1 was H or a more electron releasing group, 
only the pyridyl derivative(s) were active and those with phenyl at R2 showed no ability to 
inhibit βH formation even at a relatively high concentration. This may indicate that the 
molecules have two possible orientations of interaction with Fe(III)PPIX giving rise to βH 
inhibition. The first involves π-π stacking with central ring, which can only take place with 
the flat, electron withdrawing nitro and cyano groups. The second involves an interaction 
with the R2 ring, which appears not to occur in the case where R2 is phenyl as opposed to 
pyridyl, similar to that for naphthalene analogues of the 4-amino quinolines, which also lack 
βH inhibition activity.288  This may be as a result of the relative electron richness of the 
phenyl as opposed to the pyridyl ring, with the latter being electron deficient owing to the 
electronegative nitrogen atom. Interestingly, the high IC50 of 5o, the X = N derivative with  




R2 = pyridyl, can be explained in a similar manner to that of 2e. Since both these compounds 
have an ortho-pyridyl ring B, the influence of the ortho nitrogen in close proximity to the 
amide results in a decreased probability of π-π interaction, either by causing the molecule to 
be less planar, or by adding too much electron density at that particular site of the 
molecule. The SARs for the dibenzamides are shown in Figure 4.8. Note that the planar and 
electron withdrawing nitro and cyano substituents at R1 follow a different SAR scheme to 
that of the methyl, t-butyl, H and methoxy substituents. 
 
Figure 4.8 βH inhibitory SARs for the dibenzamides. 
 
4.2.1.6 Proposed mechanism of βH inhibition for the dibenzamides 
Compound 5k showed very low activity, indicating that a non-H substituent was required at 
the R1 position, although the reason for this was not clear. It does, however, show that 
there is a necessary role for the R1 substituent, even when R2 is pyridyl, since the lack of 
activity cannot be ascribed to hydrophobicity or electronic effects. It is possible that the 
substituent at R1 aids in directing the compound into the desired orientation to inhibit βH 
formation. This result is qualitatively consistent with the mechanism of βH inhibition by 
which drug interaction is via the growing face of the crystal and not via interaction with free 
Fe(III)PPIX. For example, the derivatives with non-planar R1 groups would preferentially 
orientate relative to the corrugated crystal face so that the substituent lies away from the 
crystal surface. This was observed from docking the molecule with the crystal face in 




Materials Studio,289 as shown in Figure 4.9. This results in the methyl, tert-butyl and 
methoxy derivatives being oriented in such a way that the R2 ring interacts with Fe(III)PPIX 
molecules at the binding site. In this case, only those derivatives where R2 is pyridyl interact 
strongly with Fe(III)PPIX, while those containing more electron rich phenyl rings may be able 
to reach the binding site, but are probably readily displaced by another Fe(III)PPIX molecule, 
allowing for continuation of crystal growth (Figure 4.9). On the other hand, 5c and 5e 
contain R1 substituents which can fit into the crystal grooves, allowing the central ring to 
bind via π-π interactions to Fe(III)PPIX and for both the pyridyl and phenyl analogues to have 
equally potent activity. In the case of the pyridyl derivative 5k, there is no R1 substituent to 
aid in directing the molecule into the required binding groove and presumably as a result of 
statistically controlled binding orientations; a larger concentration is required for inhibition 
and a higher IC50 is observed.   
 
   
Figure 4.9 A possible mode of interaction to explain the observed βH inhibition activities. In 
this example, the dibenzamide, 5j interacts with the fastest growing haemozoin crystal face 
{001} with the R1 tert-butyl moiety directed outwards. It is likely that this substituent forces 
or directs the benzamide rings into the groove on the crystal face were it binds, accounting 
for the strong βH inhibitory activity. Images were supplied by R. Muller and generated using 
Materials Studio.289  
 
  




4.2.2 Activity of benzamides against P. falciparum in culture 
4.2.2.1 Activities of the monobenzamides 
The synthesised benzamide derivatives were tested for inhibitory activity against the CQ-
sensitive NF54 strain of P. falciparum. The monobenzamides 2b-e displayed a range of IC50 
values from 2.3 to 22 µM and 2a, which was not a βH inhibitor, showed no activity below 
the maximum concentration tested, 41.3 µM (Table 4.4). A good correlation was identified 
between the inverse of the βH inhibition IC50 and inverse parasite growth inhibition IC50, 
with an r2 of 0.88 (Figure 4.10). By representing this relationship as the inverse of the IC50, 
compound 2a can be taken into account by taking its inverse IC50 as approximately zero. The 
correlation suggests that the monobenzamides do indeed exert their therapeutic action via 
inhibition of intracellular haemozoin formation. 



















Figure 4.10 A linear correlation between the inverse of the βH and parasite growth IC50 
values for the CQ-sensitive NF54 strain (r2 = 0.8750; P = 0.0195). 
 
  




4.2.2.2 Activities of the di- and tri-benzamides 
The parasite activities of the monobenzamides were at least four-fold weaker than that of 
the parent compound from the HTS in the CQ sensitive D6 strain with an IC50 of 0.19 µM 
(Table 2.3). This hit 5a was resynthesised and tested in the available CQ-sensitive NF54 
strain. The activity was found to be three times weaker than that of the D6 strain, with an 
IC50 of 0.7 µM. The 3-pyridyl and phenyl analogues, 5b and 5c, exhibited a further 2-fold 
lower activity, similar to their decrease in βH inhibition IC50 values.  
The other derivatives were also tested in the NF54 or D10 strains of P. falciparum, both of 
which are CQ-sensitive. Where comparisons were made, both strains gave similar IC50 values 
for tested compounds (Table 4.4). The strain used for a specific derivative was dictated by 
availability of material in combination with the strain in culture at the time of testing.  
Replacing the nitro substituent (R1) with cyano caused a 3-fold increase in IC50 to 1.9 µM for 
5d, the pyridyl derivative. A further IC50 increase to 5.2 µM was observed for the phenyl 
derivative 5e. A similar reduction in activity was noticed when replacing the R2 pyridyl ring 
with a phenyl group for the derivatives where R1 is methyl (5f and 5g), t-butyl (5i-j), 
hydrogen (5k and 5l) or methoxy (5m and 5n). Both compounds with X = N (5o and 5p) were 
inactive up to 315 µM in the parasite, most likely because they did not possess sufficient βH 
inhibition activity. Only compound 5i, the t-butyl derivative, showed a slight improvement in 
parasite activity relative to the parent compound, with IC50 of 0.6 µM. The trend in activities 
for the 4-pyridyl vs 3-pyridyl vs phenyl analogues of the t-butyl derivatives (5h-j) was 
different from that of the nitro derivatives (5a-c), whereby the order of potency between 
the 3-pyridyl vs 4-pyridyl was reversed. In all cases, however, the phenyl derivatives were 
less active against P. falciparum in vitro. The tribenzamide, 10, showed very poor parasite 
activity despite being a good βH inhibitor. This may have been as a result of its excessive 
hydrophobicity (predicted logP = 5.21). The data are summarised in Table 4.4. 
 
  




Table 4.4 βH inhibition and CQ-sensitive parasite activities for the synthesised mono-, di- 
and tri-benzamides.  
Compound Derivative info 
βH inhibition  
IC50 (µM) 
NF54 
parasite IC50 (µM) 





>1000 >41.3 ± ND ND 
2b 22. ± 1 5 ± 1 ND 
2c 10.9 ± 0.3 2.3 ± 0.3 2.4 ± ND 
2d 13 ± 1 5 ± 1 2.3 ±ND 
2e 134 ± 8 22 ± 4 24 ± 5 
Dibenzamides 
5a 
R1 = Nitro 
4.3 ± 0.1 0.7 ± 0.2 0.9 ± 0.1 
5b 4.7 ± 0.7 1.32 ± 0.04 ND 
5c 7.0 ± 0.2 1.4 ± 0.2 ND 
5d 
R1 = Cyano 
6.34 ± 0.09 1.9 ± 0.2 2.0 ± 0.2 
5e 4.4 ± 0.2 ND 5.2 ± ND 
5f 
R1 = Methyl 
8 ± 1 2.5 ± 0.6 ND 
5g >1000  146 ± 1 ND 
5h 
R1 = Tert-butyl 
13.3 ±  0.7 1.6 ± 0.2 ND 
5i 6.8 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 
5j >1000  8.1 ± 0.5 ND 
5k 
R1 = H 
507 ± 33 9 ± 4 ND 
5l >1000  >314  ND 
5m 
R1 = Methoxy 
22 ±  1 3.0 ± 0.5 ND 
5n > 1000  37 ± 13 ND 
5o 
R1 = H (X = N) 
260 ± 7 >315  ND 





21 ± 1 81 ± 12 >42  
4-Aminoquinoline 
CQ Standard 31.5 ± 0.5 0.008 ± 0.002 0.021 ± 0.002 
 
As with the monobenzamides alone, inverse activity of both the βH and NF54 parasite IC50s 
were correlated when all the benzamides were taken into account. The relationship was 
statistically significant with P < 0.0001. Furthermore, a moderately good r2 value of 0.68 was 
observed for the correlation, which increased to r2 = 0.84 upon removal of the point 
corresponding to compound 5i, which was an apparent outlier (Figure 4.11). This compound 
showed a better parasite activity than expected based on its βH inhibition IC50. Possible 
reasons for this could be that its properties differ markedly from the other compounds, that 
there is favourable uptake in the parasite, or that the βH IC50 measured for this compound 




in the NP-40 assay does not accurately represent its haemozoin inhibitory activity in the 
parasite. Nevertheless, this correlation strongly suggests that haemozoin formation is the 
target. 
 

















Figure 4.11 The correlation between the inverse of NF54 parasite activity and the inverse of 
βH inhibition activity (r2 = 0.68, P < 0.0001). The statistics improve when derivative 5i (red 
circle) is excluded (r2 = 0.84, P < 0.0001). 
 
Attempts to improve the SARs further were carried out by including other parameters in the 
correlation analysis. A range of physicochemical properties were predicted for each 
compound using Molecular Modelling Pro Plus Software290 and linear regression with all the 
combinations of properties was carried out in silico. The addition of properties such as 
solubility, surface area or dipole moment to the βH inhibition activity, the two-parameter 
linear combination of which predicted parasite activity, was found to favourably influence 
the statistics. These relationships suggested that compounds with lower solubility, larger 
surface area or larger dipole moment resulted in a higher parasite activity. Indeed, 
compound 5i, with unpredictably good parasite activity, possessed one of the lowest 
predicted aqueous solubilities, while also having one of the largest surface areas and the 
biggest dipole moment of all the combined mono and dibenzamides. Including each of these 
parameters in the equation individually, resulted in three new correlations with r2 values of 




0.74 - 0.75, compared to the initial 0.68 with only βH inhibition activity, however, unlike the 
inverse βH inhibition IC50, these new parameters were not significant with P > 0.05 (2-tailed 
t-test). Furthermore, when attempts were made to find correlations with three or more 
parameters, those included, other than the inverse βH inhibition IC50, were also not 
significant. This was most likely since, even though the solubility, surface area and dipole 
moment parameters improved the r2 values, the additional parameters primarily enabled 
compound 5i to better fit the trend, while not providing improvements in the correlation for 
the other compounds. Indeed when 5i was excluded, the addition of solubility, surface area 
or dipole moment did not significantly improve the r2 value for the relationship involving 
only the βH inhibition activity. This gave further indication that βH inhibition may be the 
mechanism of action for these benzamides, however more advanced techniques were 
required to convincingly demonstrate this. 
 
     
 
  




4.2.2.3 Target validation for the benzamides 
Direct comparison of the benzamide derivatives with known drugs such as AQ and CQ is 
valid only if their mechanisms of action within P. falciparum cells are similar. Section 2.2.4.1 
describes the target validation for the HTS hits. In particular, it was shown that compound 
5a induces a 33% increase in free haem, accompanied by a decrease in haemozoin 
formation in the parasite. However, data for additional derivatives was required in order to 
be confident of the biological mechanism of action for this scaffold. Three benzamides were 
sent for analysis in the cell fractionation assay. Two of the selected compounds (2d and 5i) 
showed excellent βH inhibition activity in the NP-40 assay, while one compound was not a 
βH inhibitor (5j). The latter served as a negative control. The monobenzamide 2d and the 
dibenzamide 5i were chosen because they have relatively low and high parasite growth 
inhibition activity respectively. This was desirable so as to observe whether free haem levels 
had an influence this activity. Compound 5j had a relatively low activity against the parasite, 
probably because it is unable to inhibit βH formation. However, its ability to inhibit parasite 
growth, albeit at a high concentration, suggested that either 5j did inhibit haemozoin 
formation in the cell at sufficiently high concentration or that it had an alternate, off-target 
mechanism of action. As shown in Figure 4.12a, there was no significant change in the free 
haem or haemozoin levels with increasing concentration of 5j. This was in agreement with 
the NP-40 assay for βH inhibition and provided strong support for the technique for finding 
haemozoin inhibiting compounds used in this study. It would appear that this compound 
acts weakly on an alternate target. Investigation of identity of the non-haemozoin target 
was considered to be beyond the scope of this study and was of relatively little interest, 
given the low parasite activity of 5j. In contrast, 2d and 5i showed a large increase in the 
percentage free haem (>50% at 2.5 times the IC50) with a corresponding dramatic decrease 
in haemozoin (<40% at 2.5 times the IC50) within the parasite (Figure 4.12b,c). The 
significant changes in free haem and haemozoin levels for these benzamides suggested that 
the precise manner by which they cause haem-related toxicity differs from that of CQ, since 
less accentuated changes in free haem and haemozoin levels of ~15% and ~80% 
respectively were observed at 2.5 times the CQ IC50. Other quinoline antimalarials, such as 
AQ, QN and MF showed even smaller changes than CQ.113 This finding demonstrates that 
higher levels of free haem are required for disrupting parasite growth in the case of the 
benzamides relative to CQ and other quinoline antimalarials.  





























































































































































Figure 4.12 Free haem and haemozoin levels from cultured P. falciparum treated with 
varying concentrations of benzamides a) 5j, a negative control, b) 2d, a monobenzamide and 
c) 5i, a dibenzamide. Asterisks indicate statistical significance relative to no drug (2-tailed t-
test): *P < 0.05; **P < 0.01; ***P < 0.001, n = 3. 
In the case of the βH inhibitors, the free haem curves and the parasite survival curves with 
varying test compound concentrations crossed over close to the D10 IC50 of 2d (Figure 
4.13a) and 5i (Figure 4.13b), convincingly supporting the target as haemozoin formation. 
a) b) 
 
Figure 4.13 The concentration dose response curves for the % free haem and the % parasite 
survival, which cross near the IC50 for compounds a) 2d and b) 5i. Scales adjusted so that the 
IC50 for parasite survival coincides with the 50% value for increase in free haem (indicated by 
the dotted line). 




4.2.3 Attempts to improve activity through pH trapping 
4.2.3.1 Design of a basic analogue and pH trapping predictions 
Many of the phenyl derivatives were not βH inhibitors, however, 5c and 5e did inhibit βH 
formation. The observed decrease in activity for these phenyl derivatives relative to their 
pyridyl analogues 5a and 5b, were initially thought to be the result of decreased 
accumulation. This was because, at pH 4.8, the basic derivatives 5a and 5d are predicted to 
be about 75% diprotonated owing to the two pyridyl rings on each molecule (pKa1 = 5.92, 
pKa2 = 5.32). This may be expected to result in pH trapping of these derivatives in the DV, 
leading to improved IC50s relative to their phenyl analogues. If this were the case, designing 
a compound with greater basicity may be expected to enhance the pH trapping effect and 
result in improved parasite activity. This is believed to be the case for the 4-aminoquinolines 
AQ and CQ. Egan et al.182 reported that 4-amino-7-chloro-quinoline is able to inhibit βH 
formation, but is only weakly active in the parasite with a D10 IC50 of 3.8 µM. Upon 
attachment of a variety of tertiary amino containing side chains at the 4-amino position, βH 
inhibition was maintained and parasite activity was greatly enhanced by approximately 100-
fold. According to the study, this was probably as a result of improved accumulation in the 
DV. In addition, it was proposed that rational design could be employed to develop novel 
antimalarials from scaffolds that form π-π complexes with Fe(III)PPIX and inhibit βH 
formation (Figure 4.14).182 
 
Figure 4.14 Diagram showing the potential for βH inhibiting compounds to be derivatised to 
potent antimalarial compounds by introducing basic tertiary amino side chains, as was the 
case for AQ and CQ.  




This strategy was applied to the benzamide scaffold. A sufficiently basic compound required 
introduction of a nitrogen atom with a lone pair which was not delocalised into a π-orbital 
system, implying an aliphatic amine. Since the R1 substituent was shown to have a 
significant influence on activity, while the R2 rings could be varied without abolishing the 
activity for 5a-5e, phenylmethanamines were initially envisaged for the R2 substituents. 
However, a derivative with two primary amines would have resulted in a diprotonated 
compound, even at neutral pH, owing to the predicted high amine pKas of 9.76 and 9.16 for 
the first and second protonations respectively. Further calculations showed that such a 
compound would be too hydrophilic, with a logD of -1.7 at neutral pH and would therefore 
be unlikely to cross the four parasite membranes to reach the DV. Alternatively, alkylation 
of the primary amine to form secondary and tertiary amines improves hydrophobicity and 
logD at pH 7.4. The physiochemical properties for a range of alkylated derivatives were 
predicted in order to identify the most suitable with molecular weights below 500 g/mol 
and small, but positive logD at 7.4. Derivatives with secondary amines had predicted logD 
values below -1 for neutral pH, making them too hydrophilic, as in the case of the primary 
amine. The introduction of ethyl or propyl groups onto the primary amine derivative 
resulted in compounds with high molecular masses that exceeded 500 g/mol. Instead, a 
derivative where the R2 substituents were each N,N-dimethyl-phenylmethanamine (7), 
possessed a molecular weight of 475 g/mol and a positive logD value of 1.12 at neutral pH 
(Figure 4.15). This compound was thus selected for synthesis in order to probe the effect of 
greater basicity and pH trapping for the benzamide series. 
 
Figure 4.15 The dibenzamide 7 selected for synthesis with basic side chains, where R2 = N,N-
dimethyl-phenylmethanamine. The tertiary amine derivative possessed an improved logD 
relative to a primary amine derivative at neutral pH and a molecular mass below 500 g/mol. 
 




Compound 7 was tested for both βH inhibition and parasite activity. In the NP40 assay, the 
compound maintained potent βH activity with an IC50 of 7.9 ± 0.2 µM, appearing more 
active AQ and CQ. This confirmed that the R2 rings did not greatly influence βH inhibition 
activity for derivatives with an electron withdrawing group at R1. The result also agreed with 
the hypothesis that these analogues most likely inhibit βH formation via π-π interactions 
between Fe(III)PPIX and the central ring, as opposed to the R2 ring. However, upon assessing 
the activity against P. falciparum of this more basic derivative, which was expected 
accumulate to a greater extent in the parasite DV than 5a and hence possess enhanced 
activity, no improvement was found. An NF54 parasite IC50 of 1.5 ± 0.2 µM was obtained. 
This activity was the same as that of the phenyl derivative, 5c, within the error margin, 
suggesting that no significant accumulation had taken place. This lack of effect was 
especially striking when compared with the predicted accumulation that should have taken 
place due to pH trapping. The predicted VAR due to pH trapping alone was calculated using 
the Henderson–Hasselbalch equation (Eq. 4.1), the derivation of which is shown in Section 
8.1.3.2, at an external pH of 7.4 (pHe) and intravacuolar pH of 4.8 (pHv) for a compound (B) 
with two protonatable sites. 






   Eq. 4.1 
Using the predicted pKa values of 9.12 and 8.52 for compound 7, the expected VAR was 
estimated at ~147,000. This indicated that the derivative should have been about 147,000 
times more concentrated in the DV compared with 5c, which is not able to pH trap. Since 
the compounds possessed the same activity, two hypotheses were suggested; either 
compound 7 does not effectively cross the parasite membrane, resulting in a higher 
required concentration to inhibit parasite growth, or compound 7 accumulates but is not 
able to inhibit haemozoin formation in the DV.  
 
4.2.3.2 Target validation for derivative 7 
In order to evaluate whether the basic derivative, 7, was actually capable of preventing 
haemozoin formation in the parasite, the compound was sent for cell fractionation studies 
and subjected to similar analysis as that of 5a in the CQ sensitive D10 strain of P. falciparum. 
At a concentration of 450 nM, a 15 percentage point increase in free haem was observed for 




7 relative to the control with a concentration of zero nanomolar. At a concentration of 900 
nM, approximately the IC50 of 7 in this strain, the amount of free haem increased further, 
with 41% free haem observed compared to the control of 7%. A simultaneous decrease in 
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Figure 4.16 A sharp increase in the % free haem accompanied by a decrease in the % 
haemozoin within the CQ-sensitive D10 strain of P. falciparum for compound 7. Asterisks 
indicate statistical significance relative to no drug (2-tailed t-test): **P < 0.01;  
***P < 0.001, n = 3. 
This method conclusively demonstrated that 7 inhibits cellular haemozoin formation, 
accompanied by an increase in the percentage free haem. This strongly suggests that the 
proposed haemozoin target is indeed valid. The compound showed a similarly large increase 
and decrease in free haem and haemozoin respectively as the pyridylbenzamides (Section 
4.2.2.3). 
 
4.2.3.3 The inoculum effect and cellular accumulation 
With the biological target for the basic analogue strongly supported, the ability of 7 to 
accumulate in parasitised red cells relative to 5a-c was investigated by measuring the 
inoculum effect for several derivatives. The inoculum effect is the phenomenon whereby a 
significant increase in the inhibitory concentration of a drug is observed when the number 




of organisms inoculated is increased.291 The effect is only detected when accumulation of 
the drug occurs in the organism, in this case, the parasitised erythrocyte. The apparent 
decrease in activity with greater parasitaemia can be rationalised by the depletion of total 
drug concentration in the extracellular medium upon incubation with infected red blood 
cells, due to a significant uptake by the parasite. By measuring the changes in IC50 with 
varying initial parasitaemia levels, the amount of drug accumulation can be quantified.292,293  
 
Accumulation measurements were initially carried out for the standard drugs CQ and AQ. 
Significantly large differences in the IC50 values were found at varying concentrations of 
infected erythrocytes. Figure 4.17 shows plots of the antimalarial IC50 obtained from the 
LDH assay versus the inoculum size for a particular experiment. The inoculum size is the 
product of the parasitaemia and haematocrit. In these experiments the haematocrit was 
maintained at 1% and the parasitaemia varied from 1 to 10%. A direct linear trend, 
characteristic of the inoculum effect, was observed for both AQ and CQ, with greater 
parasitaemia associated with a decrease in drug activity. This relationship was extrapolated 
to give the absolute IC50 at an inoculum size of zero in order to calculate the CAR defined in 
Eq. 4.2. This equation takes into account the fractional volume of the parasitised red blood 
cells (Vfrac.PRBCs), which is the product of the parasitaemia and haematocrit, expressed in 
decimal form. See Section 8.1.4.3 for the derivation of Eq. 4.2. 
 












a)  b) 
  
Figure 4.17 The inoculum effect observed for a) amodiaquine, with a CAR of 98024 ± 15296 
and b) CQ with a CAR of 105,343 ± 3365. 
 
The calculated CAR values for AQ and CQ were the same within the standard error and 
suggest that there was a 100,000-fold increase in concentration from the extracellular 
medium to the parasitised cell. The large measured accumulation value for CQ (105,343 ± 
3365) is close to that determined by Walden of 130,081.3 ± 14,343.8 in the D10 strain.294  
It is possible to predict the CAR due to pH trapping for CQ from the predicted VAR, which in 
turn can be calculated from the experimental pKa values of CQ reported by Warhurst et 
al.122 This molecule has two protonatable sites, namely the quinoline ring nitrogen and the 
tertiary diethylamine nitrogen, resulting in two measured pKas of 8.38 and 10.18 
respectively. The VAR at an external pH of 7.4 (pHe) and intravacuolar pH of 4.8 (pHv) for a 
doubly protonatable compound can be calculated directly from these pKa values using the 
Henderson–Hasselbalch equation (Eq. 4.1).  
This gives a predicted VAR of ~143,000 for a pHv of 4.8, which can be used to calculate the 
CAR based on vacuolar pH trapping alone. The DV occupies an estimated 5% of the total 
erythrocytic volume.14,295 The volume of the parasitised red blood cell is therefore 
approximately 20 times larger than that of the DV, resulting in a CAR which is 20 times 
smaller than the VAR. Thus, the corresponding predicted CAR for CQ is ~7000, at least 10-
fold lower than the experimentally derived CAR in D10 parasites. However, the predicted 
CAR is close to that experimentally determined by Hawley et al.99 also using inoculum effect 
measurements, of 5,768 for CQ in the CQ-sensitive 3D7 strain. A much lower CAR for CQ of 
1859 was reported by O’Neill and co-workers in the CQ-sensitive HB3 strain.293 This may 




indicate a difference in the accumulation mechanism of these antimalarials in the D10 
strain. Alternatively, differences in the DV pH would have a significant effect on the pH 
trapping-based accumulation ratio, since the predicted VAR is highly sensitive to this 
parameter. For example, an assumed pHv of 4.5 results in a VAR of ~570,000 and a 
predicted CAR of ~28,000, greatly increased from the value of ~7000 calculated using a pHv 
of 4.8. However, this would still not be able to account for the observed ~100,000-fold CAR 
for CQ. Instead, it is possible that these values are an overestimation of the CAR, due to the 
fact that the IC50 at low inoculum size is very small and extrapolation leads to a y-intercept 
value (IC50absolute) which is close to zero. For example, if the true IC50absolute was 1.8 instead of 
the 0.8 observed from extrapolation, the experimentally determined CAR would only be 
~40,000.  
Nevertheless, the large cellular uptake of these drugs in the D10 strain appears to be due to 
more than pH trapping alone since the calculated and experimentally determined pH 
trapping ratios for CQ and AQ are not in agreement. Interestingly, only the unsaturable 
uptake of CQ can be taken into account by pH-trapping, while Bray et al.59 have shown that 
a significant quantity of saturable CQ-Fe(III)PPIX binding seems to occur and can account for 
differences in accumulation and activity between CQ-sensitive and CQ-resistant parasite 
strains. This idea was originally suggested by Fitch and co-workers in in 1980s.296,297 In fact, 
saturable accumulation was shown to be responsible for the four-fold greater accumulation 
of CQ in the sensitive HB3 strain as opposed to the resistant K1 strain. The data derived 
from the experiments in this project are also in support of the saturable accumulation 
theory, since Fe(III)PPIX-binding may account for the large CARs determined in the D10 
strain. This is investigated and described in more detail in Section 4.2.4. 
A much lower level of accumulation was expected for the benzamides as a result of their 
higher parasite IC50 values compared to CQ and AQ. This was especially since the 
benzamides were shown to be as good as or better than the 4-aminoquinolines at inhibiting 
βH formation. The resynthesised hit compound from the HTS (5a) along with the most 
potent dibenzamide (5i) and the derivate with basic tertiary amino side chains (7) were 
evaluated for accumulation in the parasite and the linear relationship for activity versus the 
inoculum size was extrapolated to obtain the absolute IC50 at zero percent parasitaemia 
(Figure 4.18).  
 






Figure 4.18 The inoculum effect observed for (a) compound 5a with a CAR of 6046 ± 2736 
and (b) compound 5i with a CAR of 5934 ± 945.  
 
Both compounds 5a and 5i showed at least 16-fold lower accumulation than CQ and AQ 
with CARs of ~6000. This decreased accumulation likely accounts, in part, for the 30-fold 
weaker activity of these dibenzamides compared with CQ. Initially this was believed to be 
due to the lack of highly basic functionalities for pH trapping that are present in CQ. 
However, upon testing the CAR for 7, an even weaker accumulation of approximately 1000-
fold was found and a relatively small change in activity with inoculum size was observed 
(Figure 4.19).  
 
Figure 4.19 The inoculum effect observed for compound 7 with CAR of 1321 ± 533. 
This 100-fold decrease in accumulation compared to that of CQ indicated that the basic 
benzamide derivative was not capable of pH trapping to the extent of CQ. This was 
intriguing given the two very basic substituents which were present, which resulted in a 




predicted pH trapping ratio (VAR) of ~147,000 using predicted pKa values from 
MarvinSketch software.269 This corresponds to a predicted pH trapping-based CAR of ~7000, 
similar to that of CQ. The lack of correlation between the calculated pH trapping ratio and 
the observed accumulation ratio for the 4-aminoquinolines and the benzamides suggested 
that the mechanism of drug accumulation is much more complex, at least in the CQ-
sensitive D10 strain. This is especially evident when noting that, although the CARs for 5a 
and 5i are lower than CQ and AQ, they are still concentrated by over 1000-fold in the 
parasitised cell despite having very little pH trapping ability. The predicted CARs due to pH 
trapping for 5a and 5i were calculated to be ~2.8 and ~0.1 respectively, showing that 
accumulation of these pyridyl benzamides is not as a result of pH trapping. These studies 
further showed that the parasite activity of haemozoin inhibitors cannot necessarily be 
improved by adding basic moieties, as proposed by the hypothesis in Figure 4.14.  
 
4.2.4 Possible role of Fe(III)PPIX association in cellular accumulation  
Although pH trapping could not directly account for the poorer activities and weaker 
accumulation of the benzamides relative to the known drugs, some studies have suggested 
that the cellular uptake of aminoquinolines and bis-quaternary ammonium compounds is 
via binding to ferriprotoporphyrin IX.125,59,298,299 Although there is no consensus as to the 
validity of the conclusions of these studies, the extent of Fe(III)PPIX binding for selected 
benzamides was investigated in an attempt to determine whether there is a correlation with 
cellular accumulation. This involved measurement of the association constants via titration 
of the compounds into a solution of 7.5 µM monomeric haematin in 40% v/v DMSO at pH 
7.5. Upon titration of the test compound solution into the haematin solution, a 
hypochromism or convergent decrease in intensity of the characteristic monomeric 
haematin spectrum at 401 nm (Soret band) was observed owing to significant Fe(III)PPIX 
binding. The information gained from this experiment could be extended by monitoring the 
maximum absorbance at 405 nm as a function of test compound concentration. This 
allowed the association constant (K) to be calculated from a non-linear least squares fitting 
model for a 1:1 complex. A representative example is shown in Figure 4.20. It should be 
noted that the benzamide solutions were made up in 100% DMSO owing to their low 
solubility in 40% DMSO. This resulted in a small increase in total percent DMSO in the 




working solution over the course of the titration. However, this did not appear to affect the 
absorbance and isosbestic points were observed as expected, confirming the 1:1 association 





Figure 4.20 Measurement of the association constant between compound 5a and Fe(III)PPIX 
at pH 7.5 in 40% v/v DMSO. Plots of a) the hypochromic effect of the Fe(III)PPIX absorbance 
spectra with increasing compound concentration, showing 1:1 binding confirmed by the 
isosbestic points (*) and b) the maximum Fe(III)PPIX absorbance vs the concentration of 
compound 5a.  




Haematin binding experiments were also attempted for compounds 2c, 5f and 7. However, 
the last precipitated out of solution and useable data could not be obtained owing to its low 
solubility. The data relating to strength of Fe(III)PPIX binding are shown in Table 4.5 for 
synthesised benzamides 2c, 5a and 5f, as well as for selected 4-aminoquinolines. The three 
benzamides showed similar logK values, on the order of 100-fold lower than those of the 
known antimalarials and 10-fold lower than 4-amino-7-chloroquinoline. These values are 
consistent with the hypothesis that the benzamides associate with Fe(III)PPIX through π-π 
interactions alone, in accordance with the predicted LogK values reported by Kuter et al.300 
The linear free energy equation reported by these authors to predict the association 
constant due to π-π interactions with Fe(III)PPIX (logKπ−calc) incorporates the number of 
available π electrons (nπ) by logKπ−calc = 0.23 × nπ. Assuming fourteen available π electrons 
in compound 2c are able to interact with Fe(III)PPIX (six for each aromatic ring and two for 
the amide), the logKπ−calc is 3.22, remarkably close to the experimentally obtained value. This 
is despite the fact that the predicted value does not take into account substituent effects on 
the strength of the interaction, suggesting that they do not play a role in this interaction. In 
addition, the fact that the dibenzamides 5a and 5f do not have significantly larger logK 
values than the monobenzamide 2c, suggests that association does not take place over the 
entire molecule, which would result in a logKπ−calc of ~5 for the 22 π electrons in the 
dibenzamide. 




Table 4.5 Association constants for the interaction of selected benzamides and quinolines 
with Fe(III)PPIX.  
Compound logK 
Binding constant ratio 
relative to 2c (K/K2c) 
 
2c 
3.20 ± 0.36 1 
 
5a 
3.23 ± 0.11 1.1 
 
5f 
3.92 ± 0.21 5.24 
QD 5.26 ± 0.01 115 
CQ 5.52 ± 0.03a 209 
4-amino-7-chloroquinoline 4.43 ± 0.01a 17 
a Data from Egan et al.182 
It should be noted that these values are calculated by assuming a 1:1 Fe(III)PPIX binding 
ratio. CQ has recently been shown to have a binding stoichiometry of 1:2 CQ:Fe(III)PPIX in 
aqueous solution, resulting in a logKobs of 13.3 ± 0.2.150 However, here the 1:1 complexes 
were compared in 40% DMSO and the value reported by Egan et al.182 for CQ in this medium 
was used. 
The concentration of test compound-haem complex (B-Fe(III)PPIX) relative to the 
concentration of free Fe(III)PPIX can be approximated by Eq. 4.4 using the equilibrium 
binding constant (K) and the free compound concentration (B), assuming the latter remains 
constant and is equal to the concentration added.  
  





𝐵 + 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋                   𝐵 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋    
 





𝐾 × [𝐵] =  
[𝐵−𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]
[𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]
         Eq. 4.4 
 
For CQ, the intracellular concentration of unbound compound at the IC50 is on the order of 1 
mM, based on the parasite activity and CAR. This indicates that at least 99% of the free 
haem is bound to CQ in the parasite for a logK of 5.5. In contrast, the amount of haem 
bound to a benzamide compound is ~60% for a logK of 3.2.  
The decreased ratio of B-Fe(III)PPIX to Fe(III)PPIX for the benzamide 5a as a result of the 
100-fold decrease in logK compared with CQ, may suggest a connection between haem 
binding and accumulation, since a similar 100-fold decrease was measured in the CARs.  
In this case the decreased parasite activity of 4-amino-7-chloroquinoline relative to its basic 
derivatives, CQ and AQ (Figure 4.14), may relate to decreased accumulation arising from the 
10-fold weaker haem binding (logK of 4.4), in addition to the lack of pH trapping. 
In order to test this theory on the benzamide scaffold, an analogue expected to π-π interact 
with haem more effectively, was proposed for synthesis. This required conversion of the R2 
pyridyl rings into fused aromatic rings in order to increase the number of π electrons 
available for interaction. Since it was intended to avoid the inclusion of a quinoline moiety 
and because a variety of benzimidazoles were shown to be good βH inhibitors in the HTS, a 
derivative where R2 was benzimidazole was suggested. This group was predicted to add a 
log unit to the logKπ−calc value since it contains ten π electrons, as opposed to the six of the 
pyridyl group. Owing to synthetic problems relating to the physical properties of a 
compound with two benzimidazole moieties, the molecule had to be desymmetrised to an 
analogue containing just one benzimidazole unit (Figure 4.21). Although this compound (8) 
could be synthesised and isolated, its solubility in aqueous solution and most organic 
solvents was poor and it could not be used in haem-binding experiments. In addition, the 
K 




activities of compound 8 were found to be uninteresting. It was a moderate inhibitor of βH 
formation with an IC50 of 68 µM but displayed no parasite activity up to the maximum dose 
concentration of 249 µM. It was concluded that adding more fused rings does not 
necessarily improve parasite activity, although this needs further investigation. 
 
Figure 4.21 The desymmetrised benzimidazole 8 containing a benzimidazole for an 
anticipated increase in the π-π interactions with haem compared with 5a. 
 
  




4.3 Summary and conclusions 
A variety of purchased or synthesised benzamides were evaluated for their ability to inhibit 
βH formation and prevent parasite growth. The activities were related to their molecular 
features in order to determine their minimum structural requirements and SARs.  
In general, the benzamides were only able to inhibit crystal growth when the substituents 
on the ring A (that adjacent to the amide carbonyl group) were meta to each other. For the 
dibenzamides, ring B (R2) could be varied but only those compounds where R1 was a planar 
electron withdrawing group showed βH inhibition activity with both pyridyl and phenyl R2 
groups. The observed SARs indicated that only predominantly planar molecules were able to 
inhibit βH formation and that this most likely takes place by interaction with the fastest 
growing face of the crystal, in agreement with previous studies on 4-
aminoquinolines.154,113,155 The dibenzamides were identified to have better biological 
activity than the corresponding mono or tri-benzamides and the pyridyl derivatives had the 
lowest IC50s. Only one compound, where R1 was varied to t-butyl and R2 to 3-pyridyl, 
showed better parasite activity than the parent hit compound. However, this activity was 
not comparable with clinical haemozoin-inhibiting antimalarial drugs and attempts to 
improve the activity were unsuccessful. Nonetheless, the benzamides investigated here 
were useful as mechanistic probes.  The basicity of the benzamide had no effect on the 
parasite activity or CAR, however, their 100-fold weaker Fe(III)PPIX binding constants 
compared with those of the 4-aminoquinonlines, indicated that haem association may have 
some influence on parasite accumulation and activity. Although lower than that of CQ and 
AQ, the experimentally determined CAR values for the benzamides were 1000-fold larger 
than that expected if accumulation was due to pH trapping alone. This strongly suggests 
that haem binding or binding to the fastest growing face of the haemozoin crystal may be 
involved in the accumulation of these compounds. 
 






STRUCTURE-ACTIVITY RELATIONSHIPS FOR  
β-HAEMATIN INHIBITION AND PARASITE ACTIVITY 
 
5.1 Introduction 
Seven triarylimidazoles were found to inhibit parasite growth in the HTS discussed in Section 
2.2.4.3, with three showing IC50 values below 1 µM. Interestingly all seven were very good 
βH inhibitors at least twice as active as CQ, but parasite activity decreased significantly upon 
variation of the 3,5-dimethoxy-4-hydroxy substituents on ring A (Figure 5.1). This prompted 
investigation into the SARs for this chemotype, especially given its novelty as a potential 
class of antimalarials. 
 
 a)                              b) 
              
Figure 5.1 Examples of parasite-active hits found in the HTS; a) a representative 3,5-
dimethoxy-4-hydroxyphenyl substituted triarylimidazole (VU0132562 IC50 of 0.31 µM) and 
b) a 4-hydroxy substituted triarylimidazole (VU0099289, IC50 of 9.1 µM). 
  




5.1.1 Specific goals 
The specific goals for Chapter 5 were to: 
 Test the purchased or synthesised simple triarylimidazole derivatives to determine 
minimum structural requirements for βH inhibition activity. 
 Use the synthesised compounds containing substituents possessing a range of 
electronic, lipophilic and spatial properties to evaluate the βH inhibition activity for 
this series in the NP-40 assay. 
 Determine the inhibition of parasite growth activity of the derivatives using the LDH 
malaria parasite assay. 
 Identify SARs. 
 Validate the biological target within pRBCs. 
  




5.2 Results and discussion 
5.2.1 β-Haematin inhibition activity for the triarylimidazoles 
As in the case of the benzamides, the triarylimidazole scaffold was initially deconstructed in 
order to determine the minimum structural features for βH activity. Ring B and C in the 
triarylimidazole HTS hits appeared to have a less important influence on βH activity than 
ring A. As a result, rings B and C were removed (Figure 5.2) to evaluate their necessity. The 
monoarylimidazole, 2-phenylimidazole P11 was obtained commercially and tested in the 
NP-40 assay described in Section 1.8.5 to 1.8.6. The compound was found to be inactive 
against βH formation. Additional data on the triarylimidazole chemotype, which was made 
available via the collaboration between UCT and Vanderbilt University (VU), indicated that 
2,4,5-triphenylimidazole (VU_IMR-1-101) was also unable to inhibit βH formation, however, 
substituting ring A with pyridyl resulted in the simplest active compound (VU_SC1_1D) with 
an IC50 of 25.36 µM (Table 5.1). The next evaluated derivative was the purchased compound 
4-(4,5-diphenyl-1H-imidazol-2-yl)phenol (P12), which was identified as the simplest 
triphenylimidazole to inhibit βH formation (IC50 of 17.7 µM). This established that at the 
minimum active scaffold required at least one substituent on ring A. In order to further 
investigate the SARs for this scaffold, derivatives of the parent compound (Figure 5.1a) were 
synthesised as shown in Figure 5.2.  
 
Figure 5.2 The synthesised triarylimidazole derivatives 




Compound 15c resembled the parent compound with the exception of the bromo 
substituent on ring B. This derivative maintained potent activity against βH formation 
confirming that the substituents on ring B and C were not vital for inhibition of βH. The 
substituents on ring A were then varied by replacing the 4-hydroxy group with a hydrogen 
atom (15a) or methoxy group (15b). These analogues also maintained activity against βH 
formation. This was surprising given that VU_IMR-1-101 was inactive, however it 
demonstrated that the substituents on ring A were important for βH activity. The data for 
the 4-trifluoromethoxy analogue (15d) further suggested that only specific substituents give 
rise to βH inhibition, since the compound was inactive. To evaluate whether this was an 
electronic effect, a nitro and an amino derivative were synthesised and assayed, both of 
which displayed good βH activity. This showed that compounds with both electron 
withdrawing and releasing groups on ring A were capable of inhibiting crystal growth. The 
data also demonstrated that both planar and non-planar substituents were tolerated. 
However, the predicted logD at pH 4.8 for 15d was ~6.8, significantly higher than the active 
derivatives with logD values ranging from ~4.2 to ~5.1. The large hydrophobicity of 15d may 
have altered the orientation of the interaction between the triarylimidazole and Fe(III)PPIX 
compared to the active analogues, resulting in a weaker interaction and the inability to 
prevent crystal growth. Finally, analogues of 15a, which contained either a 4-chloro atom on 
ring B (15e) or 4-methoxy groups on both ring B and C (15f) were evaluated in order to 
measure the extent of ring B and C influence on βH activity. These compounds displayed 
similar activity to 15a, with IC50 values of 16.6 µM and 13.8 µM for the chloro and 
dimethoxy analogues respectively. This also demonstrated that both electron withdrawing 
or releasing and planar or non-planar substituents were tolerated on rings B and C. The βH 
activity data for the triarylimidazoles are shown in Table 5.1. 
 
  




Table 5.1 βH IC50 values for the triarylimidazole scaffold. 
















25.4 ± ND 
15a 
 
Synthesised 14.6 ± 0.2 
15b 
 
Synthesised 10.9 ± 0.3 
15c 
 







Synthesised 16.6 ± 0.6 




Table 5.1 (Continued) 
Compound Structure Source βH inhibition IC50 (µM) 
15f 
 
Synthesised 13.8 ± 0.4 
15g 
 
Synthesised 19 ± 1 
16 
 





31.5 ± 0.5 
 
5.2.2 Parasite growth inhibition activity  
The 2,4,5-triphenylimidazole from VU which was not a βH inhibitor also showed no parasite 
activity up to 20 µM, while the 2-pyridyl-4,5-diphenylimidazole which was a potent βH 
inhibitor showed weak activity of 10.76 µM in the CQ-sensitive D6 strain. The purchased and 
synthesised triarylimidazoles were tested in the LDH parasite growth inhibition assay using 
the CQ sensitive NF54 strain (Table 5.2). Compound P12 was found to be inactive at 
concentrations up to 32 µM, despite displaying potent βH activity.  Other derivatives which 
performed poorly in the assay were the 4-nitro (15g) and 4-amino (16) analogues of P12. 
This showed that having substituents only in the para position of ring A was not sufficient 
for parasite activity. What was surprising however, was the IC50 of 4.19 µM for 15d, the 
trifluoromethoxy analogue, which was identified as inactive against βH formation, but which 
inhibited parasite growth with moderate activity. This suggested that this compound was 
able to kill the parasite via an interaction with an alternate target. This might be attributable 
to the high lipophilicity of the molecule, which would allow it to interact favourably with 
parasite membrane proteins. Nonetheless, this result appeared to be specific to 15d and not 
triarylimidazoles in general, since the other non βH inhibitor (VU_IMR-1-101) was inactive 
against the parasite. For the βH inhibiting compounds containing 4-hydroxy and 3,5-




methoxy groups on ring A, 15a-c, the parasite activity improved from 6.98 to 1.3 µM with 
variation of the para substituent H < OMe < OH, illustrating that the ring A substitution 
pattern of the parent compound (VU0132562, Figure 5.1a) was superior for activity. Since 
the most active triarylimidazoles in the HTS, with submicromolar activity, contained a para 
Br or OH substituent on the ring B (Table 2.5), the effect of these groups, while not a 
significant factor for βH inhibition, appeared to increase parasite activity. This prompted the 
synthesis of 15e and 15f in an effort to determine whether the activity of triarylimidazoles 
with other ring A substituents could also be improved via adding ring B and ring C 
substituents. Owing to the availability of starting materials for synthesis, the 4-chloro and 
4,4’-dimethoxy analogues were tested and found to improve the activity from 6.98 µM for 
15a to ~1.7 µM for both 15e and 15f. This 4-fold activity improvement for the introduction 
of ring B and/or C substituents was almost identical to that of 15c vs VU0132562 (Figure 
5.1a). This was also true when comparing P12 with poor activity (>32 µM) to its 4-bromo 
derivative (VU0099289, Table 2.5) from the HTS with IC50 of 9.1 µM. However, overall the 
activity of the synthesised compounds could not be improved relative to the HTS hits, but 
the study revealed the specificity for parasite growth inhibition of the 4-hydroxy-3,5-
methoxy substituents on ring A. This is summarised in Figure 5.3. 
 




NF54 IC50 (µM) 
P11 Commercial >1000 ND 








25.4 ± ND  10.8 ± ND* 
15a Synthesised  14.6 ± 0.2 7.0 ± 0.1 
15b Synthesised 10.9 ± 0.3 3 ± 2 
15c Synthesised 10.2 ± ND 1.3 ± 0.5 
15d Synthesised >1000 4.2 ± 0.1 
15e Synthesised 16.6 ± 0.6 1.7 ± 0.5 
15f Synthesised 13.8 ± 0.4 1.7 ± 0.4 
15g Synthesised 19 ± 1 15 ± 4 




31.5 ± 0.5 0.008 ± 0.002 
* Activity values from Vanderbilt University in the CQ-sensitive D6 strain. 





Figure 5.3 The favourable (blue) and unfavourable (red) substituents for parasite activity 
within the triarylimidazole HTS hits and synthesised analogues.  
 
5.2.3 Target validation for the triarylimidazoles 
Compound 15d was found to have a moderate parasite IC50, even though it did not appear 
to inhibit βH formation in the NP-40 assay. This result led to the need for confirmation of 
haemozoin inhibition within parasitised red cells. While the triarylimidazole VU0099289 
(Table 2.5) from the HTS was shown to cause a 43% increase in free haem, data for 
additional derivatives was required in order to be confident of the biological mechanism of 
action for this scaffold.  Compounds 15a and 15f were sent for cell fractionation studies and 
both were shown to cause a very large increase in free haem in the cell (>40 fg/cell 
concentration corresponding to >50% free haem) at 2.5 times the relevant IC50 of the 
compound (Figure 5.4). This study confirmed that the triarylimidazoles inhibit haemozoin 
formation in the malaria parasite in a dose dependent manner that coincides with 
decreased parasite survival. This strongly suggests that inhibition of haemozoin formation is 
the mechanism of action of these compounds. 
  






Figure 5.4 The concentration dose response curves for the amount of free haem (fg/cell) 
and the percent parasite survival which cross close to their respective IC50 values for 
compounds a) 15a and b) 15f. 
 
5.2.4 Correlation analysis for triarylimidazole SARs  
The ability of βH inhibiting derivatives with a greater number of hydroxyl and methoxy 
substituents to inhibit parasite growth can be seen graphically in Figure 5.5. This had a much 
greater impact on the parasite activity than the βH inhibition IC50. Indeed, the relationship 
with βH activity was not statistically significant.  





















Figure 5.5 A linear correlation between the log of the parasite activity with the number of 
hydroxyl or methoxy substituents on the phenyl rings in a triarylimidazole given by 
log(NF54IC50) = -0.30(# of OH or OMe) + 1.23; (r2 = 0.76, P = 0.0048).  
 
Correlations between the parasite activity and other physiochemical properties were 
identified. The most statistically relevant correlation with the least number of parameters 
was that of the inverse of the NF54 IC50 with the water solubility (H2O-Sol) and the 
molecular weight (MW) of the compound (Figure 5.6). The correlation equation revealed 
that the MW parameter had 2.5 times more weighting on the activity than that of the H2O-
Sol. This relationship showed that an increase in the H2O-Sol as well as an increase in MW 
was favourable for parasite activity. This was reasonable in light of the finding regarding the 
need for more hydroxy and methoxy groups for improved in vitro antimalarial activity. 
Analogues with the 3,5-dimethoxy-4-hydroxy substitution pattern possessed a larger MW 
and were predicted to be more aqueous soluble than those without these groups. 
Furthermore, 15e and 15f, the more potent derivatives of 15a, had larger MWs since they 
contained ring B and C substituents. It is important to note that a triarylimidazole with a 
larger MW and H2O-Sol will probably not necessarily give rise to better activity, but rather 
that an increase in these features is able to explain the observed SARs for this set of data.  



























Figure 5.6 Multiple correlation analysis for the inverse of NF54 parasite activity with 
physiochemical properties revealed a statistically significant correlation as 1/NF54IC50 = 
0.284(H2O-Sol.) + 0.008(MW) – 1.404; (r2 = 0.78; P = 0.0016); statistically significant for both 
individual parameters (t = 3.10, 4.09, 3.77 > t-crit = 2.45) and overall correlation (F-stat = 
10.67 > F-crit = 5.14) at the 95% confidence level. 
  




5.3 Summary and conclusions 
A variety of purchased or synthesised triarylimidazoles were evaluated for their ability to 
inhibit βH formation and prevent parasite growth. The activities were related to their 
molecular features in order to determine the minimum structural requirements and SARs.  
The triarylimidazole series was much more challenging to investigate compared to the 
benzamide series since the trends relating to βH inhibition activity could not be explained 
and parasite activity relied on very specific substituents. This showed that the scaffold was 
not amenable to structural changes. In addition, there did not appear to be a correlation 
between βH inhibition and parasite activity, however, a correlation may have become 
apparent had the relative accumulation ratios for the triarylimidazoles been taken into 
account. Measurement of these CARs was beyond the scope of this project, but may be 
important in future if investigation of triarylimidazoles is continued. However, the scaffold 
was generally very aqueous insoluble, which is undesirable for medicinal compounds, and as 
a result, haem binding measurements in 40% aqueous DMSO could not be carried out. 
Correlation analysis revealed that both larger MW and aqueous solubility improved the 
activity of this series. The hydrophilic nature of the 3,5-methoxy-4-hydroxy substitution 
pattern may explain the improved solubility and therefore, the greater parasite activity of 
these derivatives.  
Although these compounds do not possess appropriately high activities for further 
development as antimalarials, they are important for enriching the structure-activity data 
sets, particularly for use in training sets to develop predictive models for both βH inhibition 
and parasite activity. To this end, the structure-activity data for the triarylimidazole 
derivatives together with the benzamides from Chapter Four can be incorporated into 
training sets to create probability models based on Bayesian statistics, in order to predict 
the probability of activity for new test compounds. 
 





BAYESIAN MODELS FOR PREDICTING β-HAEMATIN 
INHIBITION AND ANTIMALARIAL ACTIVITY 
 
6.1 Introduction 
The primary goal of HTS is the identification of validated hits that have potential to become 
chemical leads in drug discovery programmes. Determining which of these compounds has 
the appropriate chemical characteristics as well as pharmacodynamic and pharmacokinetic 
properties, is a resource and time-intensive task.301 The increasing popularity of HTS as a 
starting point for drug discovery has led to a surge in the availability of both phenotypic and 
target-based activity data. Realising the maximum value of these data remains a challenge, 
since hit compounds with only moderate activity are often not further investigated. In 
addition, the usefulness of the data for the non-hits or negative data is not always 
appreciated. Large quantities of structure-activity data from HTS projects, including the 
negative data (non-hits), are underutilised as a result of this. One way to make use of all the 
screening results is by analysing the data in parallel by employing in silico data mining 
algorithms. These machine learning techniques not only help with data interpretation, but 
can also be used for predicting the activities of new compounds.302 Methods that allow such 
data to be used for virtual screening have potential to maximise efficiency and reduce costs. 
Currently, this work is the only one reported in the literature303 demonstrating Bayesian 
probability applied to antimalarial activity prediction. This is despite the availability of 
published P. falciparum activity datasets, including whole-cell screens from GSK (the TCAMS 
library) and the St Jude Children’s Research Hospital.171,172 
 
6.1.1 Bayesian probability 
6.1.1.1 Bayes’ theorem 
In drug discovery, Bayesian probability provides a formal mathematical method for 
combining prior structure-activity data with current data to create a model for analysis of 
structurally important features and prediction of future data.197 Bayesian statistics is based 




on Bayes’ Theorem (Eq. 6.1), published first in 1763 by Thomas Bayes in “An Essay Towards 




        Eq. 6.1 
Where, in the context of drug discovery, p(h|d) is the probability that a molecular feature 
(d) contributes to activity (h) in a test molecule, p(d|h) is the prior probability of the feature 
being present in an active compound in the training set, p(h) is the probability of any 
compound in the training set being active and p(d) is the probability of the feature being 
present in any molecule in the training set.  
 
6.1.1.2 Bayesian classification in Discovery Studio 
The Bayesian classification method for modelling structure-activity data in the Accelrys 
Discovery Studio software305 uses the knowledge of prior data in the training set to quantify 
the probability of an external compound in a test set being active or inactive. The 
probability can then be updated in light of new evidence, which is subsequently added to 
the training set. Bayesian statistics also takes into consideration the complexity of the 
model, automatically identifying the simplest model to explain the observed data and 
hence, avoiding overfitting.200 
In the Bayesian modelling component in Discovery Studio,305 which was employed in this 
project, learned models are created when the user marks active sample data (chemical 
structures) as “good” at a chosen activity cut-off. The system then learns to distinguish the 
features of those active compounds from the background data (inactive or “bad”). These 
features are input descriptors including logP, MW, #HBD, #HBA, #RB, #AR, #R, FPSA and 
extended-connectivity fingerprints of depth 6 (ECFP_6). The learning process collects the 
frequency of occurrence of each feature in the good subset as well as in all the data 
samples, then assigns a weighting to each feature using a Laplacian-adjusted probability 
estimate (Section 6.1.2.3). This accounts for the different sampling frequencies of the 
individual features. Upon creation of a model from a particular training set with a user-
defined activity cut-off, a receiver operating characteristic (ROC) score is determined. The 
ROC score indicates the performance of the model and is calculated from the area under the 
curve of the true positive (TP) rate versus the false positive (FP) rate (ROC curve). To 




determine the TP rate, samples are excluded consecutively from the model and then their 
activities predicted using the leave-one-out model. These are compared to the real user-
defined activities and each sample assigned as a TP or FP. A ROC score of 1 indicates a 
perfect model, predicting all molecules correctly, while that of 0.5 indicates no enrichment 
from random activity assignments. 
The probability of activity for an external molecule X is calculated from the training set 
model by generating the features of the molecule X and calculating the Laplacian adjusted 
weight for each feature. Then, after normalisation, the weights are summed to provide a 
probability estimate, which is a relative predictor of the likelihood of molecule X being from 
the good subset, indicated by a more positive value. 
 
6.1.1.3 The Laplacian-adjusted probability estimate 
In order to account for the fact that not every generated feature has an influence or equal 
weighting on the activity of the sample data, a Laplacian-corrected estimator is used to 
adjust the uncorrected probability estimate. The derivation is given by means of an example 
from Discovery Studio.305  
Assuming that there are N molecules in the training set of which M are active, the estimated 
baseline probability of activity for a molecule X from the test set is P(Active) = M/N. 
However, if A of those N molecules contained a feature F (Section 6.1.1.2) and only B of 
those A molecules were active, then the uncorrected estimate of activity for a molecule with 
the same feature F would be P(Active|F) = B/A. However, if there are too few molecules in 
the training set with feature F then the estimator is less reliable. For example, if only one 
molecule in the training set contains feature F, and that molecule is active, then the 
calculated P(Active|F) of 1 is overconfident for that feature. This is due to inadequate 
sampling of the feature. On the other hand, in most cases the vast majority of the features 
do not correlate with activity and if this is the case for feature F, P(Active|F) is equal to the 
baseline probability P(Active).  
  




If an additional D molecules containing feature F are added to the original training set then 
the number of new molecules expected to be active is P(Active)*D. Having included these 




        Eq 6.2 
This corrected probability stabilises the estimator so that as A (and therefore B) approaches 
zero, the probability for feature F converges to P(Active), as expected for most features.  
Lastly, the probability estimator is normalised to a relative final probability estimate by 
dividing by P(Active) and then taking the log to give Eq. 6.3.  
𝑙𝑜𝑔 𝑃𝑓𝑖𝑛𝑎𝑙(𝐴𝑐𝑡𝑖𝑣𝑒|𝐹) = 𝑙𝑜𝑔
𝑃𝑐𝑜𝑟𝑟(𝐴𝑐𝑡𝑖𝑣𝑒|𝐹)
𝑃(𝐴𝑐𝑡𝑖𝑣𝑒)
         Eq 6.3 
These logPfinal values for each feature are summed to predict the complete probability of a 
molecule being active. For most features, logPfinal will be approximately zero, however, for 
those features which are more common in active molecules, logPfinal will contribute 
positively. Conversely, for those features more common in the inactives, the logPfinal will be 
negative. 
 
6.1.2 Available antimalarial datasets  
The green-fluorescence based assay used in the whole-cell screens by GSK and the St Jude 
Children’s Research Hospital is phenotypic, not target specific and as a result, the active 
compounds cover a range of chemical and physical properties, depending on the 
mechanism of action of that molecule. Ekins et al.200,201 used Mtb whole-cell data for model 
generation. Currently, their studies appear to be the only available references to Bayesian 
modelling of multimodal distributions. Other studies apply Bayesian probabilities to specific 
targets. The extent to which inhibitors of different antimalarial targets differ in chemical 
space is not fully understood, however it is reasonable to hypothesise that Bayesian models 
may perform better using compounds acting on a single target in the training set. Another 
reason for the lack of published models is the absence of available inactive or negative data. 
The exception to this is the St Jude’s set where the structures and bioactivities for the entire 
library of 309,474 compounds have been disclosed. 
  




Since 2010, the NP-40 based detergent mediated pyridine ferrichrome assay has been 
applied in HTS efforts to discover new antimalarial scaffolds. Structure-activity data from a 
pilot screen161 on 38,400 compounds as well as a larger screen204 on 144,330 remaining 
compounds in the Vanderbilt University (VU) compound library (Chapter 2) revealed a total 
of ~700 novel βH inhibitors, of which ~200 inhibited parasite growth by ≥90% at 23 µM. The 
NP-40 assay has also been employed to test ~200 parasite active compounds synthesised by 
the group of Inokuchi and co-workers at Okayama University (OU) in Japan. These 
compounds are neocryptolepine and isocryptolepine derivatives with long amine side chains 
for which the data are already publically available (Section 1.7.3).107,108,282,109,110 
 
In this section of the project, a virtual screening approach for discovering βH formation and 
P. falciparum growth inhibitors has been validated by employing combined HTS data, 
including published data and as yet unpublished H screening data for the 13,533 active 
TCAMS compounds as training sets. Two models were created, the first which uses VU, 
TCAMS, OU as well as in-house UCT structure-activity data, which includes the benzamide 
(Chapter 4) and triarylimidazole (Chapter 5) derivatives, as a training set to predict βH 
activity. The second model includes the biologically inactive St Jude’s compounds in the 
training set for modelling P. falciparum activity. It is important to note that only known βH 
inhibitors were used as actives in the training set for in vitro antimalarial activity. Although 
the detergent based assay for βH formation does not give definitive proof of the mechanism 
of whole-cell therapeutic action, it was hypothesized that most of the parasite active 
molecules used in generating the model would be haemozoin inhibitors, allowing for a 
single-target training set. For this reason, the St. Jude’s actives were excluded since their 
targets are, for the most part, unknown. Finally, the generated Bayesian models were 
employed to predict the βH inhibitory and antimalarial activity of 1510 U.S. Food and Drug 
Administration (FDA) approved drugs as well as purchasable compounds from Sigma-
Aldrich’s drug-like molecule library (AldrichCPR). A selection of 34 of these compounds were 
purchased and tested for both H inhibition and in vitro parasite growth inhibition.303 
  




6.1.3 Specific goals 
The specific goals for Chapter 6 were to: 
 Generate training sets as structure data files (SDFs) using published or internal HTS data. 
 Create and optimise a Bayesian model for βH inhibition activity by evaluating the output 
ROC scores and predictions of test sets, resulting from variation of training set data and 
activity cut-offs. 
 Create and optimise a Bayesian model for parasite growth inhibition activity by 
evaluating the output ROC scores and predications of test sets, resulting from variation of 
training set data and activity cut-offs. 
 Validate the models by:  
-  virtually screening structural data of the FDA approved drugs, 
-  assessing the resulting Bayesian scores of the known antimalarial drugs, 
-  virtually screening the Sigma-Aldrich drug-like molecule library (AldrichCPR),  
-  purchasing a range of compounds, predicted to be active or inactive, and 
-  finally, experimentally determining the accuracy of the Bayesian model predictions 
using the NP-40 βH inhibition assay and the LDH parasite growth inhibition assay. 
 
  




6.2 Results and discussion 
6.2.1 Optimisation of Bayesian models 
6.2.1.1 Model for predicting inhibition of βH formation 
It is generally accepted that Bayesian models perform more effectively when the training 
data cover sufficient chemical space and if meaningful molecular features can be 
generated.191 This was tested by creating models based only on the VU data with increasing 
numbers of negative data points. A group of 339 randomly selected VU compounds was 
excluded from the training set to be used as a test set and the models were used to predict 
whether they were active or inactive. Finally, all the βH data from TCAMS, OU and UCT were 
also added to the training set (Table 6.1). As expected, the ROC score increased with 
increasing numbers of compounds in the training set, resulting in an excellent score of 0.915 
(Figure 6.1). In addition, the test set containing 339 samples was evaluated. The activity 
predictions also improved from 78% to 83% correct as VU inactives were added, however 
the percentage dropped to 77 when compounds from different libraries (covering wider 
chemical space) were incorporated into the training set.  
 
Table 6.1 Optimisation of βH model using a cut-off of 100 µM, with increasing numbers of 
inactive compounds from the VU set. The test set consisted of 339 VU samples.  
Total βH actives 










VU test set 
correctly 
predicted 
1,000 1,000 0.876 Good 78% 
1,000 6,000 0.901 Excellent 80% 
1,000 31,000 0.901 Excellent 83% 
1,000a 51,000a 0.905 Excellent 83% 
2,113b 64,118b 0.915 Excellent 77% 
a These compounds were prepared at pH 5 in the calculation.  
b This set incorporated VU, TCAMS, OU and UCT data at pH 5. 





Figure 6.1 ROC curve for βH inhibition activity. 
 
6.2.1.2 Model for predicting parasite activity 
An advantage of using Bayesian models over multiple linear correlations, typical in QSAR 
analysis and prediction, is that the precise IC50 becomes less important. The data are divided 
into an active and inactive set at some appropriate user-defined IC50 cut-off and the model 
built on the frequency of occurrence of particular molecular features.  Conversely, 
traditional QSAR uses the measured IC50 value to build a mathematical model, where fairly 
small differences in experimental procedures can lead to significant effects on the fitted 
coefficients. This was an important consideration in electing to build a Bayesian model to 
predict parasite activity, since data were sourced and compared from different compound 
sets and tested in different laboratories with non-standardised assay procedures. However, 
this did not appear to disadvantage the models, because for most of the samples, their 
assignment to the active or inactive set was not dependent on a precise IC50 value, since 
they lay either well below, or well above the cut-off value. Initially, a 2 µM cut-off with only 
the H inhibiting TCAMS and VU compounds was used in the training set, where the latter 
compounds inhibited parasite growth by 90% at 23 µM. Then a selection of unpublished in-
house UCT compounds were added as well as the VU <90% set in order to increase the 
numbers of inactive compounds. Finally, the inactive compound set from the St Jude’s 
screen was incorporated for ROC optimisation. A test set consisting of 156 molecules from 
the TCAMS and VU screening data was used for basic validation of the models with excellent 
prediction statistics for the 2 µM cut-off model (Table 6.2 and Figure 6.2).  




When an additional model was developed with a 0.5 M cut-off using the same training 
sets, the test set prediction percentage dropped considerably when the St Jude’s inactives 
were incorporated in the training set (Table 6.2). In this case, it was found that 95% of the 
test set compounds with IC50 values <2 µM were classified as active and 88% of compounds 
with IC50 values >2 µM were classified as inactive. This caused many false positive values 
based on an activity cut-off of 0.5 µM. This was probably as a result of the paucity of active 
compounds in the training set (only 352 actives out of 42194 compounds, 0.8% of the 
training set) below the 0.5 M cut-off. Interestingly, this model predicted 92% of the 
compounds correctly if active test compounds were reclassified as those with IC50 values <2 
µM.  
 
Table 6.2 Optimisation of P. falciparum activity models using IC50 cut-offs of 2 µM and 0.5 
µM. The test set contained 156 molecules from the TCAMS and VU libraries. Data in bold are 
for the optimised model after adding all the data to the training set. 
Dataset added 





























and VU (>90% 
inhibition at 23 
µM) 
351 549 0.5 0.796 FAIR ND 
806 94 2 0.937 EXCELLENT 85% 
As above + VU 
(<90% inhibition 
at 23 µM) + UCT 
352 790 0.5 0.842 GOOD 70% 
817 325 2 0.959 EXCELLENT 94% 
As above + St 
Jude’s (inactives 
only) 
352 42194 0.5 0.989 EXCELLENT 
55% (at 0.5 
µM) / 92% 
(at 2 µM) 
817 41729 2 0.991 EXCELLENT 92% 
 
 





Figure 6.2 ROC curve for whole-cell parasite activity. 
 
6.2.1.3 Comparison of molecular descriptors for βH and parasite activity 
The calculated descriptors which were used to build the models were compared in order to 
find the optimal ranges for best activity. In Table 6.3, the values represent the ranges for 
each feature which were most favourable amongst the active training set molecules. For the 
majority of features, ranges are similar for the two models, suggesting that having a higher 
logP, MW, #HBD, #HBA, #RB and #AR would improve both activities. However, the βH model 
requires a lower #RB for optimal inhibition, whilst the parasite model requires a much larger 
#RB. This could be interpreted as a molecule needing to be planar for efficient haem 
interaction and requiring lipophilic saturated side chains to cross membranes for parasite 
activity. In addition, the βH model favours a FPSA of 0.29-0.33 whereas the parasite model 
prefers a lower range of 0.13-0.17. This analysis demonstrates the balance between these 
two features which needs to be achieved for a βH inhibiting antimalarial. However, both 
features had a low priority when calculating the Bayesian score, since they were ranked at 
or near the bottom of the probability weightings for both models. On the other hand, the 
features which agree between the models are more important in terms of calculating a 
probability for βH and parasite activity, suggesting that by optimising these features for βH 
activity, the likelihood of creating a βH inhibiting antimalarial is also improved. In addition to 
the molecular descriptors in Table 6.3, a large number of extended-connectivity fingerprints 
of depth 6 (ECFP_6) were used to create the model. These were invariably the highest 
ranking descriptors.  





Table 6.3 Optimal feature ranges for the two activity models with the probability score rank 
for each feature. The word in brackets refers to the range values relative to the less 
favourable ranges. Those in italics exhibit contrary preferences. 
Feature 











#HBD 2 3-7 (More) 4 3-8 (More) 
#AR 3 4-7 (More) 2 5-8 (More) 
MW 4 460-719 (Larger) 5 459-911 (Larger) 
logP 5 5-11 (Larger) 7 4-11 (Larger) 
#R 6 5 (More) 3 5-8 (More) 
#HBA 7 6 (More) 9 7-13 (More) 
#RB 8 0-2 (Fewer) 6 9-20 (More) 
FPSA 9 0.29-0.33 (Larger) 8 0.13-0.17 (Smaller) 
 
The good ECFP_6 features for βH inhibition were 2-aryl benzimidazoles, indoles and 
quinolin-4(1H)-ones, while bad features included 2-thiolimidazoles and a variety of non-
aromatic rings and heteroalkyl chains (Table 6.4). This result was consistent with the other 
feature observations which revealed greater #AR and fewer #RB for βH inhibition activity. 
Similarly, for parasite activity, fingerprints such as imidazoles, benzimidazoles and indoles 
dominated the good features. Interestingly, almost all the bad ECFP_6 features for parasite 
activity contained sulfur, either in an alkyl chain, as a sulfonamide or within a 5-membered 
heteroaromatic ring. A selection of the dominant fingerprints is shown in Table 6.4. 
 
  




Table 6.4 Examples of some of the most important extended-connectivity fingerprints of 
depth 6 (ECFP_6) for a) the βH inhibition model (cut-off of 100 µM) and b) the parasite 
growth inhibition model (cut-off of 2 µM).  
a) βH inhibition model b) Parasite growth inhibition model 








95/121 active 0/495 active 194/194 active 0/2111 active 
    
127/176 active 1/982 active 141/141 active 0/2087 active 
 
6.2.2 Chemical space analysis 
Spitzmüller et al.306 predicted the target space for the St Jude’s and TCAMS whole-cell hit 
compounds and found over 200 P. falciparum hit proteins for 20,000 compounds. However, 
until recently, data for βH inhibitors has been largely unavailable. Analysis of the principle 
components (PC) of the TCAMS compounds used in the training set (Figure 6.3a) 
demonstrates a distinct difference in the chemical space between those that inhibit βH 
formation by at least 60 % (red) at 19 M and those with <40% inhibition (blue). The βH 
inhibitors are shifted in space such that they have a greater first and third PC relative to the 
non-βH inhibitors. This shift corresponds to a lower #RB and larger FPSA, #AR, #R, #HBD, 
#HBA and MW. There were no significant differences in logP. Furthermore, 1029 assembly 
fragments were present in the TCAMS actives and only 50 were found to be common 
between the two sets, resulting in a low similarity score (Tanimoto distance) of 0.0486. This 
agrees with the Bayesian model comparison method where a large Bayesian distance of 
72.3 was found, indicating that a training set consisting of only βH inhibitors may be more 




specific towards predicting haemozoin inhibiting antimalarials than one incorporating all 
13,533 TCAMS actives. The VU βH hits which were incorporated into the training set cover a 
more confined chemical space, shifted relative to the TCAMS compounds by lower PC1 
(Figure 6.3b). This indicates a lower MW and #AR or #R based on feature weighting for PC1. 
The OU compounds are largely scattered between the TCAMS and VU chemical space with 
several molecules possessing high MW, larger #R and #RB (long amine side chains) shifted 
into the higher PC1 range. The analysis demonstrates the relatively large chemical space 
covered in the training set by βH inhibitors from the different libraries. 
a)      b) 
  
Figure 6.3 a) Plot of the three PCs for the TCAMS βH inhibitors (red-larger PC1 and PC3) vs 
non-βH inhibitors (blue) and b) The VU (cyan) and OU (lime green) βH inhibitors relative to 
the TCAMS βH inhibitors (red) and non-βH inhibitors (blue).  
 
With the chemical space of the training set identified, the validation sets were plotted in the 
same PC space in order to determine how closely related the libraries are (Figure 6.4). As 
expected, the purchasable AldrichCPR drug-like compounds are contained within the space of 
the FDA approved drugs which are themselves more dispersed relative to the other sets.  
The VU compounds lie closest to the known drugs and the TCAMS and OU compounds with 
the largest PC1 are furthest in space from the validation sets. This diversity is important for 
training set verification as it demonstrates the degree of model versatility for predicting test 
sets which differ from the training sets.     
 





Figure 6.4 Validation sets including the FDA approved (light blue) and 1000 randomly 
selected molecules from the AldrichCPR drug-like compounds (dark blue) in relation to the 
TCAMS (red), OU (gold) and VU (green) βH inhibitors from the training set. 
  
6.2.3 FDA approved compounds for model validation 
For the purposes of validation, the optimised Bayesian model was applied to known drugs. 
Although βH inhibition is mostly unknown for FDA approved compounds, in vitro 
antimalarial activity is often available through PubChem (https://pubchem.ncbi.nlm. 
nih.gov/), even if they are not clinical antimalarials. The parasite bioactivity was predicted 
(using the 2 µM cut-off model) for 1510 molecules and ranked by likelihood of being 
bioactive from highest to lowest Bayesian score (selected portions shown in Table 6.5). In 
the sorted list, all six of the known βH inhibiting drugs that are clinical antimalarials (as well 
as QD barbiturate and hydroxychloroquine) were found in the top 2.1% of the 1510 
compounds. The clinical antimalarials were AQ, QN, QD, CQ, QC and HF. MF was also found 
within the top 4%. Additionally, of the 24 compounds that are not clinical antimalarials in 
the top 2.1%, nine have reported in vitro antimalarial activity in PubChem, ten have not 
been tested on P. falciparum and only three are reported inactive below 10 µM (Figure 6.5). 
Thus, among the 14 compounds for which antimalarial activity has been reported, this 
represents a hit rate of 81%. On the other hand, in the bottom 2.1%, 24 are reported as 
inactive (below 10 M), seven have not been determined and only two compounds are 
reported as having in vitro antimalarial activity (in one case with contradicting evidence), 
representing a hit rate of 8% among those tested. However, finding active compounds in the 




bottom set does not negate the model since the active training set compounds were 
specifically βH inhibiting antimalarials. Thus, for example, the clinical antimalarials that are 
known to have a different mechanism of therapeutic action were also predicted at least 23 
Bayesian score units lower than the βH inhibiting ones. These included the antifolates 
proguanil, pyrimethamine and sulfadoxine;307 primaquine which causes redox cycling308, the 
apicoplast inhibitor, doxycycline;309 and atovaquone, which disrupts mitochondrial electron 
transport.310  
 
Table 6.5 FDA Approved compounds ordered by parasite activity Bayesian prediction score 
(2 µM model). The top 2.1% of compounds showing the known βH inhibiting antimalarials 
(bold), a list of non-βH antimalarials with their scores and the bottom 2.1% are listed. 










Top ranked 2.1% 
1 Lapatinib 121.907 81.4034 Active 
2 Amodiaquine 55.9673 4.97018 Clinical Antimalarial 
3 Imatinib 55.1797 17.2137 Active 
4 Nafarelin 50.2008 -19.0656 ND 
5 Nilotinib 48.8765 18.0575 ND 
6 Antrafenine 43.3054 -12.1206 ND 
7 Vapreotide 41.9603 16.0751 ND 
8 Gefitinib 41.7064 15.5785 Active 
9 Quinine 40.4845 -11.527 Clinical Antimalarial 
10 Quinidine 40.4845 -11.527 Clinical Antimalarial 
11 Quinidine barbiturate 39.6127 -15.6597 Active 
12 Rilpivirine 38.4368 15.1667 Active 
13 Thiabendazole 37.0463 15.0677 Active 
14 Erlotinib 34.2159 14.7457 Inactive <10 M 
15 Gonadorelin 33.8182 -18.7343 ND 
16 Goserelin 32.5423 -17.1688 Inactive <10 M 
17 Afatinib 30.9591 11.0776 ND 
18 Vandetanib 30.2873 2.8095 Active 
19 Lomitapide 29.8482 -15.6564 ND 
20 Hydroxychloroquine 29.579 -7.90028 Active 
21 Chloroquine 28.9237 -7.38423 Clinical Antimalarial 
22 Quinacrine 26.9148 0.964427 Clinical Antimalarial 
23 Terazosin 24.2283 -20.9691 Inactive <10 M 
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24 Dasatinib 23.8589 3.44577 Active 
25 Pazopanib 23.8397 13.2397 Inactive <10 M 
26 Lansoprazole 23.4241 -1.71826 Active 
27 Cetrorelix 22.9426 -26.9078 ND 
28 Sorafenib 22.8016 6.40403 Active 
29 Regorafenib 22.1709 10.9474 Inactive <10 M 
30 Octreotide 21.8772 0.0651364 ND 
31 Avanafil 21.125 -6.335 ND 
32 Halofantrine 20.8674 3.41694 Clinical Antimalarial 
Non-βH inhibiting antimalarials 
317 Primaquine -2.66276 -8.36974 Clinical Antimalarial 
469 Doxycycline -5.95531 -5.4519 Clinical Antimalarial 
718 Pyrimethamine -10.3092 -10.695 Clinical Antimalarial 
873 Sulfadoxine -13.429 -3.24919 Clinical Antimalarial 
964 Proguanil -15.1309 -6.73212 Clinical Antimalarial 
1172 Atovaquone -19.699 -10.4775 Clinical Antimalarial 
Bottom ranked 2.1% 
1479 Drotaverine -38.3959 -22.9142 ND 
1479 Ethopropazine -38.6606 -27.2162 ND 
1480 Cefonicid -38.7062 -13.6207 ND 
1481 Niclosamide -39.3053 -22.1728 Active 
1482 Cisatracurium Besylate -39.4671 -30.1177 Inactive <10 M 
1483 Ceforanide -39.6463 -8.66601 ND 
1484 Nicardipine -39.6929 -31.0469 Contradicting Data 
1485 Chlorpromazine -40.0968 -30.5136 Inactive <10 M 
1486 Furazolidone -41.1267 -25.7797 Inactive <10 M 
1487 Acepromazine -41.2932 -26.769 Inactive <10 M 
1488 Nilutamide -42.0274 -14.8976 Inactive <10 M 
1489 Aceprometazine -42.3818 -32.5787 ND 
1490 Diltiazem -42.5729 -17.633 Inactive <10 M 
1491 Sildenafil -43.0273 -33.237 Inactive <10 M 
1492 Clonazepam -43.6032 -24.5517 Inactive <10 M 
1493 Nitrofurantoin -43.9518 -20.7281 Inactive <10 M 
1494 Nifedipine -44.2094 -15.5129 Inactive <10 M 
1495 Propiomazine -44.4947 -15.9686 ND 
1496 Clobazam -45.7832 -20.2821 Inactive <10 M 
1497 Nisoldipine -46.6286 -34.8889 Inactive <10 M 
1498 Apixaban -47.7752 -12.0871 Inactive <10 M 
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1499 Probenecid -48.0048 -21.7798 Inactive <10 M 
1500 Cefmetazole -48.6828 -26.0458 Inactive <10 M 
1501 Entacapone -49.5917 -17.3079 Inactive <10 M 
1502 Vardenafil -50.4405 -35.2596 Inactive <10 M 
1503 Nitazoxanide -52.1584 -6.27099 Inactive <10 M 
1504 Cefazolin -52.5087 -22.5625 Inactive <10 M 
1505 Dantrolene -56.3814 -18.768 Inactive <10 M 
1506 Nitrendipine -56.4016 -25.1557 Inactive <10 M 
1507 Flunitrazepam -56.5882 -14.6742 ND 
1508 Nimodipine -56.659 -21.5478 Inactive <10 M 
1509 Nilvadipine -56.8842 -26.4166 Inactive <10 M 
1510 Acenocoumarol -57.1474 -29.3544 Inactive <10 M 
 
These activity predictions demonstrate the power of the model for specifically prioritising 
antimalarials that inhibit βH and are therefore likely to be haemozoin inhibitors. The 0.5 µM cut-
off model was also tested and performed even better, finding the βH inhibiting antimalarials 
within top 1.8% of sorted compounds. Besides primaquine, which went from rank #317 using the 
2 µM model to #767 with the 0.5 µM model, only minor changes to the ranking of the other 
compounds was observed. The βH model was also applied to the FDA compounds. AQ, QC and 
HF were predicted correctly to be βH inhibitors while QD, QN and CQ were falsely predicted 
negative. The reason for this is most likely the presence of the quinuclidine or alkyl amino side 
chains, absent in AQ, which are predicted to be unfavourable for βH inhibitory activity, possibly 
because they add too many rotatable bonds (Table 6.3). Although QC and HF contain alkyl side 
chains, they also have an extra aromatic ring which contributes favourably to the βH inhibition 
score. This reveals a shortcoming of the βH model for recognising inhibitors that contain these 
functional groups. 
  





Figure 6.5 Graphical representation of the 2.1% of 1510 FDA approved drugs with highest and 
lowest Bayesian scores for activity against P. falciparum based on training sets of H inhibiting 
compounds using activity data against the parasite. Active compounds consist of clinical 
antimalarials as well as other drugs with proven activity against P. falciparum reported in 
PubChem. 
 
6.2.4 Prioritization of a commercial library 
In order to test how the models would perform if used to prioritise compounds for HTS, 4,998 
purchasable compounds were virtually screened (Figure 6.6). After calculating the Bayesian score 
using the βH model and selecting only those predicted active, about 900 compounds remained. 
The top 650 were chosen to screen using the whole-cell Bayesian parasite model (2 µM cut-off) 
which predicted 178 compounds to be active. Compounds were then selected for purchase 
according to the criteria specified in the methods (Section 8.1.5.4). By applying the βH model and 
only selecting predicted actives from this dataset, the bio-active and bio-inactive subsets were 
nested within the βH active subset (Table 6.6). This allowed for the most efficient and cost-
effective way of validating the model.  





Figure 6.6 Flow chart of the strategy used to purchase and screen a small commercial library. 
 
All of the ten purchased compounds predicted to be inactive against βH formation below 100 
M were indeed found to be inactive, even up to 500 µM. Of the 24 predicted H inhibiting 
compounds, six showed IC50 values below 100 µM and two between 200-500 µM. This gave a hit 
rate for βH activity of 25%, a >25-fold enrichment over random screening for βH inhibitors at a 
cut-off of 100 µM (based on the hit-rate in the VU screen).204 Of these six compounds, five were 
also predicted to be bioactive (SA23, SA27, SA29, SA33 and SA34). Two were found to have 
whole-cell IC50 values below 2 µM in the CQ-sensitive NF54 strain of P. falciparum (SA27: 82 nM 
and SA34: 79 nM). Interestingly, both of these compounds were quinolines bearing structural 
similarities to known antimalarials QN/QD and CQ respectively, despite the drug molecules being 
absent from the training set. The QN/QD derivative (SA27) was represented in the ZINC database 
and sold by Sigma-Aldrich as an analogue lacking both the 9-hydroxy and 6-methoxy groups. 
However, Roepe and co-workers have previously shown the importance of the hydroxyl moiety 
for βH and parasite activity in QN.311 This was consistent with crystal structures reported by de 
Villiers et al.158 which demonstrated coordination of the QN and QD hydroxyl oxygen atoms to 
the Fe(III) centre of haem, an interaction deemed critical for inhibition of haemozoin formation. 
In light of this previous research, which seemed to contradict our finding, nuclear magnetic 




resonance (NMR) and mass spectrometry (MS) experiments were carried out in order to confirm 
the structure of SA27. As anticipated, the spectra confirmed that the major structure of the 
QN/QD derivative (>90%) did indeed possess the hydroxyl moiety after all, revealing that SA27 is 
either cinchonine (CN) or cinchonidine (CD). Furthermore, there was evidence of an impurity 
(<10%) containing the quinoline methoxy group, possibly corresponding to QN or QD (See Figure 
6.7 for spectra). This finding reemphasises the importance of proving the composition of hit 
compounds obtained from HTS, particularly those in milligram quantities for which structural 
and purity information is often not supplied by the distributor. Additional proof of identity was 
evident from the parasite activity (NF54) for SA27 of 82 nM found in this study which 
corresponds closely to the activity of CN against the Dd2 strain.311 We retrospectively calculated 
the Bayesian probability score for the actual structure of SA27 with the hydroxyl group in place 
(Table 6.6) which showed that CN/CD was in fact more likely to be active both against βH 
formation (Bayesian score of -0.91 vs -3.58) and parasite growth (19.19 vs 5.74) than the 9-
dehydroxy derivative.  
As expected, none of the other compounds were potent parasite growth inhibitors, either 
because they were predicted bio-inactive or because they were false positives for βH inhibition 
activity. Since two of the 14 testable bioactive compounds were actually active, the hit rate was 
14%, a 140-fold enrichment over random screening for compounds targeting haemozoin 
inhibition (based on the hit rate from the VU screen for H inhibiting antimalarials).204 However, 
in a HTS protocol for discovery of βH actives, only this subset would have been tested against the 
parasite, resulting in a 33% hit rate.  
 
  




Table 6.6 Experimentally active βH inhibitors from the purchased AldrichCPR compounds, 









































































a0.5 µM cut-off model  
b2 µM cut-off model 
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Figure 6.7 a) 1H NMR spectrum of SA27. The protons attached to C19 and C10 overlap in the 
1H NMR spectrum at 5.7 ppm integrating for 2H. b) 13C NMR spectrum of SA27 and c) 1H and 
13C two-dimensional heteronuclear correlation HSQC spectrum. The proton peak at 5.7 ppm 
couples to carbon C19 at 142 ppm and C10 at 71 ppm. The downfield chemical shift of C10 
relative to that expected for an aliphatic carbon nucleus is a result of the electron 
withdrawing effects of the hydroxyl substituent. NMR spectra were collected using a Bruker 
Ultrashield 400 Plus (at 399.95 MHz for 1H and 100.64 MHz for 13C) spectrometer in 
deuterated chloroform (CDCl3). 
 
The parasite model built on βH inhibitors successfully identified the haemozoin inhibiting 
FDA approved antimalarials without first filtering out those predicted to be inactive against 
βH formation. The same approach was retrospectively applied to the AldrichCPR compounds 
to compare the procedures for prioritisation. At a cut-off of 0.5 µM (which performed best 
when predicting the FDA compounds), there were few differences in the prioritised 
compounds that would have been purchased for bioactivity (aside from small changes in the 
C19 
C10 




order of their probability scores). In fact, an additional derivative of QD (a 6-ethoxyquinoline 
with a quinuclidine ethyl instead of a 6-methoxyquinoline with a quinuclidine vinyl group) 
appeared in the top three predicted bioactives which had previously been filtered out as a 
non-βH inhibitor. Overall, 13 of the 14 molecules purchased were also predicted active 
when filtering only for bioactivity. 
 
6.3 Summary and conclusions 
In this study both in vitro antimalarial activity and inhibitory data for βH formation, obtained 
from the VU HTS, synthesised analogues and the publically available GSK (TCAMS) and St 
Jude Children’s Research Hospital HTS data sets, were used to develop Bayesian models for 
inhibitors of βH formation and in vitro antimalarial activity. The models were optimised by 
evaluating different activity cut-off values with increasing sample numbers in the training 
set. The optimised models exhibited excellent ROC scores of 0.915 and 0.991 for the βH 
inhibition model (cut-off of 100 μM) and parasite growth inhibition model (cut-off of 2 μM) 
respectively. These models were used to screen two in silico compound libraries. In the first, 
the 1510 U.S. Food and Drug Administration (FDA) approved drugs available on PubChem 
were ranked from highest to lowest Bayesian score based on a training set of βH inhibiting 
compounds active against P. falciparum that did not include any of the clinical antimalarials 
or close analogues. The six known clinical antimalarials from the FDA list that inhibit βH 
formation were ranked in the top 2.1% of compounds. Furthermore, the in vitro antimalarial 
hit-rate for this prioritised set of compounds was found to be 81% in the case of the subset 
where activity data are available in PubChem. In the second, a library of ~5000 
commercially available compounds (AldrichCPR) was virtually screened for ability to inhibit 
βH formation and then for in vitro antimalarial activity. A selection of 34 compounds was 
purchased and tested, of which 24 were predicted to be βH inhibitors. The hit rate for 
inhibition of βH formation was found to be 25% and a third of these were active against P. 
falciparum, corresponding to enrichments estimated at about 25-fold and 140-fold relative 
to random screening, respectively. 
  




Although HTS has become a vital tool for drug discovery, it remains an expensive, time 
consuming and extremely specialised process. The implementation of machine learning 
approaches such as Bayesian modelling is able to prioritise compounds for HTS resulting in 
improved hit rates using fewer test compounds. Creating in silico models from data 
contributed by previous HTS efforts is not only useful for future HTS prioritisation, but is an 
effective way to make use of all the available data, including inactives, from previous 
screens. The results of this work have shown that Bayesian models can be applied to 
antimalarial compounds which are βH inhibitors with impressive enrichment rates relative 
to random screening. The validation sets strongly suggest that the chemical space of the 
active compounds in the parasite model is specific for haemozoin inhibiting antimalarials. 
Bayesian modelling may have a role in the future identification of novel antimalarials, 
particularly when combined with other in silico techniques. 





CONCLUSIONS AND FUTURE WORK 
 
7.1 Conclusions 
The rapid development of drug resistance by P. falciparum caused a decline in the efficacy 
of previously successful antimalarials, particularly CQ, MF and QN, in most parts of the 
world. Now, the recent reports of artemisinin resistance, which as of early 2015 was 
confirmed in five countries of the Greater Mekong sub-region in southeast Asia, threatens a 
vital component of the WHO’s top recommended malaria therapeutics, ACTs.312  This has 
caused a critical need for novel antimalarial chemotypes and a better understanding of 
intracellular drug mechanisms towards target-based, rational drug design and development. 
To this end, HTS has been very successful in identifying numerous compounds, both with 
known and novel scaffolds that are active against various strains of the malaria parasite. 
However, owing to the limited capacity for research on only moderately active HTS hits, 
many novel scaffolds exhibiting some degree of activity are not often exploited, especially 
by pharmaceutical companies or research groups primarily focused on delivering a new 
drug. These compounds can be used to probe mechanistic aspects and may have potential 
to be derivatised into sufficiently potent drugs further down the development line. In 
addition, many inactive compounds are disregarded or not reported, despite the fact that 
they add significantly to the structure-activity data pool.  
The two types of HTS, namely phenotypic or target-based, each have advantages in certain 
situations. Phenotypic screening for antimalarials results in identifying all the compounds in 
the HTS library, regardless of their mechanism or target, which show activity against the 
parasite directly. This is the best way of finding the most active compounds. However, 
further studies are necessary to determine the drug target, which often requires multiple 
experiments. This is very time consuming, expensive and challenging for target validation of 
multiple hits.177 On the other hand, in target-based screening, a cheaper and more efficient 
assay can be carried out first, to identify inhibitors of a specific pathway. Hits from the initial 
screen can then be tested against the parasite in a secondary whole-cell screen, resulting in 




active compounds with a known target.204 In this case, both the active and inactive data can 
be conveniently used to create structure-activity relationships or models for predicting 
activity, since the compounds, acting at the same target site in the parasite, can be directly 
compared. This is beneficial for establishing the important structural features of novel 
chemotypes and to aid in the understanding of mechanism. 
In this project, target based screening in the form of βH inhibition was carried out on 43,520 
compounds, as part of a larger screen of 144,330 compounds. Of the total screened, 530 
compounds (0.37%) were confirmed to inhibit βH formation by ≥80%, all exhibiting IC50 
values below that of CQ. The hits generally possessed a greater logP, MW, #AR, #HBA, 
#HBD, #R and FPSA than the average for the library as a whole, but preferentially contained 
fewer RB, which supported the hypothesis that βH inhibitors are planar, aromatic 
compounds capable of hydrogen bonding and π-π interactions with Fe(III)PPIX, as previously 
determined for several quinoline haemozoin inhibitors.157,158 In a secondary screen against 
P. falciparum, 171 compounds were identified as inhibiting parasite growth by ≥90% at 23 
µM, showing a favourable hit rate of 32.3% out of the 530 βH inhibitors. This confirmed the 
relative reliability of the NP-40 based assay and its ability to more accurately mimic the 
parasite’s lipophilic environment through detergent micelles, compared with previous βH 
inhibition assays.180 Moreover, 73 and 25 of the hits displayed CQ-sensitive D6 parasite 
activity below 5 µM and 1 µM respectively, with diverse structures. Fourteen primary 
scaffolds were identified and representative compounds from twelve of the fourteen were 
shown to cause a significant increase in free haem in parasites at their respective IC50s 
relative to the negative control. This showed that indeed, compounds active in the parasite 
are haemozoin inhibitors as expected from first screening for βH inhibition, giving further 
validation for the hit identification protocols used in this project. 
Two non-quinoline chemotypes, the benzamides and triarylimidazoles were selected for 
further studies to discover SARs and probe drug mechanisms. Both scaffolds lent themselves 
well to synthesis of small libraries of derivatives from relatively inexpensive starting 
materials, owing to the readily-formed amide bond for benzamide synthesis and the 
condensation cyclisation of the triarylimidazole synthesis.   
The benzamides (Scaffold 1) were particularly interesting since SARs for βH inhibition clearly 
showed that only mono- and di-benzamide analogues capable of adopting planar 




conformations, particularly those with electron deficient rings, could inhibit βH formation. 
Specifically, dibenzamides without an electron withdrawing group on the central ring 
required pyridyl rings attached to the amide nitrogen for βH inhibition activity, while those 
with an electron withdrawing group tolerated phenyl rings (Figure 7.1). This, together with 
the relatively weak Fe(III)PPIX binding of representative mono- and di-benzamides 
supported the hypothesis that haemozoin inhibitors prevent crystal formation via docking 
into the groove on the fastest growing face of the crystal.  
 
Figure 7.1 βH inhibitory SARs for the dibenzamides. 
 
The in vitro parasite IC50s of the benzamides correlated well with their βH inhibition IC50s, 
apart from one particularly active analogue, which was an outlier. However, their CQ-
sensitive NF54 parasite activities were at least 50 times lower than that of CQ and AQ, 
despite their greater or equipotent βH inhibition activities. 
The minimum pharmacophore for βH inhibition in the triarylimidazole series (Scaffold 2) 
was identified as a triaryl-substituted imidazole where either the 2-aryl ring (ring A) was an 
unsubstituted pyridyl or a substituted phenyl, although 4-trifluoromethoxy was not 
tolerated on the phenyl ring. The SARs for βH inhibition could not be related to electronic or 
hydrophobic effects or to incorporation of planar or non-planar substituents. Hydroxyl, 
methoxy and halogen substituents were also tolerated on the other phenyl rings (rings B 




and C). In fact, substitution generally improved parasite activity (Figure 7.2), although not in 
correlation with βH inhibition activity. The series suffered from poor solubility which made 
further experiments, such as Fe(III)PPIX association, impossible in 40% aqueous DMSO. The 
5-methoxy-4-hydroxy substitution pattern assisted with solubility, which may well explain 
the significantly improved parasite activity for these analogues.  
 
Figure 7.2 The favourable (blue) and unfavourable (red) substituents for parasite activity 
within the triarylimidazole HTS hits and synthesised analogues.  
 
Representative benzamides and triarylimidazoles caused significantly higher levels of free 
haem in the parasite at their respective IC50s, relative to the quinoline antimalarials, 
validating haemozoin inhibition as the target for both series. These results were intriguing, 
given that both series showed at least 30 to 50-fold lower activity than CQ. The P. 
falciparum cell fractionation experiment to measure free haem levels suggested that a drug-
Fe(III)PPIX complex may be responsible for in vitro toxicity. One might expect free haem 
levels to be similar at the IC50 of diverse compounds, if free haem alone causes the toxicity 
which leads to parasite growth inhibition. However, the lower levels of free haem in the 
quinoline antimalarials compared with the benzamides and triarylimidazoles, suggests that 
the quinolines complex a large proportion of the free haem, forming a toxic complex. This is 
reasonable given the strong association between Fe(III)PPIX and the quinolines, especially in 
the case of CQ and QD. In the case of the benzamides, being ~100 fold weaker Fe(III)PPIX 
binders, larger amounts of free haem are required in order for parasite cell death to occur. 
Given that the triarylimidazoles, like the benzamides, are only able to interact with 
Fe(III)PPIX via π-π interactions, since they do not necessarily possess groups capable of 




coordination or hydrogen bonding, this may well also be the case for this series. As a result, 
higher concentrations of benzamide and triarylimidazole compounds are required to inhibit 
haemozoin formation to a greater extent in order to release enough free haem for 
necessary toxicity levels. 
The cellular accumulation of several benzamide derivatives was measured. Two 
pyridylbenzamides showed ~20 fold lower accumulation than CQ and AQ in the D10 strain 
of the parasite, partially accounting for their 50-fold weaker activity. The phenomenon of pH 
trapping is believed to account for the large accumulation of CQ and AQ, which contain 
basic moieties. To this end, a benzamide analogue with basic side chains, predicted to have 
a VAR of ~147,000, was synthesised with dimethyl amine side chains via reductive 
amination. Although the compound maintained βH inhibition activity, it displayed a slightly 
lower IC50 of ~1 µM compared with the pyridyl derivatives in the D10 strain and was 
subsequently shown to accumulate ~6-fold less than the pyridylbenzamides. This suggested 
that the basic compound could not accumulate via pH trapping in the DV. Alternatively, it 
was very recently shown that triethylammonium ion and protonated basic amino acids are 
probably transported out of the DV by PfCRT.67 In addition, triethylammonium uptake was 
unaffected by neutral or acidic amino acids or by organic anions, but could be strongly 
inhibited by verapamil and QD, as well as CQ, and nutrients, such as arginine, lysine, and 
peptides. Even in wild type CQ-sensitive strains, transport of CQ was observed, although less 
than in resistant strains. This uptake of protonated basic compounds (BH+ and BH22+) from 
low to high pH, may well explain the poor accumulation ratios measured for the basic 
benzamide analogue. It is reasonable to hypothesise that a basic compound, not able to 
bind strongly to free haem, may accumulate in the acidic compartment via pH trapping but 
simultaneously be effluxed via PfCRT transport out of the DV. In the case of strong haem 
binders, such as CQ and related quinolines, the drug-haem complex is either not effluxed 
out of the DV (at least in the CQ-sensitive strain), allowing for a toxic build-up in the DV, or 
alternatively, if able to cross the DV membrane, exerts its toxic effect within the parasite 
cytosol. Both these hypotheses would account for the larger CARs and lower free haem 
levels measured for CQ and AQ relative to weaker haem binders, such as the benzamides. 
 




The benzamides and triarylimidazoles have been useful probes of the mechanisms by which 
antimalarials exert their therapeutic effects. Without target-based HTS, novel chemotypes 
are unlikely to be discovered. However, HTS is an expensive, time consuming and extremely 
specialised process, requiring dedicated resources. As a result it is logical to fully exploit the 
acquired HTS data, particularly if it could simplify future HTS efforts. This has been 
successfully demonstrated for haemozoin inhibitors identified via HTS, by the 
implementation of the machine learning technique using Bayesian modelling. Here, in silico 
prioritisation of compounds for HTS resulted in improved hit rates using fewer test 
compounds. In addition, parameter details of the created models illuminated trends 
between data sets, specifically βH inhibitors and parasite growth inhibitors. For example, 
the validation sets strongly suggested that the chemical space of the active compounds in 
the parasite model is specific for haemozoin inhibiting antimalarials. These approaches are 
especially important for combating neglected tropical diseases such as malaria, where 
resources and capacities for research are limited. This finding also raises the intriguing 
possibility that models trained from compounds with other known targets may be able to be 
similarly used in antimalarial drug discovery and to identify hits as probes with alternative 
mechanisms. Furthermore, when combined with in silico techniques for prioritising ADMET 
properties, this approach may have a role in the future identification of novel antimalarials. 
In this project, HTS was successful in identifying many novel βH inhibiting scaffolds as well as 
compounds active against P. falciparum via haemozoin inhibition. The scope of the HTS hits 
as probes for biological mechanisms was revealed after fairly inexpensive and simple 
synthetic procedures were applied to generate analogues for two selected scaffolds, 
benzamides and triarylimidazoles. Different characteristics relating to βH and parasite 
growth inhibition activities, levels of free haem, haem binding affinity and parasite 
accumulation were revealed for the novel chemotypes compared with the relatively widely-
studied quinoline antimalarials, despite also being haemozoin inhibitors. These data were 
then successfully used to develop a model predicting activity on the basis of Bayesian 
statistics, demonstrating the value of generating structural diversity via HTS, even when the 
hits cannot themselves be further developed as antimalarials. 
 




7.2 Future work 
The relatively large numbers of haemozoin inhibiting antimalarials identified via HTS in this 
project, compared with previous efforts,180,159 has resulted in several novel chemotypes that 
have future potential to be used as probes in similar experiments to that of the benzamides 
and triarylimidazoles. Table 2.3 in Chapter Two presents a list of the 25 most potent 
compounds against the CQ-sensitive D6 strain of P. falciparum, which were hits in the 
primary βH inhibition assay. Synthesis of analogues and SAR investigations into several of 
these chemotypes has already been initiated by other members of the Egan/Hunter 
research group, including the benzimidazoles (VU0002101), dihydropyridines (VU0122653) 
and the quinazolines (VU0129813) shown in Table 7.1, however, their Fe(III)PPIX association 
constants, free haem levels and CARs are unknown. While many of the other parasite active 
hit compounds contain quinoline moieties, they also have potential to be used as a way of 
demonstrating correlations. For example, compounds VU0098755 and VU0065708, exhibiting 
high potency and containing a charged N-alkyl substituted quinoline may be used to probe 
the relationship between accumulation, free haem levels, haem binding and parasite 
activity, given that they do not contain basic moieties for pH trapping. Correlations between 
these parameters may become more obvious by eliminating the factor of pH trapping.  
  




Table 7.1 Selected hits, other than the benzamides and triarylimidazoles, from Table 2.3 for 
which investigation has been initiated or which have potential to further probe mechanisms. 

















For example, if VU0098755 and VU0065708 are found to accumulate to a large extent, 
resulting in their observed good activity, but are weak Fe(III)PPIX binders, this would suggest 
that accumulation is via another mechanism, possibly active uptake into the DV. In this case, 
finding trends between different classes of haemozoin inhibitors based on physicochemical 
or biological properties may be impossible, if each class or derivative possesses its own 
unique system for therapeutic action. However, this is unlikely since the data in this project 
suggest a relationship exists between the observed biological parameters, specifically, haem 
binding affinity, free haem levels, accumulation and parasite activity for the different 
chemotypes. Uncovering this relationship has great potential for rational drug design. The 
design of an analogue possessing the correct structural features for coordination, hydrogen-
bonding and π-π interactions with Fe(III)PPIX should result in a strong haem binder. With 




the assistance of a basic group for initial pH-trapping-driven accumulation of the compound, 
this would lead to drug-haem complex formation, which could indirectly be measured via 
free haem levels in cell fractionation experiments. If this hypothesis is correct, saturable 
accumulation via haem binding will prevent PfCRT efflux of the protonated base and result 
in improved CARs and hence higher potency against the parasite. Since this hypothesis has 
been proposed based on only three scaffolds, similar haem-binding, accumulation and cell-
fractionation experiments need to be carried out for other classes. In addition, the selected 
classes should not only be the most potent but also involve moderately active compounds, 
such as the benzamides and triarylimidazoles, so that potential correlations can be 
determined. 
Subsequently, the new SAR data should be added to the Bayesian training sets, in order to 
update the statistical models. Once the hits from the initial HTS have been explored, 
additional screening of new diverse libraries would enrich knowledge of the chemical space 
of haemozoin inhibitors. Before these libraries are screened using βH inhibition assays, they 
could be screened in silico using the continually-updated Bayesian models for haemozoin 
inhibiting antimalarials. This could be carried out at varying user-defined cut-offs in order to 
prioritise the library compounds for screening. Compounds with high Bayesian scores can be 
screened first to attain the largest hit rates with minimal time and economic resources, 
while compounds with low scores may be disregarded entirely from the experimental HTS. 
Indeed, the Bayesian models were 100% accurate at predicting true negatives. 
The complexity of P. falciparum demands a holistic approach to discovering novel 
antimalarials. No data should be taken for granted, especially considering the limited 
resources for research into diseases prevalent in impoverished and developing countries. 
Successful techniques for directly identifying the most highly potent compounds, such as 
large-scale phenotypic HTS, are very specialised and expensive, and involve challenging 
target discovery programmes. In the future, methods for prioritising compounds for 
screening and thereafter, designing hit derivatives with the appropriate structural features 
for improved accumulation in the parasite, could have a significant impact on antimalarial 
drug discovery. 







8.1 Physical methods, assays and cell culture protocols 
8.1.1 Materials and general procedures 
Commercially obtained chemicals (AR or higher grade) were purchased from the suppliers 
listed in Table 8.1 and used without further purification. 
Table 8.1 Chemical suppliers 
CHEMICAL SUPPLIER 
Haemin (≥98%) Fluka 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich 
Acetone (AR grade) Kimix 
Pyridine Sigma-Aldrich 
Sodium acetate trihydrate (NaOAc) Sigma-Aldrich 
Glacial acetic acid (AcOH) Kimix 
HEPES buffer Sigma-Aldrich 
Sodium hydroxide (NaOH) Kimix 
Nitric acid (HNO3) Kimix 
Chloroquine (CQ) Sigma-Aldrich 
Amodiaquine (AQ) Sigma-Aldrich 
Nonidet P-40 (NP-40) Pierce Biotechnology, Rockford, IL, USA 
Phosphate buffer solutions BDH Laboratory Supplies 
Compounds P1-P10 Vitas-M Laboratory 
Compounds P11 and P12 Sigma-Aldrich 
Compounds SA1-SA34 Sigma-Aldrich 
 
The water used in all the experiments was double distilled deionised Millipore® Direct-Q 
water (D.H2O). All pH measurements were carried out using a Crison 2000 MicropH meter or 
Jenway 3510 benchtop pH meter, calibrated using standard phosphate buffer solutions at 
pH 4.00 ± 0.02 and 7.00 ± 0.02 prior to use. Manual micro-volume additions were delivered 




using Eppendorf single-channel micropipettes or multichannel micropipettes. All glassware 
in contact with haematin was washed with 0.2 M NaOH, and then 1 M HNO3, with H2O 
rinsing in between washes. For moderately or poorly soluble compounds, sonication and 
heating were employed while dissolving solids in the relevant solvent. 
 
8.1.2 High throughput screening methods 
8.1.2.1 Manual β-haematin formation assay preparation 
Deionised water (D.H2O, 15 μL) was added to all the wells of a 384 well plate followed by 
the addition of either D.H2O (5 μL) or AQ (5 μL, 1000 μM) in a checkerboard pattern across 
the plate. NP40 (5 μL, 305.5 μM) was dispensed first to all AQ wells and then to all D.H2O 
wells after which a Fe(III)PPIX suspension an in acetate buffer (1 M, pH 4.8 ± 0.5) was 
prepared. Haemin (16.3 mg) was dissolved with sonication in 1 ml of DMSO (25 mM) and 
filtered through a 0.22 μm polyvinylidene fluoride (PVDF) membrane syringe driven filter 
unit.  This 25 mM solution (177.8 μL) was immediately added to 20 ml of the 1 M acetate 
buffer and vortexed for 10 seconds. The suspension (25 μL) was then swiftly pipetted into all 
the wells giving a final NP40 concentration of 30.55 μM and AQ concentration of 100 μM. 
The plate was incubated at 37°C for 5 h followed by the addition of acetone (15 μL) to all 
wells. A solution of pyridine (50 % v/v) and acetone (20 % v/v) in HEPES (0.2 M) was also 
added to each well and the plate was left to develop in the dark for 1 h before reading the 
maximum UV-vis absorbance at 405 nm on a Spectramax 190 plate reader. The data were 
analysed using Microsoft Excel 2010.313 
 
8.1.2.2 Manual concentration dose response experiments 
The assay was carried out as in 2.2.1 with the following changes: 12 wells of varying AQ and 
CQ concentration (0 – 1000 μM final concentration) were repeated 6 times each (no 
checkerboard) resulting in IC50 curves which were analysed used GraphPad Prism v5.0.314  
  




8.1.2.3 Verification of drift, Z’ and edge effects 
An alternating checkerboard pattern of positive and negative control wells were delivered 
to the first and last two columns of each plate. The positive control contained AQ at the 
100% βH inhibitory concentration (IC100). The quality of the assay was validated using the Z’ 
statistical test.175 Edge effects were analysed using established guidelines of the NIH 
Chemical Genomics Center.203  
 
8.1.2.4 HTS Procedures 
The library of test compounds was provided by the Vanderbilt University HTS Facility. The 
compounds were originally sourced from the commercially available ChemDiv and 
ChemBridge libraries. Stock compounds (10 mM stock) were delivered in singlet to columns 
3 to 22 of ten 384-well plates per day by a Labcyte Echo 550 noncontact liquid handler (19.3 
µM final concentration). The Labcyte Echo 550 noncontact liquid handler uses acoustic 
energy to accurately transfer liquids.  Sound waves eject precisely sized droplets from a 
source onto an inverted microplate. Controls were added to the first and last two columns 
of every plate. The positive controls contained AQ (10 mM stock, 100 μM final 
concentration) while negative controls contained the same volume of DMSO without drug. 
These volumes were added in a checkerboard pattern using the same liquid handler. All 
solutions were freshly prepared on the day of the experiment. Water, the haematin 
suspension and the NP-40 solutions were delivered using a Thermo Scientific Multidrop 
Combi bulk reagent dispenser. The plates were incubated at 37°C for 5 h in a shaking water 
bath after which the pyridine and acetone solutions were delivered using the bulk reagent 
dispenser. The plates were left to shake for ~30 min before reading the absorbance values 
at 405 nm on the SpectraMax 190 plate reader with SoftMax Pro software.315 The data were 
analysed using Microsoft Excel.313 Compounds with absorbance values which corresponded 
to ≥50% βH inhibition at 19.3 µM were considered active “hits”. Dose response curves were 
determined in duplicate for all the hits using a similar procedure to the single concentration 
experiment, but without checkerboard controls on the edges. GraphPad Prism v5.0 was 
employed for IC50 generation.314 
 




8.1.2.5 Plasmodium falciparum SYBR green I-based fluorescence assay 
The P. falciparum CQ-sensitive D6 strain (Walter Reed Army Institute of Research 
[WRAIR]/Sierra Leone) and multidrug resistant C235 strain (WRAIR/Thailand) were 
maintained using a modification of methods described by Trager and Jensen.70 Culture 
medium was prepared with RPMI 1640 medium supplemented with 25 mM HEPES, 11 mM 
glucose, 0.24% sodium bicarbonate, 10% human A (+) plasma (heat-inactivated) and 29 µM 
hypoxanthine. Cultures were maintained at 5% hematocrit and <5% parasetemia in A (+) 
blood, which was washed two times with RPMI medium before use. Culture flasks were 
incubated at 37 °C in a gas mixture of 5% O2, 5% CO2 and N2. 
Using modified literature methods,84 the hits from the NP-40 βH inhibition assay were 
tested against the D6 and C235 strains of P. falciparum. The compounds were dissolved in 
DMSO (final concentration of 0.23%) and prescreened at 23 µM in 384-well plates with 0.3% 
starting parasitaemia at 2% haematocrit. Compounds which inhibited >90% of parasite 
growth were delivered at a range of concentrations from 0 to 23 µM to generate dose-
response curves from which the IC50 values were determined with GraphPad Prism v5.0.314 
 
8.1.3 β-Haematin assays, titrations and physical analysis methods 
8.1.3.1 Detergent mediated assay for β-haematin inhibition 
The inhibition of βH formation assay method described by Carter et al.160 was modified for 
manual liquid delivery. Samples were dissolved in DMSO to give 20 mM solutions and 20 µL 
of each was delivered to wells in the last column (column 12) of a 96-well plate together 
with distilled water (140 µL) and NP40 detergent (305.5 mM, 40 µL). A solution containing 
water/NP40 (305.5 mM)/DMSO at a v/v ratio of 70%/20%/10% respectively was prepared 
and then 100 µL was added to all other wells (columns 1-11). A serial dilution of each 
compound (100 µL) from column 12 down to column 2 was carried out. Column 1 served as 
a blank with 0 mM sample. A 25 mM haematin stock solution was prepared by sonicating 
haemin in DMSO for one minute and then suspending 178 µL of this in a 1 M acetate buffer 
(20 mL, pH 4.8). The homogenous suspension (100 µL) was then added to the wells to give 
final buffer and haematin concentrations of 0.5 M and 100 mM respectively. The plate was 




covered and incubated at 37 °C for 5-6 h in a water bath or incubator. Analysis was carried 
out using the pyridine-ferrichrome method developed by Ncokazi and Egan.103 A solution of 
50% (v/v) pyridine, 30% (v/v) H2O, 20% (v/v) acetone and 0.2 M HEPES buffer (pH 7.4) was 
prepared and 32 mL added to each well to give a final pyridine concentration of 5% (v/v). 
Acetone (60 mL) was then added to assist with haematin dispersion. The UV-vis absorbance 
of the plate wells was read on a SpectraMax P340 plate reader. Sigmoidal dose-response 
curves were fitted to the absorbance data using GraphPad Prism v3.02314 to obtain a 50% 
inhibitory concentration (IC50) for each compound.  
 
8.1.3.2 Derivation of the vacuolar accumulation ratio (VAR) equation  
The equilibrium expression for a compound with two protonation sites can be written as 
follows: 
 
Where BH22+ is the doubly protonated conjugate acid of the basic compound and B is the 
neutral species. The equilibrium constant can then be written as:   
[𝐾𝑎1] =  
[𝐵𝐻+][𝐻+]
[𝐵𝐻2
  2+ ]




The total concentration of compound compound B can be defined by the sum of 
concentrations of the individual species and the equation can be formulated in terms of [B], 
[H+] and the equilibrium constants, Ka1 and Ka2 : 
[𝐵]𝑇 = [𝐵] + [𝐵𝐻
+] + [𝐵𝐻2
2+] 







          = [𝐵](1 + 10−𝑙𝑜𝑔(𝐾𝑎2) + 𝑙𝑜𝑔 (𝐻
+) + 10−𝑙𝑜𝑔(𝐾𝑎1) − 𝑙𝑜𝑔 (𝐾𝑎2) + 2𝑙𝑜𝑔 (𝐻
+) ) 
          = [𝐵](1 + 10𝑝𝐾𝑎2−𝑝𝐻 + 10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻 ) 
The total external concentration of B at the external pH (pHe) is given by: 
[𝐵]𝑇,𝑒 = [𝐵](1 + 10
𝑝𝐾𝑎2−𝑝𝐻𝑒 + 10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻𝑒 ) 
The total concentration of B in the DV at the vacuolar pH (pHv) is given by: 
[𝐵]𝑇,𝑣 = [𝐵](1 + 10
𝑝𝐾𝑎2−𝑝𝐻𝑣 + 10𝑝𝐾𝑎1+𝑝𝐾𝑎2−2𝑝𝐻𝑣 ) 




Assuming that the neutral species B equilibrates equally across membrane and that the 
membranes are totally impervious to the charged forms BH+ and BH22+, then the 
extracellular and intravacuolar [B] values are equal and the VAR for B is given by the ratio of 
the total external and vacuolar concentrations (Eq. 8.1): 
 






                                          Eq. 8.1 
 
8.1.3.3 Haem binding 
The association constant for the interaction between selected benzamides and Fe(III)PPIX 
was determined using a modified version of the titration method reported by Egan and co-
workers.316 Briefly, a stock solution of the test sample in either 40% aqueous DMSO and 
HEPES buffer (0.02 M, pH 7.4) or 100% DMSO (for the benzamides) was prepared. The initial 
concentrations the quinolines (CQ and QD) and benzamides were 2 mM and 20 mM 
respectively. A working solution of haematin (7.5 µM) and HEPES buffer (0.02 M, pH 7.4) in 
40% aqueous DMSO was prepared and used immediately. Identical volumes of the stock 
solution were added with a Hamilton syringe into quartz cuvettes (Hellma) of 1 cm path 
length containing the haematin working solution or a blank solution of 40% aqueous DMSO 
and HEPES buffer (0.02 M, pH 7.4). The UV-vis absorbance values of the blank were 
automatically subtracted from that of the haem working solution. The UV-vis absorbance 
was monitored from 350 nm to 650 nm at 25 °C with each addition of the test sample on a 
Varian Cary 100 UV–Visible spectrophotometer. The data obtained were corrected for 
dilution and analysed using non-linear least squares fitting methods. Titrations were 
performed in triplicate and the average association constant (K) values were reported with 
the standard error of the mean (SEM). The value of logK was calculated from the best fit 
model, which described a 1:1 association using Eq. 8.2, where A0 is the initial absorbance 
(no test sample), A∞ is the final limiting absorbance and [L] is the concentration of the free 
ligand, which in the case of weak association is approximately the total test sample 
concentration in the haem working solution.  
𝐴 =  
𝐴0+ 𝐴∞𝐾[𝐿]
1 + 𝐾[𝐿]
                                                     Eq. 8.2 




8.1.3.4 Correlation analysis 
Identification of statistically significant correlations was carried out using Molecular 
Modelling Pro Plus (MMP+) software.290 The MDL Molfile containing structural data for each 
set of test samples (benzamides or triarylimidazoles) was input into the programme and an 
extensive range of physicochemical properties were calculated for each molecule. The data 
were stored as a .txt file and then edited in Microsoft Excel313 to include the parasite and βH 
activities as the inverse, therefore allowing inactive compounds to be entered with an 
inverse activity of zero. The resulting database was opened in MMP+ where the data were 
analysed by “regression with all combinations”. The output correlations, which were both 
physically relevant and displayed the highest r2 were considered. The predicted activity 
values for each molecule were then calculated from the output linear equation and plotted 
vs the experimental activity. Those correlations which appeared as two clusters of 
connected points, where no correlation existed within each cluster, were omitted. 
 
8.1.4 P. falciparum cell culturing methods  
8.1.4.1 LDH malaria parasite survival assay 
Cultures of CQ-sensitive D10 and NF54 P. falciparum in the asexual erythrocyte stages were 
continuously maintained in vitro using a modified version of the method of Trager and 
Jensen.70 The antimalarial activity of the purchased and synthesised benzamides and 
triarylimidazoles were assessed using the parasite lactate dehydrogenase (LDH) assay 
described by Makler et al.79 All samples for NF54 testing and ten of the samples for D10 
testing were sent to the Department of pharmacology at the University of Cape Town 
Medical School, where the experiments were carried out by others. The remaining samples 
were tested in D10 parasites, which were also continuously cultured, by the author of this 
thesis using the method described below.  
The D10 strain of P. falciparum was maintained in culture flasks containing O+ human 
erythrocytes (2% haematocrit, 1-10% parasitaemia)  suspended in RPMI 1640 medium (10.4 
g/L) with glutamine, glucose (22 mM), HEPES buffer (25 mM), hypoxanthine (0.65 mM), 
Albumax (5 g/L), gentamicin (0.1 mM) and NaHCO3 (32 mM). Flasks were gassed before 
incubation at 37 °C with a mixture of 3% O2, 4% CO2, and 93% N2. CQ, tested up to 100 




ng/ml maximum concentration, was used as a control on each plate. Parasitised red blood 
cells (pRBCs) were prepared via dilution from the culture flask to give a 2% haematocrit and 
2% initial parasitaemia. The samples were prepared as 2 mg/ml stock solutions in DMSO and 
diluted with complete cell culture medium before testing in triplicate in a 96-well plate. Row 
1 of the plate was reserved as a blank with uninfected RBCs (200 µL 1% haematocrit). Row 2 
contained the positive control with no test compound (200 µL, 1% haematocrit, 1% 
parasitaemia). Rows 3-12 contained the inoculated pRBCs at a range of sample 
concentrations, prepared by adding 200 µL of the required sample stock to row 3 and 
performing a two-fold serial dilution across the plate to row 12. Finally, the pRBCs (100 µL) 
were added to rows 3-12 to give a final volume of 200 µL, haematocrit of 1% and 
parasitaemia of 1%. The plate was incubated at 37 °C for 48 h in a gas chamber containing 
3% O2, 4% CO2 and 93% N2. Following resuspension of the plate contents in a non-sterile 
environment using a multichannel pipette, 15 µL from each well was transferred to the 
corresponding well of a new plate containing Malstat (100 µL per well).  Nitroblue 
tetrazolium (NBT, 25 µL) was added to each well and the plate was left to develop in the 
dark for 10 min before measuring the absorbance at 620 nm on a microplate reader. The 
highest concentration of solvent to which the parasites were exposed had no measurable 
effect on the parasite viability. The IC50 values were obtained from fitting analysis using a 
non-linear least-squares dose response curve in GraphPad Prism v.3.0 software.314  
 
8.1.4.2 Cell fractionation 
Target validation was carried out by measuring the increase in free haem and the decrease 
in haemozoin formation via cell fractionation studies. The samples were sent to the Division 
of Pharmacology, Department of Medicine at the University of Cape Town Medical School 
for testing by Jill Combrinck using the procedure described by Combrinck at al.113  
 
8.1.4.3 The inoculum effect 
The CAR was determined via the inoculum effect using a procedure similar to those 
previously reported.99,293 The LDH assay described above was employed to measured IC50 
values in triplicate at inoculum sizes ranging from 1 to 10 and fractional volumes of 




parasitised erythrocytes from 0.0001 to 0.001. The relationship was extrapolated via linear 
regression to give the absolute IC50 from the y-intercept in Graph Pad Prism v3.0.314 The 
derivation for the equation describing the CAR (Eq. 8.3) for compound A is shown below. 
The total number of moles and volume are given by: 
𝑛𝑇 = 𝑛𝑖𝑛𝑡 + 𝑛𝑒𝑥𝑡  
𝑉𝑇 = 𝑉𝑖𝑛𝑡 + 𝑉𝑒𝑥𝑡  
The fractional volume of pRBCs for low haematocrit and parasitaemia is defined as: 
𝑉𝑓𝑟𝑎𝑐𝑃𝑅𝐵𝐶𝑠 =  
𝑉𝑖𝑛𝑡
𝑉𝑇




The CAR is defined as the ratio of internal to external compound concentration:  








































For a particular experiment with pRBCs, the measured concentration which inhibits 50% of 
parasite growth is based on the total number of moles and volume delivered to the system. 




In the case where there is no parasite, the total number of moles is equivalent to the 
number of moles externally, since there is no depletion of compound A in the medium: 
𝐼𝐶50𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 =  
𝑛𝑒𝑥𝑡
𝑉𝑇
   (no parasite) 
Substituting these expressions into the equation gives the CAR in terms of the measured 
and absolute inhibitory concentrations. 





                                                      Eq. 8.3 
 




8.1.5 Bayesian modelling methods 
8.1.5.1 Training set data 
GSK (TCAMS) and St Jude’s whole-cell screening data were downloaded from the ChEMBL 
database (www.ebi.ac.uk/chemblntd). The βH activity data were sourced from previous HTS 
collaborations between VU, UCT and OU, most of which are publically 
available.107,204,108,282,109,110 
 
8.1.5.2 Comparing the chemical space of libraries 
Principle component analysis (PCA) was carried out in Discovery Studio305 using the 
following descriptors: logP, MW, #RB, #R, #AR, #HBA and #HBD. The assembly method for 
comparing libraries decomposed the molecules into unique occurrences of ring, bridge or 
chain assemblies.317 The libraries were then compared using Tanimoto similarity of the 
assemblies. The H hits (taken at >60% inhibition at 19 M) were compared to the non-hits 
(<40%) using two Bayesian classification models and a Bayesian distance based on the 
Bayesian scores of each sample in the set. 
 
8.1.5.3  Building Bayesian models 
All data were modelled using Discovery Studio’s305 built-in Bayesian categorization, based on 
Bayes’ theorem (Eq. 6.1). Input structure data files (SDFs) containing structural and activity 
data were imported into Discovery Studio and the sample data marked as active or inactive 
based on a user-defined IC50 cut-off. In the case of the βH inhibiting model, the samples 
were represented at pH 5 to match the conditions of the acidic DV. Default input descriptors 
from which the program can learn to distinguish active from inactive compounds were 
chosen. These 2D parameters were calculated by the program during the simulation: logP, 
MW, #RB, #R, #AR, #HBA, #HBD and ECFP_6. The model allocated each feature a probability 
score, weighted by a Laplacian-corrected estimator based on the frequency of occurrence of 
that feature in the active and inactive sets. In order to predict the likelihood of activity for a 
test compound, weights for the different features were summed to give a probability 
estimate.  




Internal validation of the generated models was determined by the ROC score, based on the 
area under the plot of true positive rate vs false positive rate (ROC curve). These rates were 
calculated by leaving each molecule out of the training set one at a time (leave-one-out 
cross validation), or by leaving one fifth of the training set out (5-fold cross validation) and 
predicting their activities with those remaining. A score of 1 represents a perfect prediction 
with no false positives while 0.5 represents no enrichment. The ROC score was optimised by 
combining several datasets and generating models with different IC50 cut-offs for activity 
input. Training sets excluded several compounds for use as external test sets.  
 
8.1.5.4 Model validation using external datasets  
The DrugBank database (http://www.drugbank.ca/) contains 1510 FDA approved small 
molecule drugs.318,319 These compounds were used as a test set to measure the accuracy of 
the Bayesian models since many have reported antimalarial activity data in PubChem 
(https://pubchem.ncbi.nlm.nih.gov/). In addition to this validation method, the ZINC 
database (http://zinc.docking.org/), a free collection of commercially available compounds 
for virtual screening was employed.320 Purchasable samples from the AldrichCPR catalogue in 
ZINC were filtered through the models, listed according to predicted activity probabilities 
and where similar structures occurred; only one analogue was selected. Compounds were 
also excluded if they were currently unavailable or if they were expensive. Three sets of 
compounds were then purchased from Sigma-Aldrich; ten molecules predicted to be 
inactive for βH inhibition (SA1-SA10), ten with high probability of being βH inhibitors (SA11-
SA20) and fourteen predicted to be both H inhibitors and biologically active (SA21-SA34). 
These compounds were then tested for βH inhibition using the NP-40 method described in 
Section 8.1.3.1 321 and against the NF54 strain of P. falciparum (Section 8.1.4.1).79,70,208 
 
  




8.2 Synthetic methods 
8.2.1 Materials and general procedures 
Glassware was washed with combinations of dishwashing detergent, water and acetone and 
in certain cases, nitric or sulphuric acid. Calcium chloride was used as a drying agent above 
the reflux condenser for all reflux reactions. Heating was carried out on a IKA® RCT basic 
IKAMAG™ safety control hot plate with a IKA® ETS-D5 temperature controller probe. All 
reactions were monitored by thin layer chromatography (TLC) using silica gel plates (Merck 
F254 aluminium-backed).  TLC plates were visualised with ultraviolet light (254 nm) and, 
where an amine was present, plates were stained with ninhydrin spray (0.2% w/w in EtOH). 
Silica gel flash column chromatography was carried out with Fluka 60: 70-230 mesh on 
either a Biotage Isolera One Flash Chromatography System or using a combination of a D-
star DVW-10 variable wavelength detector with a Teledyne ISCO fraction collector. Melting 
points were measured using a Reichert-Jung Thermovar hot stage microscope. Proton (1H) 
and carbon (13C) NMR spectra were recorded using a Varian Mercury spectrometer (300 
MHz for 1H), a Bruker 300 (at 300.08 MHz for 1H) or a Bruker Ultrashield 400 Plus (at 399.95 
MHz for 1H and 100.64 MHz for 13C) spectrometer. NMR experiments were performed in 
deuterodimethyl sulfoxide (DMSO-d6), deuterochloroform (CDCl3), deuteromethanol 
(MeOD) or deuteroacetone (acetone-d6) with internal standards at δH = 2.50, 7.26, 3.31 or 
2.05 ppm respectively for 1H NMR and δC = 40.05, 77.16, 49.00 or 29.8 and 206.26 ppm 
respectively for 13C NMR. All chemical shifts were reported in ppm and J coupling values in 
Hz. 
Electron ionisation mass spectrometry was recorded using a JEOL GC mate II single magnetic 
mass spectrometer. High resolution mass spectrometry (HRMS) was performed on a Time-
of-flight (TOF) Waters Synapt G2 instrument using leucine encephalin as a standard. All mass 
spectra for the benzamide series were recorded using the electrospray negative (ES-) 
technique and introduction of the sample was via an ESI probe injected into a stream of 
MeOH.  Mass spectra for the triarylimidazole series were recorded using the electrospray 
positive (ES+) technique and the sample injected into a stream of acetonitrile. 




High performance liquid chromatography (HPLC) was carried out on an Agilent Technologies 
1220 Infinity LC (G4288C) with a C18 reverse phase column in HPLC grade acetonitrile (ACN) 
and double distilled deionised Millipore® Direct-Q water. 
Commercially available solvents, chemicals and starting materials were purchased from the 
suppliers listed in Table 8.2. EtOAc and hexane were distilled before use. Tetrahydrofuran 
(THF) was distilled under nitrogen and dried over sodium wire with benzophenone. Dry 
DCM was distilled under nitrogen. Deuterated solvents for NMR were stored in a desiccator 
with phosphorus pentoxide (P2O5) drying agent. 
Table 8.2 Suppliers for the commercially available chemicals used without purification 
unless otherwise stated in the synthesis, workup, purification and characterisation. 
ITEM SUPPLIER 
Solvents 
Dichloromethane (DCM) AR grade Kimix 
Ethyl acetate (EtOAc) Protea Chemicals 
Methanol (MeOH) Kimix 
Ethanol (EtOH) 99.9% Kimix 
Hexane Kimix 
Acetone Protea Chemicals 
Acetone AR grade Kimix 
Tetrahydrofuran (THF) Kimix 
Toluene Kimix 
Pyridine (Pyr.) Sigma-Aldrich 
Dimethylformamide (DMF) Sigma-Aldrich 
Acetonitrile (ACN) HPLC grade Kimix 
Deuterodimethylsulfoxide (DMSO-d6) Sigma-Aldrich 
Hexadeuteroacetone (Acetone- d6) Sigma-Aldrich 
Deuterochloroform (CDCl3) Sigma-Aldrich 
Deuteromethanol (MeOD) Sigma-Aldrich 
Starting materials 
5-Nitroisophthalic acid Sigma-Aldrich 
5-Cyano-1,3-benzenedicarboxylic acid Sigma-Aldrich 
5-Methylisophthalic acid Sigma-Aldrich 
5-Tert-Butylisophthalic acid Sigma-Aldrich 
Isophthalic acid Sigma-Aldrich 
5-Methoxyisophthalic acid Sigma-Aldrich 
2,6-Pyridinedicarbonyl dichloride Sigma-Aldrich 
Aniline Sigma-Aldrich 
4-Amino pyridine Sigma-Aldrich 
3-Amino pyridine Sigma-Aldrich 
 




Table 8.2 (Continued) 
ITEM SUPPLIER 
Starting materials  












Miscellaneous reagents and chemicals 
Formaldehyde (37 wt. % in H2O) Sigma-Aldrich 
Trifluoroacetic acid (TFA) Sigma-Aldrich 
Sodium cyanoborohydride (NaBH3CN) Sigma-Aldrich 
Triethylamine (Et3N) Sigma-Aldrich 
Iron powder (Fe powder) Unilab 
Sodium hydride (NaH) Sigma-Aldrich 
Ammonium acetate (NH4OAc) Kimix 
Celite Sigma-Aldrich 
Magnesium sulphate anhydrous (MgSO4) Kimix 
Sodium carbonate (Na2CO3) Kimix 
Sodium chloride AR (NaCl) Kimix 
Ninhydrin  Sigma-Aldrich 
Hydrochloric acid (32 wt. %) Kimix 
Sulphuric acid (H2SO4) Kimix 
Nitric acid (HNO3) Kimix 
Phosphorus pentoxide (P2O5) Sigma-Aldrich 
    
8.2.2 Synthesis, purification and characterisation 
8.2.2.1 Benzamides 
General procedure for the synthesis of the monobenzamides 2a-b 
Aniline and the relevant acid chloride (1a or 1b) were stirred in dry pyridine under N2 at RT. 
Upon completion of the reaction, indicated by TLC analysis, the organic components were 
extracted in EtOAc (3 x 20 ml) and then washed with 1M HCl to remove excess pyridine. The 
organic fractions were combined, stirred with MgSO4 and concentrated by evaporation 








Scale: aniline (186 mg, 2 mmols) and 2-nitrobenzoyl chloride (371 mg, 2 mmols), stirred for 
1 h.  Yield of 2a: 477 mg, 99%. Recrystallisation from AR-grade MeOH and AR-grade DCM 
afforded 2a as off-white crystals: Mp 149-151 °C; Lit Mp265 155-156 °C; 1H NMR (300 MHz, 
DMSO-d6) δ ppm 10.62 (br. s, 1H), 8.13 (td, J = 0.70, 7.89 Hz, 1H), 7.86 (m, 1H), 7.76 (m, 2H), 
7.66 (m, 2H), 7.35 (m, 2H), 7.11 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ ppm 164.6, 147.0, 
139.3, 134.5, 133.2, 131.4, 129.8, 129.3, 124.7, 124.4, 120.2; HRMS-ES-: Observed 241.0604 




Scale: aniline (200 mg, 2.1 mmols) and 3,5-dinitrobenzoyl chloride (606 mg, 2.6 mmols), 
stirred for 2 h. Yield of 2b: 505 mg, 84% as a pale-yellow solid. Recrystallisation from 
absolute EtOH afforded 2b as white needles: Mp 236-238 °C; Lit Mp322 236 °C; 1H NMR (300 
MHz, DMSO-d6) δ ppm 10.80 (s, 1H), 9.15 (d, J = 2 Hz, 2H), 8.98 (t, J = 2 Hz, 1H), 7.76 (m, 2H), 
7.39 (m, 2H), 7.16 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ ppm 161.7, 148.6, 138.8, 138.0, 
129.3, 128.5, 125.0, 121.6, 121.2; HRMS-ES-: Observed 286.0450 (M-H)+; Calculated 
286.0464 for C13H8N3O5; HPLC: 97.3%. 
  




General procedure for the synthesis of the monobenzamides 2c-e 
The relevant aminopyridine and acid chloride were added to dry pyridine, followed by the 
addition of Et3N (1 eq.). The mixture was stirred under N2 at RT. Upon completion of the 
reaction, indicated by TLC analysis, a saturated solution of Na2CO3 (20 ml) was added and 
the organic components were extracted into EtOAc (3 x 20 ml). The fractions were 
combined, washed with brine and then stirred with MgSO4 before being concentrated by 
evaporation under reduced pressure. Excess pyridine was removed by an azeotropic 
evaporation with toluene to give a solid, which was dried under high vacuum for 2 h to yield 




Scale: 4-aminopyridine (94 mg, 1 mmol) and 3,5-dinitrobenzoyl chloride (230 mg, 1 mmol), 
stirred for 2 h. Yield of 2c: 268 mg, 93% as an off-white solid. Recrystallisation from AR grade 
acetone afforded 2c as a white powder: Mp 267-268 °C; Lit Mp234 240-250 °C; 1H NMR (300 
MHz, DMSO-d6) δ ppm 11.11 (br. s., 1H), 9.15 (d, J = 2 Hz, 2H), 9.02 (t, J = 2 Hz, 1H), 8.54 (d, J 
= 6.4 Hz, 2H), 7.78 (d, J = 6.4 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ ppm 162.8, 151.0, 
148.7, 145.7, 137.3, 128.7, 122.0, 114.8; HRMS-ES-: Observed 287.0411 (M-H)+; Calculated 
287.0416 for C12H7N4O5; HPLC: 99.7%. 
  






Scale: 3-aminopyridine (94 mg, 1 mmol) and 3,5-dinitrobenzoyl chloride (230 mg, 1 mmol), 
stirred for 3 h. Yield of 2d: 234 mg, 81% as an off-white solid. Recrystallisation from AR-
grade acetone afforded 2d as a white powder: Mp 236-238 °C; Lit Mp233 231-232 °C; 1H 
NMR (300 MHz, DMSO-d6) δ ppm 11.02 (s, 1H), 9.17 (d, J = 2.0 Hz, 2H), 9.02 (t, J = 2.0 Hz, 
1H), 8.94 (d, J = 2.4 Hz, 1H), 8.38 (m, 1H), 8.20 (m 1H), 7.45 (m, 1H); 13C NMR (101 MHz, 
DMSO-d6) δ ppm 162.3, 148.7, 145.9, 142.8, 137.4, 135.5, 128.6, 128.4, 124.2, 121.8; HRMS-




Scale: 2-aminopyridine (94 mg, 1 mmol) and 3,5-dinitrobenzoyl chloride (230 mg, 1 mmol), 
stirred for 3 h. Yield of 2e: 286 mg, 99% as an off-white solid. Recrystallisation from AR-
grade MeOH afforded 2e as a white powder: Mp 196-198 °C; 1H NMR (300 MHz, DMSO-d6) 
δ ppm 11.57 (s, 1H), 9.18 (d, J = 2.2 Hz, 2H), 8.98 (t, J = 2.2 Hz, 1H), 8.42 (m, 1H), 8.19 (m, 
1H), 7.89 (m, 1H), 7.23 (m, 1H); 13C NMR (151 MHz, DMSO-d6) δ ppm 162.7, 152.1, 148.6, 
148.5, 138.8, 137.4, 129.0, 121.8, 121.0, 115.4; HRMS-ES-: Observed 287.0402  (M-H)+; 
Calculated 287.0416 for C12H7N4O5; HPLC: 99.7%. 
  




General procedure for acid chlorides (4a-n) from the corresponding isophthalic acid (3a-n) 
Thionyl chloride (10 ml) was added to the appropriate isophthalic acid (3a-n) and refluxed at 
80 °C for 4 h and then cooled and stirred for 1 h or overnight. The excess thionyl chloride 
was evaporated under reduced pressure. After drying the residue for 1 h on a high vacuum 
pump, the product (4a-n) was not isolated but used immediately in the next step from the 
same flask.  
 
General procedure for dibenzamides (5a-5p) from the corresponding acid chloride (4a-p) 
The appropriate freshly prepared acid chloride (4a-m) or purchased acid chloride (4o-p) was 
dissolved in 100% dry pyridine unless otherwise specified, followed by the addition of the 
relevant amine (aniline or aminopyridine) and Et3N (2 equiv.). The reaction was stirred 
under N2 at RT for the required time. Upon completion of the reaction as indicated by TLC 
analysis, one of three procedures was followed for the isolation. i) For the 
pyridylbenzamides (5a, 5b, 5d, 5f, 5h, 5i and 5m), a saturated solution of Na2CO3 (20 ml) was 
added and the organic components were extracted into EtOAc (3 x 20 ml). The organic 
fractions were combined, washed with brine and then dried with MgSO4. The solutions were 
concentrated by evaporation under reduced pressure and excess pyridine was removed by 
an azeotropic evaporation with toluene to give a solid. ii) For the phenylbenzamides (5c, 5e, 
5g, 5j and 5n), the organic components were extracted into EtOAc (3 x 20 ml) and then 
washed with 1M HCl to remove excess pyridine. The organic fractions were then combined, 
dried with MgSO4 and concentrated by evaporation under reduced pressure. iii) For the 
compounds 5k, 5l, 5o and 5p, precipitation of the compounds from the reaction mixture 
allowed for isolation of the white solid by filtration. All compounds 5a-5p, were dried under 
high vacuum for 2 h to yield the desired product. 
  






Scale: 4a (818 mg, 3.3 mmols) and 4-aminopyridine (627 mg, 6.7 mmols), stirred for 3 h. 
Yield of 5a: 795 mg, 92% as an off-white solid. Recrystallisation from AR-grade acetone 
afforded 5a as small off-white crystals: Mp 303-306 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 
11.93 (br. s, 2H), 9.33 (t, J = 1.5 Hz, 1H), 8.95 (d, J = 1.5 Hz, 2H), 8.69 (d, J = 6.9 Hz, 4H), 8.26 
(d, J = 6.9 Hz, 4H); 13C NMR (101 MHz, DMSO-d6) δ ppm 164.7, 150.6, 148.6, 146.0, 135.5, 
134.2, 127.1, 115.5; HRMS-ES-: Observed 362.0887 (M-H)+; Calculated  362.0889 for 




Scale: 4b (496 mg, 2 mmols) and 3-aminopyridine (394 mg, 4.2 mmols), stirred for 4 h. Yield 
of 5b: 576 mg, 79% as an off-white solid. Recrystallisation from AR-grade acetone afforded 
5b as small off-white crystals: Mp 134-136 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.91 (s, 2H), 
9.00 (br.s, 3H), 8.96 (d, J = 2.0 Hz, 2H), 8.36 (m, 2H), 8.21 (m, 2H), 7.44 (m, 8.3 Hz, 2H); 13C 
NMR (101 MHz, DMSO-d6) δ 163.7, 148.4, 145.7, 142.7, 136.6, 135.8, 133.7, 128.2, 125.8, 
124.1 HRMS-ES-: Observed 362.0880 (M-H)+; Calculated 362.0889 for C18H12N5O4; HPLC: 
98.4%. 
  






Scale: 4c (496 mg, 2 mmols) and aniline (376 mg, 4 mmols), stirred for 3 h. Yield of 5c: 675 
mg, 93% as an off-white solid. Recrystallisation from AR-grade acetone afforded 5c as white 
crystals: Mp 280-283 °C; 1H NMR (400 MHz, DMSO-d6) δ  10.69 (s, 2H), 8.79 - 9.12 (m, 3H), 
7.78 (m, 4H), 7.41 (m, 4H), 7.13 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 163.3, 148.4, 
139.1, 137.1, 133.6, 129.2, 125.5, 124.8, 121.1; HRMS-ES-: Observed 360.0970 (M-H)+; 




Scale: 4d (114 mg, 0.5 mmols) and 4-aminopyridine (108 mg, 1.1 mmol), stirred for 3 h in 
dry DCM (20 ml) and pyridine (0.5 ml). Purification by column chromatography (gravity) with 
5-10% MeOH/DCM was carried out. Yield of 5d: 45 mg, 26%. Recrystallisation from AR-grade 
acetone afforded 5d as small off-white crystals: Mp 285-288 °C; 1H NMR (300 MHz, DMSO-
d6) δ ppm 11.58 (br. s, 2H), 8.99 (t, J = 1.6 Hz, 1H), 8.68 (d, J = 1.6 Hz, 2H), 8.65 (d, J = 6.6 Hz, 
4H), 8.12 (d, J = 6.6 Hz, 4H); 13C NMR (101 MHz, DMSO-d6) δ ppm 164.5, 151.0, 145.9, 136.2, 
135.0, 132.4, 118.1, 114.6, 112.5; HRMS-ES-: Observed 342.0987 (M-H)+; Calculated 
342.0991 for C19H12N5O2; HPLC: 99.0%. 
  






Scale: 4e (228 mg, 1 mmol) and aniline (201 mg, 2.1 mmols), stirred for 2 h. Yield of 5e: 308 
mg, 90% as an off-white solid. Recrystallisation from AR-grade DCM gave 5e as a white 
powder: Mp 300-303 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.55 (br. s, 2H), 8.78 (t, J = 
1.7 Hz, 1H), 8.60 (d, J = 1.7 Hz, 2H), 7.80 (m, 4H), 7.42 (m, 4H), 7.17 (m, 2H); 13C NMR (101 
MHz, DMSO-d6) δ ppm 163.7, 139.1, 136.8, 134.3, 132.1, 129.2, 124.7, 120.9, 118.4, 112.3; 




Scale: 4f (434 mg, 2 mmols) and 4-aminopyridine (376 mg, 4 mmol), stirred for 1 h. Yield of 
5f: 557 mg, 84% as an off-white solid. Recrystallisation from absolute EtOH afforded 5f as a 
white powder: Mp 209-212 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.70 (s, 2H) 8.49 (d, J = 
6.4 Hz, 4H) 8.34 (s, 1H) 8.00 (m, 2H) 7.79 (d, J = 6.4, 4H) 2.49 (s, 3H); 13C NMR (101 MHz, 
DMSO-d6) δ 166.4, 150.8, 146.3, 139.0, 135.1, 132.2, 125.1, 114.6, 21.3; HRMS-ES-: 
Observed 331.1191 (M-H)+; Calculated 331.1195 for C19H15N4O2; HPLC: 99.3%. 
  






Scale: 4g (434 mg, 2 mmols) and aniline (372 mg, 4 mmol), stirred for 2 h. Yield of 5g: 557 
mg, 84% as an off-white solid. Recrystallisation from MeOH and AR-grade DCM afforded 5g 
as small white crystals: Mp 257-258 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 2H), 8.31 (s, 
1H), 7.95 (m, 2H), 7.79 (m, 4H), 7.36 (m, 4H), 7.10 (m, 2H); 13C NMR (101 MHz, DMSO-d6) δ 
165.7, 139.6, 138.6, 135.8, 131.6, 129.1, 124.8, 124.3, 120.9, 21.4; HRMS-ES-: Observed 




Scale: 4h (518 mg, 2 mmols) and 4-aminopyridine (376 mg, 4 mmol), stirred for 3 h. Yield of 
5h: 467 mg, 62% as an off-white solid. Recrystallisation from AR-grade MeOH and AR-grade 
DCM afforded 5h as a white powder: Mp 245-247 °C; 1H NMR (300 MHz, DMSO-d6) δ 10.74 
(s, 2H), 8.52 (d, J = 6.2 Hz, 4H), 8.41 (t, J = 1.6 Hz, 1H), 8.17 (d, J = 1.6 Hz, 2H), 7.82 (d, J = 6.2 
Hz, 4H), 1.42 (s, 9H); 13C NMR (101 MHz, DMSO-d6) δ ppm 166.7, 152.2, 150.8, 146.3, 134.9, 
128.6, 125.1, 114.7, 35.4, 31.4; HRMS-ES-: Observed 373.1657 (M-H)+; Calculated 373.1665 
for C22H21N4O2; HPLC: 99.1%. 
  






Scale: 5i (259 mg, 1 mmol) and 3-aminopyridine (188 mg, 2 mmols), stirred for 3 h in 
pyridine (2 ml) and dry DCM (2 ml). Yield of 5i: 294 mg, 79% as an off-white solid. 
Recrystallisation from AR-grade MeOH and AR-grade DCM afforded 5i as a white powder 
Mp 227-229 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.57 (s, 2H), 8.94 (t, J = 1.3 Hz, 2H), 
8.41 (t, J = 1.3 Hz, 1H), 8.33 (d, J = 4.7 Hz, 2H), 8.18 (m, 4H), 7.41 (d, J = 4.7, 2H), 1.4 (m, 9H); 
13C NMR (151 MHz, DMSO-d6) δ ppm 166.2, 152.1, 145.3, 142.7, 136.1, 135.0, 128.3, 128.1, 
125.0, 124.1, 35.4, 31.5; HRMS-ES-: Observed 373.1653 (M-H)+; Calculated 373.1665 for 




Scale: 4j (518 mg, 2 mmols) and aniline (372 mg, 4 mmols), stirred for 2 h. Yield of 5j: 603 
mg, 81% as an off-white solid. Recrystallisation from AR-grade MeOH and AR-grade DCM 
afforded 5j as white needles: Mp 285-286 °C; 1H NMR (300 MHz, DMSO-d6) δ ppm 11.26 (s, 
2H) 9.26 (t, J = 1.6, 1H) 9.00 (d, J = 1.6 Hz, 2H) 8.67 (m, 4H) 8.25 (m, 4H) 7.99 (m, 2H); 13C 
NMR (151 MHz, DMSO-d6) δ ppm 165.8, 151.8, 139.5, 135.5, 129.1, 127.9, 124.8, 124.3, 
121.1, 35.4, 31.5; HRMS-ES-: Observed 371.1749 (M-H)+; Calculated 371.1760 for 
C24H23N2O2; HPLC: 99.3%. 
  




N,N-Di(pyridin-4-yl)isophthalamide (5k)325  
 
Scale: 4k (406 mg, 2 mmols) and 4-aminopyridine (376 mg, 4 mmols), stirred for 2 h in 
pyridine (4 ml) and DCM (10 ml). The product was isolated by filtration of the white reaction 
precipitate. Yield of 5k: 422 mg, 66%. Recrystallisation from AR-grade DCM afforded 5k as a 
white powder: Mp 334-335 °C; Lit Mp326 >350 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.74 
(s, 2H), 8.54 (t, J = 1.8 Hz, 1H), 8.49 (d, J = 6.3 Hz, 4H), 8.18 (dd, J = 1.8, 7.9 Hz, 2H), 77.80 (d, 
J = 6.3 Hz, 4H), 7.73 (t, J = 7.9 Hz, 1H); 13C NMR (101 MHz, DMSO-d6) δ ppm 166.3, 150.9, 
146.3, 135.1, 131.8, 129.3, 127.8, 114.6; HRMS-ES-: Observed 317.1033 (M-H)+; Calculated 




Scale: 4l (406 mg, 2 mmols) and aniline (372 mg, 4 mmols), stirred for 2 h. Precipitation of 
the white product was assisted with DCM. The product was isolated by filtration of the 
reaction precipitate. Yield of 5l: 455 mg, 72%. Recrystallisation from AR-grade DCM afforded 
5l as a white powder: Mp 383-384 °C; Lit. Mp327 >300 °C; 1H NMR (400 MHz, DMSO-d6) δ 
ppm 10.39 (s, 2H), 8.53 (t, J = 1.6 Hz, 1H), 8.13 (dd, J = 1.6, 7.8 Hz, 2H), 7.82 (m, 4H), 7.68 (t, J 
= 7.8 Hz, 1H), 7.27 - 7.46 (m, 4H), 7.11 (m, 7.5 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ ppm 
165.5, 139.5, 135.7, 131.1, 129.1, 129.1 127.5, 124.3, 120.9; HRMS-ES-: Observed 315.1135 
(M-H)+; Calculated 315.1134 for C20H15N2O2; HPLC: 98.3%. 
  






Scale: 4m (466 mg, 2 mmols) and 4-aminopyridine (376 mg, 4 mmols), stirred for 4 h. Yield 
of 5m: 483 mg, 69% as an off-white solid. Recrystallisation from AR-grade MeOH afforded 
5m as a white powder: Mp 144-145 °C; 1H NMR (300 MHz, DMSO-d6)  δ ppm 10.74 (s, 2H), 
8.52 (d, J = 6.4 Hz, 4H), 8.16 (t, J = 1.5 Hz, 1H), 7.82 (d, J = 6.4 Hz, 4H), 7.74 (d, J = 1.5 Hz, 2H), 
3.95 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ ppm 166.1, 159.8, 150.8, 146.3, 136.4, 120.1, 
117.3, 114.6, 56.4; HRMS-ES-: Observed 347.1132 (M-H)+; Calculated 347.1144 for 




Scale: 4n (466 mg, 2 mmols) and aniline (372 mg, 4 mmols), stirred for 2 h. Yield of 5n: 637 
mg, 92% as an off-white solid. Recrystallisation from AR-grade MeOH afforded 5n as white 
needles: Mp 223-224 °C; 1H NMR (300 MHz, DMSO-d6) δ ppm 10.37 (s, 2H), 8.14 (t, J = 1.5 
Hz, 1H), 7.81 (m, 4H), 7.70 (d, J = 1.5 Hz, 2H), 7.39 (m, 4H), 7.12 (m, 2H), 3.94 (s, 3H); 13C 
NMR (151 MHz, DMSO-d6) δ ppm 165.3, 159.7, 139.5, 137.1, 129.1, 124.3, 121.0, 119.8, 
116.6, 56.3; HRMS-ES-: Observed 345.1225 (M-H)+; Calculated 345.1239 for C21H17N2O3; 
HPLC: 99.3%. 
  






Scale: Pyridine-2,6-dicarbonyl dichloride (204 mg, 1 mmol) and 4-aminopyridine (188 mg, 2 
mmols), stirred for 3 h. The product was isolated by filtration of the white reaction 
precipitate. Yield of 5o: 307 mg, 92%. Recrystallisation from AR-grade MeOH and AR-grade 
DCM afforded 5o as a white powder: Mp 327-328 °C; Lit. Mp326 >300 °C; 1H NMR (400 MHz, 
DMSO-d6) δ ppm 12.17 (s, 2H), 8.71 (d, J = 6.6 Hz, 4H), 8.49 (m, 2H), 8.46 (d, J = 6.6 Hz, 4H), 
8.39 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ ppm 164.2, 149.7, 148.6, 146.5, 140.9, 127.3, 





Scale:  Pyridine-2,6-dicarbonyl dichloride (204 mg, 1 mmol) and aniline (186 mg, 2 mmols), 
stirred for 3 h. The product was isolated by filtration of the white reaction precipitate. Yield 
of 5p: 302 mg, 91%. Recrystallisation from AR-grade MeOH and AR-grade DCM afforded 5p 
as a white powder: Mp 271-272 °C; Lit. Mp328 278 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 
11.00 (s, 2H), 8.39 (m, 2H), 8.29 (m, 1H), 7.91 (m, 4H), 7.43 (m, 4H), 7.18 (m, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ ppm 162.2, 149.4, 140.4, 138.5, 129.3, 125.8, 124.9, 121.7;  HRMS-
ES-: Observed 316.1088 (M-H)+; Calculated 316.1086 for C19H14N3O2; HPLC: 98.1%. 
  






5-Nitroisophthaloyl dichloride (173 mg, 0.7 mmols) was prepared as per 4a and then 
dissolved in pyridine (1 ml) and DCM (4 ml). 4-[(N-Boc)aminomethyl]aniline (318 mg, 1.4 
mmols) was added and the reaction stirred at RT for 2 h. Following completion of the 
reaction indicated by TLC, EtOAc and 1 M HCl were added to the flask. The product was 
extracted into EtOAc (3 x 20 ml) and washed with cold 1 M HCl (3 x 20 ml) to remove the 
pyridine. The combined organic components were dried with MgSO4 and the solvent 
removed under reduced pressure before being dissolved in dry DCM (5 ml) under inert 
atmosphere. TFA (1 ml) was slowly added at 0 °C and the mixture was stirred for 2.5 h. The 
excess TFA and DCM were removed on a rotoevaporator, followed by the addition of MeOH 
(20 ml) and K2CO3 (200 mg). The solution was stirred for 30 mins, then filtered through 
Celite and the MeOH evaporated off under reduced pressure. The resulting solid was 
dissolved in DMF (~10 ml) and formaldehyde (1.5 ml, 37% in water). Sodium 
cyanoborohydride (315 mg, 5 mmols) was added to the reaction stirred at RT for 5 h. Water 
(50 ml) was added and the product was extracted with EtOAc (3 x 50 ml), dried with MgSO4 
and the solvents evaporated under reduced pressure. The residual DMF was removed by 
heating under high vacuum on the pump for 12 h, and the resulting crude solid was 
recrystallized from MeOH to yield 7 as pale yellow crystals (111 mg, 53%); Mp 202-204 °C; 
1H NMR (400 MHz, DMSO-d6) δ ppm 11.00 (s, 2H), 9.03 (t, J = 1.7 Hz, 1H), 8.61 (d, J = 1.7 Hz, 
2H), 7.97 (d, J = 8.6 Hz, 4H), 7.55 (d, J = 8.6 Hz, 4H), 4.14 (s, 4H), 2.63 (s, 12H); 13C NMR (101 
MHz, DMSO-d6) δ ppm 163.5, 148.4, 140.0, 137.0, 133.6, 129.6, 126.5, 125.7, 120.5, 65.2, 
49.0; MS-EI+ Observed 475.1728 M+; Calculated 475.2220 for C26H29N5O4; HPLC: 97.1% 
 
  






5-Nitroisophthaloyl dichloride (1.49 g, 6 mmols) was prepared as per 5a and then dissolved 
in DCM (10 ml) under N2 and cooled to -40 °C in an acetonitrile/liquid N2 cooling bath. 2-
Aminobenzimidazole (133 mg, 1 mmol) was added and the reaction allowed to come to RT 
before the addition of pyridine (2 drops) whereupon the reaction went from cloudy white to 
clear yellow. Once TLC monitoring indicated the disappearance of the amine starting 
material, the reaction was again cooled to -40 °C and another portion of 2-
aminobenzimidazole (4 mmols) was slowly added. The reaction was left to come to RT and 
then heated to 40 °C for 30 mins, after which TLC indicated no remaining benzimidazole 
starting material, after which it was then brought back to RT. Aniline (500 mg, 5.4 mmols) 
was added and the solution stirred for a further 30 mins before commencing the work-up. 
The organic product was extracted into EtOAc (3 x 50ml) from a solution of brine and 
sodium carbonate and then the combined EtOAc fractions dried with MgSO4. The EtOAc was 
removed on a rotoevaporator and then DCM:MeOH (1:1) was added to the yellow solid and 
briefly heated. The undissolved solid was filtered off and the process repeated twice using 
acetone to remove the dissolved impurities. The product was then recrystallized in hot 
pyridine to yield 8 as yellow crystals (200 mg, 10%); Mp 339-342 °C; 1H NMR (400 MHz, 
DMSO-d6) δ 12.63 (br. s, 2H), 10.72 (s, 1H), 9.02 - 9.18 (m, 2H), 8.91 (t, J = 1.9 Hz, 1H), 7.80 
(dd, J = 1.1, 8.6 Hz, 2H), 7.42 - 7.48 (m, 2H), 7.35 - 7.41 (m, 2H), 7.18 - 7.23 (m, 2H), 7.11 - 
7.17 (m, 1H); 13C NMR (101 MHz, DMSO-d6) δ 163.5 (2), 147.8, 139.7, 138.7 (2), 136.5, 
133.9, 130.1, 128.8, 126.0, 124.5, 124.3, 122.6, 120.5, 112.2; HRMS-ES-: Observed 400.1052 
(M-H)+; Calculated 400.1046 for C21H14N5O4; HPLC: 93.2%. 
 
  






Benzene-1,3,5-tricarbonyl trichloride (9, 265 mg, 1 mmol) was dissolved in dry DCM:pyridine 
(4:1) and then aniline (279 mg, 3 mmols) was added. The reaction was stirred at RT for 1 h 
after which the precipitated product was filtered off and dried. The white solid was 
recrystallized in MeOH and DCM to give 10 as white crystals (240 mg, 55%); Mp 314-315 °C; 
Lit Mp329 327-329 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 10.55 (br. s, 3H) 8.69 (s, 3H) 7.81 
(m, 6H) 7.40 (m, 6H) 7.11 (m, 3H); 13C NMR (151 MHz, DMSO-d6) δ ppm 160.7, 133.1, 130.2, 
129.2, 128.1, 123.4, 121.4; HRMS-ES-: Observed 434.1484 (M-H)+; Calculated 434.1505 for 
C27H20N3O3; HPLC: 96.7%. 
 
  





General procedure for the synthesis of triarylimidazoles (15a-d) 
The appropriate benzaldehyde (13) and benzil (14) in a molar ratio of 1:1 were refluxed with 
excess ammonium acetate (NH4OAc) in AR-grade MeOH for 4 h. Upon completion of the 
reaction, indicated by TLC analysis, it was cooled to RT. For compounds 15a-c, the reactions 
produced a precipitate, which was collected by vacuum filtration to afford the desired 
product. For compound 15d, the contents of the reaction flask were added to a saturated 
solution of Na2CO3 and the organic components extracted with EtOAc (3 x 10 ml). The 
combined organic fractions were dried with MgSO4 before concentrating the solution under 





Scale: 13a (166 mg, 1 mmol),  benzil (210 mg, 1 mmol) and NH4OAc (230 mg, 3 mmol). Yield 
of 15a: 311 mg, 87%. Recrystallisation from absolute EtOH afforded 15a as white needles: 
Mp 254-255 °C; Lit Mp274 254-256 °C; 1H NMR (300 MHz, DMSO-d6) δ ppm 12.62 (br. s., 1H) 
7.02 - 7.72 (m, 12H) 6.50 (br. s., 1H) 3.80 (br. s., 6H); 13C NMR (101 MHz, DMSO-d6) δ ppm 
161.2, 145.8, 137.5, 135.6, 132.6, 131.6, 129.1, 129.0, 128.8, 128.6, 128.3, 127.6, 127.0, 
103.6, 101.1, 55.9; HRMS-ES+: Observed 357.1603 (M+H)+; Calculated 357.1603 for 
C23H21N2O2; HPLC: 98.5%. 
  






Scale: 13b (196 mg, 1 mmol), benzil (210 mg, 1 mmol) and NH4OAc (230 mg, 3 mmols). Yield 
of 15b: 229 mg, 59%. Recrystallisation from absolute EtOH afforded 15b as white needles: 
Mp 254-256 °C; Lit Mp264 261-262 °C;  1H NMR (300 MHz, DMSO-d6) δ ppm 12.55 (br. s., 1H) 
6.60 - 7.92 (m, 12H) 3.84 (s, 6H) 3.69 (s, 3H); 13C NMR (101 MHz, DMSO-d6) δ ppm 153.6, 
145.9, 138.3, 137.4, 135.6, 131.7, 129.2, 129.0, 128.6, 128.6, 128.3, 127.5, 127.0, 126.4, 
103.2, 60.6, 56.5; HRMS-ES+: Observed 387.1711 (M+H)+; Calculated 387.1709 for 




Scale: 13c (364 mg, 2 mmol), benzil (420 mg, 2 mmol) and NH4OAc (1.54 g, 20 mmols). Yield 
of 15c: 601 mg, 81%. Recrystallisation from absolute EtOH afforded 15c as an off-white 
powder: Mp 286-287 °C; Lit Mp 290-292 °C; 1H NMR (300 MHz, DMSO-d6) δ ppm 12.42 (s, 
1H), 8.58 (s, 1H), 7.34 - 7.62 (m, 10H), 7.15 - 7.34 (m, 2H), 3.85 (s, 6H); 13C NMR (101 MHz, 
DMSO-d6) δ ppm 148.6, 146.5, 137.1, 136.8, 135.8, 131.9, 129.1, 128.9, 128.6, 128.1, 128.0, 
127.5, 126.8, 121.3, 103.5, 56.6; HRMS-ES+: Observed 373.1558 (M+H)+; Calculated 
373.1552 for C23H21N2O3; HPLC: 99.1%. 






Scale: 13d (190 mg, 1 mmol), benzil (210 mg, 1 mmol) and NH4OAc (770 mg, 10 mmols). 
Yield of 15d: 321 mg, 84%. Recrystallisation from absolute EtOH afforded 15d as a white 
powder: Mp 234-235 °C; 1H NMR (400 MHz, Acetone) δ ppm 11.66 (br. s, 1H) 8.11 (d, J = 
8.5, 2H) 7.54 (d, J = 8.5, 2H) 7.03 - 7.47 (m, 10H); 13C NMR (101 MHz, DMSO-d6) δ ppm 
148.6, 144.7, 137.9, 135.5, 129.3 (q, JCF = 144.9 Hz, CF3), 129.2, 128.9, 128.7, 127.6, 127.5, 
121.8, 119.3; HRMS-ES+: Observed 381.1218 (M+H)+; Calculated 381.1215 for C22H16N2OF3; 
HPLC: 98.55%. 
  
 4-Chlorobenzil (14e) 
  
4-Chlorobenzoin (12e, 123 mg, 0.5 mmols) was stirred in dry THF (5 ml) and cooled to 0 °C 
before sodium hydride (60% w/w dispersion in mineral oil, 40 mg, 1 mmol) was added. The 
dark-blue solution was heated slowly to RT for 15 min upon which the mixture went yellow 
and TLC indicated consumption of the benzoin. The mixture was quenched with NaHCO3 
solution (10 ml, 0.1 M), then extracted with EtOAc (3 x 10 ml) and washed with brine. The 
organic layer was dried with MgSO4 before being concentrated under vacuum. Purification 
by column chromatography was carried out in 30% EtOAc/hexane to yield 14e which was 
then recrystallised from hot hexane, resulting in a white powder (37 mg, 30%). 1H NMR (300 
MHz, Acetone-d6) δ ppm 8.23 - 8.51 (m, 2H), 7.74 - 8.13 (m, 4H), 7.58 - 7.72 (m, 3H).  
  






4-Chlorobenzil (14e, 29 mg, 0.12 mmols), 3,5-dimethoxybenzaldehyde (13e, 20 mg, 0.12 
mmol) and NH4OAc (184 mg, 2.4 mmols) were refluxed at 70 °C in MeOH (3 ml) with stirring 
overnight. After cooling to RT, the MeOH was removed under reduced pressure followed by 
the addition of EtOAc (5 ml) and brine (5 ml). The product was extracted into EtOAc (3 x 5 
ml) and the organic layer dried with NaSO4. The remaining solution was purified by column 
chromatography in 30% EtOAc/hexane and then recrystallized from DCM/hexane to give 
15e as a white powder (30 mg, 65%); Mp 218-219 °C; 1H NMR (400 MHz, MeOD) δ ppm 7.41 
- 7.55 (m, 4H), 7.35 (m, 5H), 7.21 (d, J = 2.3 Hz, 2H), 6.53 (t, J = 2.3 Hz, 1H), 3.85 (s, 6H); 13C 
NMR (101 MHz, MeOD) δ ppm 161.4, 146.9, 145.3, 145.2, 144.7, 132.8, 131.5, 129.4, 128.3, 
128.2, 128.2, 128.1, 127.4, 103.5, 101.1, 54.6; HRMS-ES+: Observed 391.1222 (M+H)+; 




4,4’-Dimethoxybenzoin (12f, 545 mg, 2 mmol) was stirred in dry THF (20 ml) at 0 °C before 
sodium hydride (60% w/w dispersion in mineral oil, 160 mg 2.4 mmols) was added. The 
dark-blue solution was allowed to reach RT over 10 mins and then stirred for a further 3 h, 
by which time TLC showed complete consumption of the starting material. The reaction was 
quenched with NaHCO3 (40 ml, 0.1 M), extracted into EtOAc (3 x 40 ml) and washed with 
brine before drying of the organic layer over MgSO4. The solution was concentrated under 




vacuum and then recrystallised from hot EtOAc/hexane to yield 14f as a white powder (359 
mg, 66%), 1H NMR (400 MHz, CDCl3) δ ppm 7.94 (d, J = 8.8 Hz, 4H), 6.97 (d, J = 8.8 Hz, 4H), 




4,4’-Dimethoxybenzil (14f, 135 mg, 0.5 mmols), 3,5-dimethoxybenzaldehyde (13f, 83 mg, 
0.5 mmols) and NH4OAc (385 mg, 5 mmols) were refluxed at 80 °C in EtOH (7 ml) with 
stirring overnight. After cooling to RT, the EtOH was removed under reduced pressure and 
Na2CO3 (10 ml) was added to the remaining mixture. The product was extracted into EtOAc 
(3 x 10 ml) and washed with brine (10 ml). The organic layer was dried over MgSO4 before 
concentrating under vacuum. Purification of the residue was carried out using column 
chromatography in 40% EtOAc/hexane followed by recrystallization from EtOAc/hexane to 
give 15f as a white powder (167 mg, ≥), Mp 190-191 °C; 1H NMR (400 MHz, DMSO-d6) δ ppm 
12.44 (s, 1H), 7.45 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 2.3 Hz, 2H), 7.00 (d, J 
= 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 6.47 (t, J = 2.3 Hz, 1H), 3.80 (s, 6H), 3.79 (br. s., 3H), 
3.73 (br. s, 3H); 13C NMR (101 MHz, DMSO-d6) δ ppm 161.2, 159.3, 158.5, 145.1, 136.9, 
132.8, 130.3, 128.7, 128.3, 127.7, 124.0, 114.6, 114.1, 103.5, 100.9, 55.8, 55.7, 55.5; HRMS-
ES+: Observed 417.1814 (M+H)+; Calculated  417.1814 for C25H25N2O4; HPLC: 98.0%. 
  






To a well stirred mixture of 4-nitrobenzaldehyde (13g, 600 mg, 3.9 mmol) and benzil (14g, 
800 mg, 3.8 mmol) in acetic acid (25 ml), ammonium acetate (5 g, 0.06 mols) was added. 
The reaction was refluxed at 118 °C for 4 h. The solution was poured into ice-water and 
ammonia added to the acidic solution while stirring, until the pH was neutral. The dark 
orange precipitate was vacuum-filtered off and washed with water (3 x 20 ml) whilst on the 
vacuum. The precipitate was then stirred in hot absolute EtOH and an insoluble brown 
precipitate was filtered off and discarded. On cooling, 15g (1.2 g, 93%) was obtained as a 
bright-orange powder, Mp 228-230 °C;  Lit Mp330 250-251 °C; 1H NMR (400 MHz, DMSO-d6) 
δ ppm 13.11 (br. s, 1H) 8.35 (d, J = 7.9 Hz, 4H), 8.35 (d, J = 7.9 Hz, 4H), 7.18 - 7.63 (m, 10H); 
13C NMR (101 MHz, DMSO-d6) δ ppm 173.6, 134.6, 133.0, 131.3, 129.8, 129.7, 129.6, 129.5, 
129.2, 129.0, 128.7, 128.2, 127.1, 127.0, 126.6; HRMS-ES+: Observed 342.1243 (M+H)+; 
Calculated 342.1243 for C21H16N3O2; HPLC: 98.75%. 
 
  






2-(4-Nitrophenyl)-4,5-diphenyl-1H-imidazole (15g, 610 mg, 1.8 mmols), was dissolved in 
EtOH /water (2:1 v/v, 25 ml) before the addition of iron filings (785 mg, 7.8 equiv) and HCl 
(32% w/w, 4 drops). The mixture was refluxed at 80 °C for 6 h under anaerobic conditions, 
cooled and then the iron scruff filtered off. Removal of excess solvents was carried out on a 
rotoevaporator under reduced pressure at 60 °C to yield a pale brown residue. 
Recrystallisation from hexane, DCM and a few drops of EtOH resulted in 16 (398 mg, 71%) as 
an off-white solid, Mp 202-203 °C; Lit Mp330 211-212 °C; 1H NMR (400 MHz, DMSO-d6) δ 
ppm 12.11 (s, 1H), 7.69 (d, J = 8.7 Hz, 2H), 7.47 (m, 2H), 7.41 (m, 2H), 7.35 (m Hz, 2H), 7.27 
(m, 1H), 7.2 (m, 2H), 7.14 (m, 1H), 6.57 (d, J = 8.7 Hz, 2H), 5.26 (m, 2H); 13C NMR (101 MHz, 
DMSO-d6) δ ppm 149.0, 146.8, 136.3, 135.6, 131.4, 128.5, 128.1, 128.0, 127.2, 127.0, 126.7, 
126.4, 126.1, 118.2, 113.5; HRMS-ES+: Observed 312.1501 (M+H)+; Calculated 312.1501 for 
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